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Summary 
 
The obesity epidemic has risen to alarming levels in both developing and developed 
countries (Lobstein, 2011). The World Health Organization (WHO) estimates that 750 
million adults are overweight or obese worldwide (Bray & Popkin, 1998). In the United 
States (US), an estimated 65% of adults are overweight, with 30% categorised as 
obese body mass index (BMI) ≥30), and almost 5% as severely obese (BMI ≥ 40) 
(Huang, Yang & Omaye 2011). In Australia, approximately 63.3% of adults are 
overweight, out of which 28.3% are obese (Australian Bureau of Statistics, 2012). 
The exact cause of this increase in obesity is unknown at present； obesity is 
reported, however, to be caused mainly by diet, environment, genetics and lack of 
exercise (Rohrer, Vickers-Douglas & Stroebel, 2009). 
Excessive body weight (BW) has been shown to predispose an individual to various 
diseases, particularly cardiovascular diseases, Type 2 diabetes (T2D), sleep apnoea, 
and osteoarthritis. Therefore, obesity is both an individual clinical condition and 
increasingly a serious public health problem. 
In the clinical treatment of obesity, Western medicine (WM) is given priority, with 
Chinese medicine (CM) used as a supplemental adjunct approach. The main WM 
focus is to suppress appetite, increase energy consumption, prevent digestion and 
absorption of lipid metabolism, and influence insulin secretion. Whilst Western 
medicine treatment of obesity produces rapid results, these results are dependent on 
drug tolerance and are often associated with undesirable side-effects. Current 
management by pharmacotherapy shows inadequate evidence to support their 
efficacy and safety (Leung, Thomas, Chan, & Tomlinson, 2003). Surgical procedures 
such as gastric bypass have been performed successfully; this procedure is not 
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suitable for all obese patients, however, and may result in adverse events. Surgery is 
usually considered only for those with serious medical conditions and for those who 
are at high risk of obesity-related illness and death (Shippey & Macedonia, 2003). 
Globally, the increasing use of complementary and alternative therapies including 
CHM and acupuncture for many disorders has generated broad interest from the 
WHO, academia, governments, health-care professionals and the community. 
Recent advances in the understanding of the pharmacological actions of CHM and 
physiological responses related to acupuncture, such as their anti-inflammatory 
activity and effect on immune function, have contributed to clinical decision-making 
and have increased the use of CHM and acupuncture for the management of obesity 
(Chen, Xu, & Li, 2005). The objectives of this thesis are to evaluate the effects of 
acupuncture and herbal medicine formulae in the management of obesity and to 
evaluate the efficacy of the newly formed RMIT Chinese herbal formula (RCM-104).  
A systematic review of a randomised clinical trial of acupuncture using methods 
described in the Cochrane Handbook for systematic review of intervention and in 
RevMan 5.1 for analysis has been conducted. The search has been carried out since 
2006 and it has been updated untill completion of this thesis. A total of 15 electronic 
English and three Chinese databases were searched using relevant terms and key 
words relating to the treatment of obesity. Twenty-three RCTs were included in this 
review which used sham acupuncture, no treatment, and WM as a control. The 
outcome measures include BW, BMI, body fat composition, and waist and hip 
circumferences. The meta-analysis showed that acupuncture provided more benefit 
than the control when used with other adjunct therapies. Acupuncture, however, did 
not show better effects on BW, BMI or BF composition than WM. It was also found 
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that most of the included study exhibited high risk, unclear risk in selection bias, 
detection bias and attrition bias.  
Similarly, the SR of CHM clinical trials was conducted using the same methods as for 
the acupuncture SR. Fourteen RCTs were included in the review, which compared 
CHM with placebo, WM, or other therapies (dietary therapy and/or exercise), with or 
without co-intervention. This review also used outcome measures and acupuncture. 
The data analysis demonstrated that when used alone, CHM did not show any 
significant difference from either placebo or WM for BW, BMI or BF composition. 
When combined with other therapy, however (i.e. diet therapy and/or exercise), CHM 
showed some benefits for BW, BMI and WC. As with the acupuncture review, the 
RCTs in the CHM review also had high risk in performance bias, and unclear risk in 
selection bias, detection bias and attrition bias. This indicates that the included 
studies in both acupuncture and CHM were of low quality.  
The RMIT Chinese herbal medicine formula (RCM-104) was formed using findings 
from current literature from both Chinese and Western medicine. The RCT of RCM-
104 was rigorously designed and conducted between 2007 and 2009. The RCM-104 
formula demonstrated effectiveness in the reduction of BW, BMI and BFC as well as 
improved quality of life compared to the placebo group. 
In conclusion, this study comprehensively and systematically analysed modern RCTs 
of CHM and acupuncture interventions for obesity. Employing a range of methods of 
analysis, this study demonstrates the potential effectiveness of acupuncture for the 
symptomatic management of obesity. Acupuncture appears to be a safe adjunct 
therapy for adult patients with obesity. This thesis combined SRs and a RCT which 
demonstrated the efficacy of CHM in the management of obesity. 
4 
 
Further studies are needed to determine the therapeutic benefits of a complementary 
approach. Such studies should address methodological weaknesses identified in the 
relevant reviews, such as randomisation, allocation concealment, blinding and 
sample sizes, and would preferably be conducted in a multi-centre setting. Once the 
efficacy of CHM and acupuncture is confirmed, further studies to elucidate the 
mechanisms of action of CHM and acupuncture, such as its anti-inflammatory effect, 
need to be undertaken to facilitate more informed clinical decision-making for 
effective use of Chinese medicine for obesity. 
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Chapter 1. General introduction 
1.1 Background 
The International Obesity Task Force estimates that approximately 1.1 billion adults 
worldwide are overweight, with at least 312 million described as obese (Cannon & 
Kumar, 2009). Obesity is a medical condition involving more than one kind of 
biological basis or metabolic disease (Bray & Champagne, 2004). Obesity is divided 
into two categories: simple obesity and secondary obesity. Simple obesity is a 
chronic, non-communicable disease (Formiguera & Cantón, 2004) that is defined as 
a condition of weight gain due to excessive accumulation of fat. Secondary obesity is 
a weight gain condition caused by an underlying medical condition. Globally, simple 
obesity is more prevalent compared with complex obesity. Obesity accounts for a 
majority of overweight individuals worldwide (Bray & Champagne, 2004). As such, 
obesity is a global pandemic and its incidence and prevalence are increasing, 
especially in developing countries (Pietrobelli, 2005a). Because of the increasing 
prevalence of obesity and its substantial economic and social burden, awareness 
initiatives and research studies have been conducted worldwide in an attempt to 
improve the management and prevention of this global health problem. 
1.2 Definition of obesity 
The concept of obesity has evolved over a 200-year history. Pathological obesity is 
due to body composition, excessive fat accumulation, and anomalous fat distribution 
that cause weight gain equalling or greater than 20% of the standard weight 
(Westerterp-Plantenga, Lejeune, & Kovacs, 2005). Obesity results in excess energy 
being stored in the form of fat in the body. This accumulation of excess fat presents a 
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risk to an individual’s health (Kil & Swanson, 2010) and is characterised by weight 
gain, fatigue, and lassitude (Patterson, Frank, Kristal, & White, 2004). In recent years, 
studies have shown that some forms of obesity are also caused by specific 
biochemical factors (Butryn, Webb, & Wadden, 2011). How these factors influence 
food regulation and energy metabolism, chronic metabolic disease, and endocrine 
disease is very complicated and remains an open question. The association of 
obesity with cerebrovascular and cardiovascular diseases as well as diabetes 
mellitus is a major public health concern (Sharma & Iacobellis, 2006). 
Each person has their own metabolic rate, which is based on calories used or burned 
in the body. Individuals who exercise frequently or work strenuously have a higher 
metabolic rate. They require more calories, but easily burn them. An individual who is 
less active does not need to ingest or burn as many calories. Simple obesity results 
when a person ingests more calories compared to what the individual burns. If this 
continues over a period of time, the body deposits the extra calories as fat. It is 
usually the body fat (BF) surplus that causes significant health damage. When a 
person starts to lose weight, the cell reduces in the size, but the quantity of fat cells 
generally remains the same, resulting in difficulty in weight loss (Westerterp-
Plantenga et al., 2005).  
1.3 Prevalence of obesity 
The prevalence of obesity among men increased significantly between 1999-2000 
(27.5%) and 2003-2004 (31.1%). The prevalence of extreme obesity (BMI≥40) 
prevalence in 2003-2004 in men and women was 2.8% to 6.9%. The World Health 
Organization terms obesity a worldwide epidemic.  
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Much concern has been generated about the increasing incidence of obesity among 
North Americans. Some studies have noted an increase in obesity prevalence from 
12% to 18% occurring between 1991 and 1998. Other studies have estimated that 50% 
of all North Americans are overweight (Bray & Champagne, 2004) (Figure 1.1).  
 
 
 
 
 
 
 
Figure 1.1: Prevalence of obesity among adults aged 20 and over, by age group and 
sex: United States 2012. Adapted from: Centre for Disease Control (CDC)/ The 
National Center for Health Statistics (NCHS), National Health Interview Survey 2012, 
and Sample Adult Core component. 
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Today, Australia is ranked as one of the fattest nations in the developed world with 
the prevalence of obesity more than doubling in the past twenty years. Fourteen 
million Australians are overweight and obese, out of which more than five million 
Australians are categorised as obese (BMI ≥ 30 kg/m2) (Zimmet, 2010). By 2025, 
projections predict that close to 80% of all Australian adults and a third of all children 
will be overweight or obese, if weight gain continues at current levels (Zimmet, 2010). 
The Australian Health survey 2011-2012 indicated that the prevalence of obesity has 
increased by 10.5% (Figure 1.2). 
 
 
 
 
 
 
Figure 1.2: The prevalence of overweight and obesity in Australia (Health survey, 
Australia 2011-13). 
 
The prevalence of obesity , especially in children from a single generation, has also 
risen dramatically (Wang, McPherson, Marsh, Gortmaker, & Brown, 2011). 
Australians who reported experiencing heart, stroke and vascular diseases aged 15 
years and over were much more likely to be classified as overweight or obese 
compared with those without stroke and vascular disease (65% compared to 51%) 
(Zimmet, 2010).  
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1.3.1 Prevalence of pediatric obesity 
The trends show an increase in the prevalence of overweight female children and 
teenagers in 1999-2000, from 13.8% to 16.0%, and an increase in the prevalence of 
overweight male children and adolescents from 14.0% to 18.2% between 2003-2004. 
On the basis of present trends we predict that by the time they reach the age of 20, 
many children will have a shorter life expectancy compared with older generations, 
simply because of obesity. According to the CDC, the percentage of children aged 6 
to 11 years that are overweight has almost doubled since the 1980s; while the 
percentage of overweight adolescents has risen nearly 300% since the second half 
of the 20th century (Holterman, Le Holterman, & Browne, 2012). The National Health 
and Nutrition Examination Survey 2009-2010 reported that 16.9% of United States 
(US) children and adolescents were obese. In Europe, there has also been an 
increase in overweight and obese children and adolescents during the last decade 
(Figure 1.3). 
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Figure 1.3: Prevalence of obesity among 15 year olds in European countries 
(Adapted from OECD (2012), Report of Health at a Glance. 
 
1.3.2 Geographic and racial factors 
According to an international survey, there are differences in the prevalence of 
obesity amongst different geographic regions. Compared to the Americas, Europe 
and the Pacific, the prevalence of obesity was higher in Southeast Asia and Latin 
America. In 2003-2004, 17.1% of American children and teenagers were classified as 
overweight (Story et al., 1999) (Figure 1.4).  
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1.4 Causes of obesity 
As stated in the table 1.1, the causes of obesity are complex, ranging from personal 
choices and way of life, to societal influences. Four major factors contributing to 
weight gain are: metabolism, diet, physical activity and the environment (Pietrobelli, 
2005b). The most common causes of obesity are overeating and not enough physical 
activity. Ultimately, BW is the result of genetics, metabolism, environment, behaviour, 
and culture (Pietrobelli, 2005b). 
In the United States, an online survey reported that a higher percentage of office 
workers were obese as compared to other professions. One of the reasons for weight 
gain is ‘being busy in the office; there was no time for sports’ (Azarbad & Gonder-
Frederick, 2010). Most workplaces (73%) had no attached fitness facilities. Reliance 
on e-mail for communication means that workers do not go to other colleague’s 
offices to discuss business, leading to decreased activity and weight gain. Experts 
suggest that to control their weight, employees should use their lunchtime to rest, go 
to the gym, or that they should simply have a healthy lunch and then go out for a 
walk. The survey also reported that stress can lead to increased snacking (Azarbad & 
Gonder-Frederick, 2010). 
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Table 1.1: Causes of obesity 
Cause of obesity Reasons Reference 
Genetics 
More likely to develop obesity if one or both parents 
are obese. 
(González 
Jiménez, 2011) 
Overeating Overeating leads to weight gain, especially if the diet is high in fat. 
(Huang et al., 
2013) 
A diet high in 
simple 
carbohydrates 
Carbohydrates increase blood glucose levels, which 
in turn stimulate insulin-release by the pancreas. 
Insulin promotes the growth of fat tissue and can 
cause weight gain. 
(Huang et al., 
2013) 
Slow metabolism 
Women have a slower metabolism than men, and 
hence, have a tendency to put on more weight than 
men, and weight loss is more difficult for women. 
(Bleich et al., 
2013) 
Physical inactivity 
Sedentary people burn fewer calories than people 
who are active. Physical inactivity was strongly 
correlated with weight gain in both sexes. 
(Bleich et al., 
2013) 
Medications 
Medications associated with weight gain include 
certain antidepressants, anticonvulsants and 
diabetes medications. 
(Maayan & 
Citrome, 2011) 
Psychological 
factors 
Many people eat excessively in response to 
emotions such as boredom, sadness, stress, or 
anger. 
(Schafer & 
Ferraro, 2011) 
Diseases 
Hypothyroidism, insulin resistance, polycystic ovary 
syndrome, and Cushing’s syndrome are also 
contributors to obesity. 
(Gonçalves et 
al., 2012) 
 
However, the exact cause of obesity is not clear and most likely arises from a 
complex combination of factors. Genetic factors significantly influence how the body 
regulates the appetite and the rate at which it turns food into energy (metabolic rate). 
Studies of adoptees confirm this relationship – the majority of adoptees followed a 
pattern of weight gain that more closely resembled that of their birth parents 
compared with that of their adoptive parents. A genetic predisposition to weight gain; 
however, does not automatically mean that a person will be obese (McPherson, 
2007).  
Eating habits and patterns of physical activity also play a significant role in the 
amount of weight gain. Previous studies have indicated that the amount of fat in a 
person’s diet may have a greater impact on weight compared with the number of 
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calories contained (Bray & Popkin, 1998). Carbohydrates such as cereals, breads, 
fruits, and vegetables: and protein (fish, lean meat, turkey breast, skim milk) are 
converted to fuel almost as soon as they are consumed. Most fat calories are 
immediately stored in fat cells, which adds to the body’s weight and girth as the fat 
cells expand and multiply. A sedentary lifestyle, particularly prevalent in affluent 
societies, such as in the United States, contributes to weight gain. Psychological 
factors, such as depression and low self-esteem may, in some cases, also play a role 
in weight gain (Pietrobelli, 2005a). 
1.5 Impact of obesity 
Obesity is a disease requiring long-term treatment.The total burden of obesity 
involves economic, social and medical aspects. The economic burden is estimated 
by the overall costs of obesity, including both direct and indirect costs. Direct costs 
are those related to the potential health complications that arise with obesity and 
relate to detection, treatment, prevention and rehabilitation of obesity. Indirect costs 
refer to those related to the morbidity and mortality caused by obesity. 
A large number of people with mild to moderate obesity increasingly contribute to the 
public health burden as compared with the smaller number of people with severe 
obesity. Strategies and tactics focusing on lifestyle and behaviour modification have 
failed to address the burden of the disease. Personalised treatment methods may 
provide the most effective management of the disease (Abu Dayyeh & Kaplan, 2011). 
1.5.1 Economic impact of obesity 
The worldwide increase in obesity has led to greater health management costs 
affecting the healthcare budgets of many countries (Stanton, 2009). Across 
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1.5.2 Health impacts of obesity 
Excessive weight gain often results in many serious, potentially life-threatening health 
problems, including hypertension, increased risk for coronary disease, increased 
unexplained heart attack, hyperlipidaemia, infertility, and a higher prevalence of colon, 
prostate, endometrial, and possibly, breast cancer. Approximately 300,000 deaths a 
year are attributed to obesity, prompting leaders in public health, such as former 
Surgeon General C. Everett Koop, M.D. to label obesity ‘the second leading cause of 
preventable deaths in the United States’ (Richards, Beekley, & Tichansky, 2011). 
Obesity potentially leads to abnormal glucose metabolism and insulin resistance (Gil-
Campos, Cañete, & Gil, 2004). Increased blood insulin secretion leads to a blood 
glucose phenomenon in which fat cells express fewer insulin receptors, thus 
increasing the risk of diabetes. Obesity and the prevalence of diabetes are closely 
related. Obesity causes excessive blood insulin secretion, with more severe obesity, 
resulting in higher insulin concentration (Utzschneider et al., 2010). 
High levels of insulin resulting from obesity strengthen sodium ion recovery and 
sympathetic nerve frequency. In addition, plasma and cardiac output increase, 
resulting in an increased heart rate leading to high blood pressure (Landsberg, 1990). 
Persistent sympathetic nerve excitability and sodium reabsorption causes the tip 
vascular resistance to increase and produce hypertensive heart hypertrophy (Blanton 
et al., 2013). 
Cardiovascular risk factors increase rapidly with the obesity. Obesity aggravates 
cardiovascular diseases through systemic inflammation, hypercoagulability, and 
activation of the sympathetic nervous system (Zalesin, Franklin, Miller, Peterson, & 
McCullough, 2011). Obesity is associated with risks of coronary heart disease, atrial 
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fibrillation, and heart failure (Douketis & Sharma, 2005). Abnormal glucose tolerance 
and other diseases often co-exist with arteriosclerotic disease. Because left 
ventricular end-diastolic pressure increases abnormally, sometimes obesity causes 
cardiac hypertrophy. Cardiac hypertrophy produces myocardial ischemia which often 
aggravates diastolic dysfunction (Afolabi et al., 2009). 
Obesity is associated with hyperlipemia.The primary dyslipidemia related to obesity is 
characterised by increased triglycerides, decreased HDL levels, and abnormal LDL 
composition. High blood fat influences the level of cholesterol in the liver and 
increases the risk of heart disease, vascular embolisation, coronary heart disease, 
myocardial infarction and ischemic heart disease.Obesity has become the main 
cause of atherosclerosis. Recent studies suggest that fat distribution, particularly 
visceral obesity leads to many complications (Atkinson, 2013). Studies also show that, 
if an individual is able to maintain an ideal weight, the risks of cardiovascular disease, 
and congestive heart failure and the incidence of cerebral embolism are reduced 
(Uemura et al., 2000). 
Not only does obesity lead to internal conditions, the physical changes to the body as 
a result of the excess fat and skin lead to dermatological or circulatory conditions. 
Obesity often leads to the development of a rash on the head, armpits and genital 
areas (Atkinson, 2013). In addition, patients can have skin-folds that cause red itchy 
eczema. Because of the rapid growth of epidermal tissue, fat gain is often present at 
the waist, which is similar to that observed in pregnant women. Slow intravenous 
blood backflow or blocked blood flow due to heart hypertrophy leads to varicose 
veins. 
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Obesity has also been associated with a number of other conditions. For instance, 
obesity is an important risk factor for osteoarthritis in most joints, especially at the 
knee joint (the most important site for osteoarthritis) (Ahmed & Atkinson, 2005). 
Obesity increases the risk of gallstones (Ahmed & Atkinson, 2005). Obesity can also 
cause respiratory problems (Ahmed & Atkinson, 2005). Obesity has been found to be 
linked to sleep apnoea. Obesity also increases the odds of developing several rare 
diseases such as pancreatitis and health complaints such as chronic fatigue and 
insomnia (Patterson, Frank, Kristal, & White, 2004). 
 
Table 1.2: Health impacts of obesity 
Metabolic impaired glucose metabolism, insulin 
resistance, hyperlipemia, increased 
cholesterol, gall stones, pancreatitis, 
chronic fatigue 
(Ahmed & Atkinson, 2005; 
Gil-Campos et al., 2004; 
Utzschneider et al., 2010) 
Neurological impaired sodium ion recovery, 
sympathetic nerve innervations, plasma 
and cardiac output increase, increased 
heart rate, high blood pressure, 
sympathetic nervous system activation, 
insomnia 
(Landsberg, 1990) 
cardiovascular vascular embolization, coronary heart 
disease, myocardial infarction, 
ischemic heart disease, varicose veins, 
systemic inflammation, atrial fibrillation, 
heart failure and Hypercoagulability 
(Atkinson, 2013; Douketis 
& Sharma, 2005; Uemura 
et al., 2000) 
Dermatological rash, eczema (Atkinson, 2013) 
Respiratory  sleep apnoea (Ahmed & Atkinson, 2005)
 
1.5.3 Gender-specific impacts of obesity 
The prevalence of obesity in women is increasing globally, especially in minority 
ethnic groups. This is due to changes in biology, hormones, environment, and culture. 
Reproductive transitions and a sedentary lifestyle (culture) also increase the 
prevalence of obesity. In women, obesity leads to an increased risk of gynaecological, 
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pregnancy, and psychological complications (infertility, menstrual abnormalities, and 
spontaneous abortion). (Azarbad & Gonder-Frederick, 2010). 
Infertility is related to increases in the risk of endocrine dyscrasia. Women with 
dyscrasia show increased fat deposition on the inside and outside of the uterus 
(Azarbad & Gonder-Frederick, 2010). The resulting complication is an increase in 
conception difficulties due to problems with implantation. 
Women experience fluctuations in weight gain during pregnancy and postpartum 
periods. Maternal obesity is related to an increased risk of complications in 
pregnancy, resulting in the need for more resources for intensive antenatal and peri-
operative care, such as caesarean deliveries, gestational diabetes, infections and 
congenital anomalies (Gaillard et al., 2013). Healthcare professionals face difficulties 
in the management of obesity in pregnant women as it is considered an emotive and 
stigmatising topic (Heslehurst, 2011). Prim parity and maternal body size affect long-
term postpartum weight retention and development of obesity in women of 
childbearing ages. Being adjustable risk factors, weight prior to pregnancy, prenatal 
and postnatal periods are key moments when weight control interventions may be 
implemented to prevent the development of excess weight and obesity in women of 
child-bearing ages (Gunderson, 2009). 
Thirty to forty per cent of the women who had an abortion gained an average of 5-7 
kg (Davies et al., 2010). This kind of obesity is in line with normal postpartum obesity 
because hormone levels in the body are adjusting. The following three reasons 
cause weight changing after an abortion: firstly, abortion interrupts normal pregnancy, 
causing an upset in endocrine balance leading to fat accumulation; secondly, artificial 
abortions cause an imbalance in hypothalamic function, directly affecting fat 
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metabolism, making subcutaneous fat appear, resulting in the ‘backlog’; thirdly, 
hypothalamic function interferes with the body’s hormones, especially the gonadic 
hormones. For artificial abortion, appropriate exercise and a normal diet, will 
decrease excess fat (Azarbad & Gonder-Frederick, 2010). 
Hormone imbalances in women are related to obesity. There is an increased risk in 
post-menopausal women as oestrogen withdrawal often leads to a decline in 
metabolism and a change in fat distribution (Liu, Sun, & Yan, 2004). Obese 
adolescent women show ovarian and adrenal cortical function changes, and produce 
more female hormones resulting in ovarian ovulation and the production of 
progesterone (Kane & Frisco, 2013). Subclinical hypothyroidism is estimated to be 
prevalent in 4% to 5% of the general population of reproductive women but could be 
as high as 20% in obese patients (Thornburg, 2011). 
Psychologically, obese women are more affected by weight-related stigma and 
discrimination, resulting in a greater risk of depression compared with obese men. 
The risk of obesity is increased in women with psychiatric disorders and those who 
use certain psychotropic medications (Azarbad & Gonder-Frederick, 2010). There is 
a strong correlation between obese middle-aged women and depression; therefore, 
both conditions should be considered in solving this problem (Simon et al., 2007). On 
the other hand, many women worry about obesity during adolescence, which leads to 
increased dieting and often over-dieting. Over-dieting often results in psychological 
anorexia and serious lack of nutrition. To avoid obesity and over-dieting in normal 
adolescent development, healthy eating habits are critical (In-Iw & Biro, 2011). 
Both men and women are affected by obesity; however, there are long-term 
differences in the health complications between genders. Obesity has been linked to 
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cancer of the colon in men and women, cancer of the rectum and prostate in men, 
and cancer of the gallbladder, breast and uterus in women. Obese women are more 
susceptible to depression, psychological stress, sleep debt, and exhibit lack of 
physical activity as compared to obese men (Azarbad & Gonder-Frederick, 2010). In 
men, there is an increased tendency towards abdominal fat distribution, thus 
increasing the risk of coronary artery disease and T2D (Cleator & Wilding, 2003; 
Goldberg et al., 2000). Abdominal obesity presents the same group of symptoms 
(including high cholesterol, high blood pressure, and insulin numbness, increased 
level of inflammation in blood and increased coagulation composition of blood) as 
seen in metabolic syndromes. An increased male BMI greatly increases the risk of 
cardiac failure in men and can lead to a shortened life span (Dizdar & Alyamac, 2004; 
Onat et al., 2007; Wannamethee, Shaper, Whincup, Lennon, & Sattar, 2011). 
 
Table 1.3: Gender-specific impacts of obesity (Michalakis et al., 2013; Taylor et al., 
2013) 
Male Female 
Increased tendency towards 
abdominal fat distribution, thus 
increasing the risk of coronary 
artery disease and T2D 
Increased propensity for depression, 
psychological stress, sleep debt, and 
lack of physical activity. 
Gynaecological, pregnancy, and 
psychological complications 
Cancer of the rectum and prostate, 
cancer of the colon 
Cancer of the gallbladder, breast and 
uterus, cancer of the colon 
 
1.5.4 Effects of obesity in children 
The growing epidemic of obesity in children and adolescents demands attention due 
to its direct influence on psychological health and long-term medical complications. 
Obesity has been identified as a chronic disease in the the evaluation and treatment 
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of obese adolescents. (Holterman et al., 2012). At present, no approved drugs or 
surgical methods are available for treating obesity among children.  
Recently, there has been a focus on reducing weight modestly for achieving major 
health benefits. The most effective treatment includes substantial parental 
involvement. Psychologists and healthcare providers must be involved with the 
treatment of obese children to build their self-esteem (Zametkin, Zoon, Klein, & 
Munson, 2004). Health disorders in children such as T2D, high blood pressure, 
asthma, hypertension and sleep apnoea are directly attributed to childhood obesity. 
This is reflected in an increase in weight loss prescription drugs. In order to increase 
treatment efficacy, perceived emotional barriers of parents should be addressed for 
treating obesity in children, because they significantly predict change in total BF  
(Ells et al., 2005; Steinsbekk, Ødegård, & Wichstrøm, 2011).  
1.5.5 Morbidity and mortality of obesity 
According to the Global Burden of Disease Project conducted by the WHO, obesity 
was the fifth leading cause of death worldwide in 2002 and is projected to be the third 
leading cause of death by 2030 (Table 1.4). Based on WHO estimates, 80 million 
people worldwide have moderate to severe obesity, and more than 3 million people 
died from obesity in 2005, which accounted for 5% of all deaths globally. Therefore, 
obesity is becoming a growing health and economic burden throughout the world 
(Yap, Zimmet, Mohajeri, & Yii, 2007). 
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Table 1.4: 2008 metabolic risk factors, Australia (Adapted from: WHO，Non- 
communicable diseases country profiles 2011). 
2008 estimated 
prevalence  
Males (%) Females (%) Total 
Raised blood pressure 41.1 32.0 36.4 
Raised blood glucose 10.8 8.0 9.4 
Overweight 68.2 59.3 63.7 
Obesity 26.4 27.1 26.8 
Raised cholesterol 55.9 58.9 57.4 
  
1.6 Management of obesity 
On the face of it, eating less and exercising more is the solution for eliminating 
obesity. Unfortunately, statistical data show that obese patients rarely accept this 
simple method (Lean, 2003). Although there are many books on dieting and diet 
promoting plans for easy and fast weight loss, the escalating epidemic of obesity 
demonstrates the failure of these methods. Success of weight loss management 
improves with a patient’s understanding of the condition (Anderson & Caswell, 2009). 
An increase in public awareness will improve the health-care environment and 
support for obese patients at all levels – from the individual to the public and the 
government. The strategy for decreasing obesity is dependent on promoting a 
healthy lifestyle, encouragement for inclusion of sports in daily life, changes to food 
choices, and reform of city planning (Stanton, 2009). 
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1.6.1 Western pharmacology 
The development of new, effective and safe drugs has not kept pace with the 
increase in the prevalence of obesity in Western countries. Many different types of 
drugs used in the past to treat obesity have now been withdrawn due to long-term 
side-effects. The only drug available in Europe as an aid for the treatment of obesity 
is Orlistat. In the United States, however, adrenaline analogues such as phentermine, 
have been used for decades to treat obesity for short periods (less than 12 weeks). 
The Food and Drug Administration (FDA) recently approved a combination of 
phentermine/topiramate for the treatment of obesity. The first is a selective serotonin 
receptor agonist 2C that functions by reducing food intake. This drug appears to have 
few side-effects. The results in weight loss are not large, but may be helpful in some 
selected patients. 
A combination of phentermine and topiramate has proven to be very effective; 
showing a 10% reduction in weight for the majority of patients. Caution is advised 
with attention focussed on the development of the possible short-term and long-term 
side-effects. In order to develop new treatments for obesity, further investigations into 
the mechanisms of action of drugs, which are involved in balancing weight are 
needed.  
1.6.2 Chinese medicine 
CHM, as the main component of CM, is used by 14% of adults with obesity; 
specifically, ginseng is used by 23% of herbal medicine consumers in the US (Mehta, 
Gardiner, Phillips, & McCarthy, 2008). Numerous studies using CHM for treatment of 
obesity have been conducted in China and other countries since 1990. Some studies 
demonstrated that CHM formulae were effective for relieving symptoms, improving 
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metabolism function and quality of life in patients with obesity (Kostner, 2002). It has 
also been suggested that CHM could be potentially effective for obesity treatment in 
terms of immunomodulation, anti-inflammation, oxidant-antioxidant balance, 
promotion of hemorheology and prevention of hypoxia-induced pH; however, 
conclusive evidence of the effectiveness and safety of CHM for obesity is currently 
lacking.  
1.7 Study rationale 
1.7.1 Obesity as a significant global health problem 
The prevalence of obesity is expected to increase because of increased fatty food 
intake and decreased exercise in both high-income and low-income countries 
worldwide. Obesity is predicted to become the third leading cause of death worldwide 
by 2030 because of its high morbidity and mortality rates. Obesity is an important 
economic burden associated with globally increasing direct and indirect costs. In 
Australia, obesity is the third leading cause of disease burden and an important 
public health problem. 
1.7.2 Limitations and associated side-effects of pharmacotherapy  
Current medical approaches include the long- or short-acting are recommended as 
the first-line of treatment for patients with obesity. These medical approaches prevent 
symptoms or reduce their severity, although they do not inhibit the decline of 
metabolism function. Thus, the effectiveness of the recommended medical 
approaches are limited and are associated with side-effects such as easy bruising, 
dry mouth and minor cardiovascular events. In addition, if the consideration of cost is 
also included, high expense is a barrier (Colon-Gonzalez, Kim, Lin, Valentino, & 
Waldman, 2013). 
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1.7.3 Potential benefit of Chinese herbal medicine for the treatment of 
obesity 
CHM has a long history of use for metabolism disorders. In China, CHM is frequently 
used in the management of obesity. It is also used in conjunction with pharmaceutical 
management. There is increasing scientific evidence of the efficacy of CHM for the 
treatment of obesity. A preliminary study suggested that a single herb, Huai Hua 
extract, was effective in improving lifelong functionality and weight loss of patients 
with obesity, while other investigators have reported effectiveness using other herbal 
formulae. Nevertheless, these data have yet to be critically reviewed, and many 
clinical trials to date suffer from poor methodological design quality. Thus, a critical 
review and more stringently designed randomised, controlled clinical trials are 
needed to delineate which single herbs or formulae may be the most efficacious for 
the treatment of obesity (Kuo et al., 2009). 
Obesity cannot be cured. Therefore, it is critical to consider new approaches for 
preventing disease progression, particularly in earlier stages of obesity (Uchegbu & 
Kopelman, 2013). This study will create a profile for the efficacy and safety of CHM 
and acupuncture for the treatment of obesity based on a systematic analysis of 
contemporary literature and the results of clinical trials, and an analysis of the 
classical literature to provide scientific assessment of the available evidence for 
herbs, herbal formulae and acupuncture best suited for the treatment of obesity. 
1.8 Aims and objectives 
This study aims to evaluate the efficacy and safety of CHM and acupuncture for the 
treatment of patients with obesity through systematic reviews (SRs) of the modern 
literature, analysis of the results of RCTs and an experimental study. This study also  
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identified which herbs, formulae and acupuncture are most frequently used to treat 
patients with obesity in clinical trials.  
The study also aims to form new CHM formula RCM-104 from identified potential 
herbs then to evaluate its efficacy and safety in a rigorously designed RCT 
addressing all issues identified in the systematic reviews. 
1.8.1 Research questions 
The research questions targeted by this study are as follows: 
1. Does CHM and acupuncture reduce the BMI, BW and BF of obese patients? 
2. Which CHM and acupuncture treatments are the most effective for the 
management of obesity based on RCT trial evidence? 
3. Based on available sources of evidence, which CHM and acupuncture 
treatments are the most promising for investigation and further research in 
the clinical management of obesity. 
4. Is newly formed CHM (RCM-104) effective in the treatment of obesity? 
1.8.2 Thesis outlines 
Chapter 1: General introduction 
This chapter provides literature reviews on prevalence, causes, impacts and 
management of obesity. The rationale, aims and outlines of this thesis are stated. 
Chapter 2: Literature review: Western medicine perspectives 
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This chapter focuses on knowledge accumulated by a review of WM-based literature 
concerning obesity. The diagnosis, classification, differential diagnosis, pathogenesis, 
management, prognosis, prevention and of obesity will be discussed.  
Chapter 3: Literature review: Chinese medicine perspectives 
This chapter will introduce the history of CM and modern research related to obesity. 
It will also discuss the theories and CM research regarding the pathogenesis, 
treatment and CM therapeutic mechanism for the treatment of obesity. Finally, 
evidence derived from clinical trials using CM will be reviewed. 
Chapter 4: General methodology 
This chapter describes the methods used for performing SR on RCTs of acupuncture, 
CHM and a randomised controlled clinical trial of CHM formula (RCM-104) in the 
management of obesity. The reviews presented in this thesis were conducted 
according to the instructions specified in the Cochrane Handbook for Systematic 
Reviews of Interventions 5.1 (Higgins, 2011). The SRs were focused on the literature 
of contemporary clinical trials published from 1970 to the present.  
Chapter 5: Systematic review of acupuncture in the management of obesity  
This chapter reports the results of meta-analysis of a systematic review on RCTs of 
acupuncture for the management of obesity.  
Chapter 6: Systematic review of Chinese herbal medicine in the management of 
obesity 
This chapter reports the results of meta-analysis of a systematic review on RCTs of 
CHM for the management of obesity.  
29 
 
Chapter 7: Evaluation of efficacy and safety of a CHM formula (RCM-104) in the 
management of obesity: A randomised, placebo-controlled clinical trial 
This chapter reports the results of a clinical trial of the CHM formula (RCM-104). 
Chapter 8: General discussion and future directions 
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Chapter 2. Literature review: Western medicine 
perspectives 
2.1 Introduction 
This chapter outlines the advanced knowledge accumulated through a Western-
based literature review concerning obesity. The following areas are discussed: 
diagnosis, classification, differential diagnosis, pathogenesis, management, 
prognosis, prevention and new directions in the treatment of obesity.  
2.2 Diagnosis of obesity 
The diagnosis of obesity is made by observation and comparing the patient’s weight 
to ideal weight charts. In addition, many doctors and obesity researchers refer to the 
BMI, which uses a height-weight relationship to calculate an individual’s ideal weight 
and personal risk of developing obesity-related health problems. Physicians may also 
obtain direct measurements of BF content by using callipers to measure skin-fold 
thickness.Skin-fold measurements are generally taken at specific sites on the right 
side of the body. The tester pinches the skin at a specific location and pulls the fold 
of skin away from the underlying muscle so only the skin and fat tissue is being held. 
Special skin-fold calipers are then used to measure the skin-fold thickness in 
millimeters. Two measurements are recorded and then the results are averaged 
(Rostami et al., 2013). The most accurate means of measuring BF content involves 
immersing a person in water and measuring relative displacement; however, this 
method is very impractical in general practice and is usually only used in scientific 
studies requiring very specific assessments (Davies et al., 2010) 
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Doctors also note how a person carries excess weight on the body. Studies have 
shown that this factor may indicate whether or not an individual has a predisposition 
to develop certain diseases or conditions that may accompany obesity. ‘Apple-
shaped’ individuals, who store most of their weight around the waist and abdomen, 
are at greater risk for cancer, heart disease, stroke, and diabetes compared with 
‘pear-shaped’ people, whose extra pounds settle primarily in their hips and thighs. 
2.2.1 Symptoms of obesity 
The major symptoms of obesity are excessive weight gain and the presence of large 
amounts of fatty tissue. Aspects of the patient’s body and activity levels that are 
taken into account when diagnosing obesity include: size of the body frame, difficulty 
in doing daily activities, lethargy, breathlessness, disproportionate facial features, 
breast region adiposity (sagging fat cells) in males, large belly (abdomen), sometimes 
marked with white or purple striations, male external genitalia may appear 
disproportionately small, early arrival of puberty, flabby fat in the upper arms and 
thighs, knock-knees (genu valgum) (Salem et al., 2014). 
Obesity can also give rise to several secondary medical conditions, including: arthritis, 
orthopaedic problems, such as lower back pain, hernia, heartburn, adult-onset 
asthma, gum disease, high cholesterol levels, gallstones, high blood pressure, 
menstrual irregularities or cessation of menstruation (amenorrhea), decreased fertility, 
and pregnancy complications, shortness of breath that can be incapacitating, sleep 
apnoea and sleeping disorders, skin disorders arising from the bacterial breakdown 
of sweat and cellular material in thick folds of skin or from increased friction between 
folds, emotional and social problems (Salem et al., 2014). 
. 
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2.2.2 Description of obesity 
Obesity traditionally has been defined as a weight that is at least 20% above the 
weight corresponding to the lowest risk of illness, disability, and death rate for 
individuals of a specific height, gender, and age. Mildly obese is defined as 20%-40% 
over an ideal weight; the moderately obese range is 40-100% over an ideal weight; 
severe or morbid obesity is 100% over an ideal weight. More recent guidelines for 
obesity use a measurement called BMI, which is calculated by dividing the BW in 
kilograms (kg) by the height in metres (m) squared. A BMI of 25.9-29 is considered 
overweight, whilst a BMI over 30 is considered obese.  
Measurements and comparisons of waist and hip circumference (HC) also provide 
information regarding risk factors associated with weight. It has been shown that the 
higher the ratio of waist and HC the greater the chance for weight-associated 
complications. Callipers are used to measure skin-fold thickness to determine 
whether tissue is muscle (lean) or adipose tissue (fat) (Cleator & Wilding, 2003). 
2.3 Pathogenesis of obesity 
Several extensively investigated physiological mechanisms contribute to the 
pathogenesis of obesity. These pathogenic mechanisms are described below. In 
addition, a discussion of the aetiology of obesity is included. 
Obesity is a common nutrient obstacle disease: it causes the body to store excess fat, 
thus increasing weight. Clinical findings demonstrate obesity is associated with 
hyperhidrosis, bradykinesia, muscle weakness, fatigue, low work efficiency, and 
spiritual and psychological abnormalities. Simple obesity is often associated with 
sugar and fat metabolism disorders (Liou et al., 2007), whereas secondary obesity 
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pathogenesis is more complicated, although there are greater possible therapeutic 
approaches for an improved management with secondary obesity (Chiumello et al., 
1993). 
An average-sized person has between 30 and 35 billion fat cells.In an obese 
individual, the size and quantity of fat cells increases substantially. When a person 
increases in weight, fat cells first increase in size. After sustained fat increases, the 
fat cells increase in quantity (Arner, 2005). 
There are many underlying factors involved in the development of obesity. In recent 
years, different views and causes of obesity have been put forward; however, there is 
no single argument or theory that can accurately explain how obesity leads to 
increased onset of specific diseases. It remains unclear as to why some individuals 
have a higher tendency towards obesity regardless of their environment and lifestyle. 
Gender, age, race, and socioeconomic status often play a role in weight gain, but do 
not tell the whole story. The occurrence of excess weight and obesity is more 
common amongst women, ethnic minorities, elders, those of lower socioeconomic 
status, and of low levels of education (Jebb, 1997). 
2.3.1 Hereditary factors 
Genetic and environmental factors interact to regulate weight. In general, obesity 
heritability is estimated to be between 40% and 70%. Rare variants in the coding 
sequences of major candidate genes account for an obese phenotype in 5% to 10% 
of individuals (McPherson, 2007). More than 244 genes have been found to strongly 
affect obesity when over-expressed or deleted in mice (McPherson, 2007). These 
genes have been divided into four broad categories (Table 2.1).  
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Table 2.1: Gene categories and basic functions 
Gene category Function (McPherson, 2007) 
1 Regulation of food intake by molecular signalling in the 
hypothalamus and hindbrain by signals originating in adipose 
tissue, gut and other organs 
2 Regulation of adiposity differentiation and fat storage 
3 Regulation of spontaneous exercise activity 
4 Influence of basal and postprandial thermogenesis 
 
Human epidemiological studies indicate that being overweight and obese runs in 
families. When one parent is obese, the child obesity rate is about 50%. When both 
parents are obese, the children obesity rate increases to 80%. For obese people who 
adopt children there is no high morbidity from genes, but obesity is due to living 
habits. Studies involving adopted children have shown that adopted children’s BW or 
development of obesity is more closely related to their biological parents, rather than 
their adoptive parents (Carnell & Wardle, 2009). 
Although the genetic factors influencing appetite and eating behaviour have long 
been considered, the exact mechanism of genetic factors leading to obesity is not 
clear. High birth weight, maternal diabetes and obesity in the family are factors that 
may influence the degree of obesity. Energy consumption differences are also likely 
to be partially due to genetic factors. Individuals with a lower metabolic rate are more 
likely to put on weight. Studies have shown that there have been similarities in 
metabolic rates among family members. 
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There is a critical period for the development of excessive weight gain. The amount 
of time a child is breast-fed is negatively correlated with the development of obesity in 
later life. This may be related to the physiological factors mediated in breast milk. 
Adolescence is another crucial development period of obesity. The risk of developing 
persistent obesity in middle age is higher in obese adolescents compared with obese 
children (Jebb, 2004).  
In 1994, the obese gene (ob) was cloned in mice. Shortly thereafter, the human 
homologue of this gene was cloned and the protein named leptin. 
 
 
Figure 2.1: Molecular structure of leptin (Bahrami et al., 2013). 
 
Leptin is a hormone whose main physiological function is adjusting energy 
consumption and weight loss by regulating food intake and fat storage (Clapham et 
al., 2001b). Leptin is expressed by adipocytes, and then travels through the blood 
brain barrier where it interacts with leptin receptors in the brain. The downstream-
effects of leptin-binding are reduced energy consumption, decreased appetite, 
restrained fat synthesis and reduced weight (Clapham et al., 2001a).  
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Figure 2.2: Central effects of leptin (Sharma et al., 2002). 
 
The identification of leptin’s mechanism of action has been instrumental in increasing 
our understanding of the biological basis of obesity and energy metabolism (Oh et al., 
2009). While research into leptin is useful, most obesity is not due to changes in 
leptin concentration. In many obese individuals, there is a higher leptin content found 
in the blood, which implies the presence of leptin resistance in the BF. Recently, a 
single gene has been identified as being related to congenital deficiency in leptin or 
leptin receptors (Funahashi et al., 2003); however, as it has been confirmed that 
dozens of genes are involved in the development of human obesity (Elbers et al.), it 
is unlikely that this defect is the common cause of obesity. Those with a gene defect 
in leptin will develop leptin-resistant obesity. 
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2.3.2 Dietary factors 
On a global level, the development of economies, the improvement of living 
standards, and the social environment have all been associated with an increase in 
the incidence of obesity (Bessesen et al., 2008). For the individual, there is a trend 
for obese people to overeat, engage in poor living habits, and insufficient exercise. 
The average adult is able to maintain BW via homeopathic circuits to regulate BF 
stores; however, when there is an excess consumption of unnecessary energy, it is 
converted into adipose tissue, causing weight gain (Song et al., 2011). These factors 
combine to produce decreased energy consumption compared with caloric intake 
that leads to the accumulation of fat. 
The dietary content of food, especially fat, plays a role in metabolism. Many foods 
containing carbohydrates, fats and proteins are essential for good health, but if the 
quantity ingested is in excess of the body’s ability to burn these calories after the 
nutrients are absorbed, there will be plentiful building blocks that contribute to the 
synthesis of fat, which then leads to obesity. Generally, a high fat, high calorie diet, 
with few vegetables, barleys and grains, is associated with obesity. High intake of salt 
and fried or oily foods also contributes to obesity. The production of fatty tissue in the 
body, particularly brown fat, directly affects energy metabolism balance. In addition, 
unhealthy diet habits such as overeating, frequent intake of fast food and not 
chewing food properly also leads to obesity (Bray & Popkin, 1998). 
2.3.3 Lifestyle and environmental factors 
Increased living standards have led to a change in exercise and eating patterns. 
Apart from an increase in the amount of food intake, there has been an increase in 
consumption of food and drinks containing high fat and sugar and a decrease in 
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exercise. Many widely available foods are high in complex carbohydrates, leading to 
the phenomenon of passive over-consumption (Wilding, 2006). High fat foods cause 
subtle changes in metabolism, compromising the body’s ability to burn fat. Increase 
in alcohol intake can also contribute to obesity. Although alcohol does not contain 
nutrition, every gram provides seven kilocalories of heat energy in the body. 
Changes in lifestyle over the past several decades have affected people’s physical 
activity. As the standard of living rises, people become accustomed to comfortable 
living conditions; the lack of participation in sports and exercise contribute to obesity. 
Leisure activities (for example: watching TV and playing computer games), have 
resulted in a decline in daily physical activities by the general population (Pietrobelli, 
2005b). Furthermore, the development of technology reduces the requirement for 
manual labour, resulting in an increase in sedentary lifestyles (Wilding, 2006). The 
increase in physical inactivity contributes to the rise in the occurrence of obesity 
(Lucas & Platts-Mills, 2006). Apart from spending more time in leisure activities which 
require little exertion, there has also been a decrease in sleep time. The decrease in 
sleep time is a high-risk factor that can contribute to obesity. Taken together, the 
global epidemic of obesity is driven by an environment that encourages overeating 
and a lifestyle that limits physical activity, resulting in a tendency towards positive 
energy balance (Poortinga et al., 2011). 
2.3.4 Medical conditions and medication factors 
Obesity at times manifests due to underlying medical conditions or medical 
treatments (Jebb, 1997). Among them are physiological factors including an 
abnormal satiety centre resulting in severe disease; rare genetic endocrine disorders 
such as Prader-Willi syndrome; diseases that stimulate the secretion of endogenous 
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cortical hormones, such as in Cushing’s syndrome, hypothyroidism, exogenous 
glucocorticoid management of other medical conditions, and selected drugs, 
including insulin, oral glucose-lowering drugs, contraceptive medications and certain 
antidepressants. Psychological factors can also influence the development of obesity.  
2.3.5 Smoking factors 
Research has confirmed that smoking and BMI are inversely correlated. People who 
smoke tend to have a lower BMI. Weight gain is a common side effect of cessation of 
smoking. It has been shown that smoking can reduce high density lipoprotein (HDL), 
increase blood triglycerides, lower density lipoprotein (LDL) content, and promote 
high blood pressure (Duncan et al., 2010).  
2.3.6 Social factors 
Social and cultural factors, including socioeconomic status and education level are 
related to the incidence of obesity. Obesity rates are higher among the lower social 
economic groups and less educated individuals (Flodgren et al., 2010). In 
communities of lower socioeconomic status, the shortage of financial resources may 
limit the types of affordable food – high adipose and high carbohydrate foods are 
usually much less expensive. As a result, grocery stores in poorer communities tend 
to stock these cheaper choices of food, thus limiting food choices. In addition, in 
areas of lower socioeconomic status, there is less awareness regarding obesity and 
fewer opportunities to join support groups, sports or activities. It has been shown that 
those of high socioeconomic status in developing countries also have a high rate of 
obesity due to the introduction and availability of a high fat Western diet (Du & 
Feskens, 2010). 
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The prevalence of obesity is correlated with years of education. Research shows that 
there is a lower rate of obesity among individuals who completed a technical college 
degree and above. A lower degree of education may lead to a lack of understanding 
concerning the best way to maintain a balanced diet and the beneficial effect of 
sports. The difference in economic status difference may be associated with a 
greater or lesser degree of obesity among group members (Martín et al., 2008). 
Recently, research has shown that there is relationship between the development of 
obesity and the infrastructure and design of suburbs (Poortinga et al., 2011). Several 
characteristics of the suburban environment, such as low density population, poor 
street connectivity and relative lack of footpaths, can have an effect on the increase 
or decrease in the risk of obesity. Compared to the suburbs, the inner city population 
show higher rates of obesity, despite living in a bigger community with excellent 
streets of where there is dense connectivity and footpaths along most streets 
(Vandegrift & Yoked, 2004). 
2.3.7 Psychological factors 
The pressure of social competition is increasing. For some obese patients, mental 
stress and psychological stress can stimulate appetite hyper-function to ease 
pressure, thus resulting in the occurrence of obesity. Heshka and Allison (2001) 
published a study showing that hypertension is related to obesity. They reported that 
depressed patients show impeded characteristics when they eat and drink too much, 
which may cause or aggravate the occurrence of obesity (Heshka & Allison, 2001). 
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2.3.8 Central nervous system factors 
Energy balance requires an ability of the brain to detect the status of energy stores 
and match energy intake with expenditure. The brain receives signals from the 
gastrointestinal tract through sensory nerves and the circulation as demonstrated in  
Figure 2.3 (Schwartz, 2000). Neurons involved in the homeostatic regulation of 
feeding are located mainly in the hypothalamus and brainstem. Changes in nutrient 
composition, osmolality and pH, are transmitted to the medulla in the brainstem, the 
nucleus of the solitary tract (NTS) and the dorsal motor vagal nucleus. Projections 
from the NTS innervate the paraventricular (PVN), dorsomedial (DMN), and arcuate 
nuclei of the hypothalamus and the lateral hypothalamic area (LHA), central nucleus 
of the amygdala and bed nucleus of the striaterminalis. 
 
Figure 2.3: Signals such as leptin and insulin are produced by fat mass and circulate 
in the blood. They enter the brain in the hypothalamus. Neuroendocrine signals from 
the stomach, the gastrointestinal system and the liver are sent to the brain to regulate 
the appetite and energy balance (adapted from Schwartz 2000). 
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The function of the ventromedial nucleus (VMN) is to stimulate the feeling of fullness 
(satiety) after sufficient food intake and therefore decrease appetite. The LHA, on the 
other hand, functions to stimulate appetite. These nuclei work in opposition to keep a 
dynamic state of balance between hunger and satiety. Through this balance, appetite 
is regulated and food intake is adjusted so that excessive weight gain is avoided. 
When the balance between these two brain centres is disturbed, there is a resulting 
change in the pattern of satiety and hunger. An example of this disturbance is the 
refusal to eat in anorexic conditions (Chapman et al., 2012). 
Leptin concentration is increased with increasing amounts of adipose tissue; 
therefore, leptin levels fluctuate with weight gain such that there is more leptin 
detected as obesity increases (Ahima et al., 2000). Obese individuals typically have 
elevated leptin levels (Myers Jr et al., 2010). In the brain, the arcuate hypothalamic 
nucleus contains leptin receptors that in turn thus regulates neuropeptide expression 
(Ahima et al., 2000; Myers Jr et al., 2010). The neuropeptides cholecystokinin, 
somatostatin, suppression of stomach element, endorphins, neuropeptide Y, and 
catecholamines regulate the peripheral and central nervous system response to the 
balance between food intake and calorie usage (Kokkoris & Pi-Sunyer, 2003). Diet-
induced obesity in rodents is characterised by increased leptin levels, reduced leptin 
transport across the blood brain barrier, and impaired leptin signalling in the 
hypothalamus (Ahima et al., 2000; Myers Jr et al., 2010).  
2.3.9 Endocrine system factors 
Obesity produces major changes in endocrine function with a strong association 
clearly evident with T2D  and dyslipidemia (Kokkoris & Pi-Sunyer, 2003). In the case 
of diabetes, insulin, a hormone produced by islet B cells in the pancreas, is secreted 
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in response to meals. The function of insulin is to increase the storage of glycogen, 
fat and protein by promoting liver cell glycogen synthesis, restraining sugar dysplasia, 
promoting fat cells to absorb glucose and synthetic fat, and inhibiting fat 
decomposition (Steppan & Lazar, 2002). In obesity, the levels of blood insulin are 
increased. Often obesity and high insulin hematic disease coexist. Obesity also leads 
to insensitivity to insulin that influences the metabolism of sugars. Because obesity is 
often caused (although not always) by the disruption of the balance of food intake vs 
calorie expenditure, insulin may be maintained at a high level. In the long term, this 
high level of insulin leads to insulin resistance after which hyperinsulinemia may 
occur (Steppan & Lazar, 2002). 
2.3.10 Brown adipose tissue factors 
Brown adipose tissue (BAT) is a kind of adipose tissue that is mainly distributed 
subcutaneously and viscerally around corresponding white tissue. Brown adipose 
tissue distribution range is limited, with distribution limited to the interscapular area, 
on the back of the neck, armpits, mediastinum and renal region. BAT appearance is 
shallow brown, with a relatively small cell volume. Brown adipose tissue functions as 
a regulator of body heat around the organs. Obesity and brown adipose tissue are 
related. With obesity, there is a change in BAT, often, leading to a dysfunction of heat 
production (Kuhn et al., 2012). The nature of BAT innervation has been shown and 
the presence of an auto regulatory loop between BAT and the hypothalamic 
paraventricular nuclei via the sensory and sympathetic nervous systems has been 
delineated. 
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2.4 Assessment of obesity 
Although many obese people are monitored for chronic diseases in a clinical setting, 
preliminary weight assessment is often ignored. During any clinical examination, the 
patient’s height, weight and BMI should be noted and taken into consideration when 
assessing any condition. Equally as important is the need to record personal medical 
and family history, symptoms, and complications. The obese patient’s history and 
approach to weight loss is useful when considering social history and mental state. 
For an obese patient with a stable weight, physical activity and food intake should be 
recorded (Hawkesworth, 2011). 
In addition to patient history, further critical medical tests are required when 
assessing an obese patient. Overnight fasting glucose measurement is essential. If 
there is an observed increase shown with a fasting glucose test, further tests are 
required to determine whether the patient has or is at risk for diabetes. Measuring the 
concentration of blood lipids, triglycerides, high-density lipoprotein cholesterol 
(HDLC) and total cholesterol, in particular, allow an objective calculation of the 
probability of cardiovascular events. Non-alcoholic fatty liver disease and renal 
function are evaluated by measuring plasma urea and electrolytes. Thyroid function 
tests should rule out myxedema. An electrocardiogram detects left ventricular 
hypertrophy (Hawkesworth, 2011, 2013). 
It is important to understand what it means to have a ‘healthy weight’. An accurate 
measure of the percentage of BF contributes to the diagnosis of obesity. There are 
two widely used methods: the height/weight table and the BMI. Other ways to 
estimate BF and BF distribution include skin-fold thickness measurement and the 
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calculation of WC, waist hip ratio, and technologies, such as ultrasound, computed 
tomography and magnetic resonance imaging (MRI) (Hawkesworth, 2013). 
2.4.1 Height/weight charts and body mass index  
Most people are familiar with height/weight tables. This table was first developed in 
1943 by the Metropolitan Life Insurance Company based on their policy holders’ 
weight data as it related to disease and mortality (Rudin et al., 2007). These types of 
tables provide an indication of normal weight correlated with height for Caucasians. 
For many decades, these tables have been commonly used by most healthcare 
practitioners to make an initial diagnosis of obesity because the calculation used is 
easy and no special equipment is required. A limitation of this method is that there 
are several versions of these tables, and there is some debate concerning which 
table is most appropriate. Finally, a major limitation of these tables is that they are 
based on population data and should only be used as a general guide. If a person 
has increased muscle mass, rather than fat, this person runs the risk of being 
diagnosed as obese, when in fact the person is not (Hawkesworth, 2013).  
Because of the issues associated with the height/weight charts, BMI is the 
measurement of choice for many doctors and researchers. WHO uses the BMI 
calculation to define overweight and obesity. BMI is calculated using a mathematical 
formula: person’s BMI (kg/m2) is equal the weight (kg) divides the square of height 
(m). BMI measurements, however, create some of the same problems as the 
height/weight table. Not everyone agrees with the cutoff point for ‘healthy’ and 
‘unhealthy’ BMI range. BMI may not be an accurate measure of BF body. For 
example, in some athletes and pregnant women the BMI does not provide accurate 
information concerning BF ratio. However, like the height/weight table height, BMI is 
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a useful general guideline and provides a good estimator of fat for most adults 19 to 
70 years old. 
BMI provides a useful measure of overweight and obesity, because it is the same for 
both sexes and all ages of adults. At the same time, BMI is characterised as a rough 
guide, because it may not correspond to different individuals at the same degree of 
obesity. A BMI below 18.5 is considered underweight. Healthy weight is defined as a 
BMI between 18.5 and 24.9 and is considered normal. A BMI between 25 and 29.9 is 
defined as ‘pre-obese'. Above a BMI of 29.9, there are three classes of obesity: Class 
1 (BMI 30-34.99), Class 2 (BMI 35-39.99) and Class 3 (BMI greater than 40). The risk 
of disease increases with BMI (and WC) as shown in the table 2.2 (Hawkesworth, 
2013).  
Whilst BMI is useful as rough guide when dealing with adults, the measurement of 
childhood obesity is challenging. There is an increase in overweight and obese 
children between the ages of 5 to 14. Childhood obesity is measured according to 
age, weight and a comparison with children of similar age and gender (Atkinson, 
1998; Esposito et al., 2013). The WHO has developed a child growth standards chart 
that includes BMI for infants to young children aged 5 (Pulgarón, 2013; Rolland-
Cachera, 1993). BMI ranges for children and adolescents take into account the 
normal differences between boys and girls and the amount of fat at different ages.  
2.4.2 The classification of adult obesity for the Asia-Pacific region 
Depending on the geographic location, there is disagreement between the 
international standard and region-specific BMI cut-off points (Table 2.2). For example 
when the Asia-Pacific region is compared to the international scale, there is overall a 
good correlation between the categories of underweight; however, there are 
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differences in BMI cut-off in the normal and overweight ranges. The international cut-
off for the normal range is 18.50-24.99, whereas the Asia-Pacific rim has a range of 
18.50-22.99, thus having a range that is narrower by two BMI measures. The 
differences in ranges become more pronounced in the obese range with the 
difference becoming more than 5 BMI index points. Therefore, individuals begin to be 
considered overweight or pre-obese at lower BMIs in the Asia-Pacific population 
(Hawkesworth, 2011, 2013). As Asian populations develop negative health 
consequences at a lower BMI than Caucasians, some nations have redefined 
obesity; the Japanese have defined obesity as any BMI greater than 25 (Kanazawa 
et al., 2005) while China uses a BMI of greater than 28 (Wei & Xie, 2002). 
 
Table 2.2: The classification of adult underweight, overweight and obesity according 
to BMI (Adapted from Haththotuwa et al., 2013). 
Classification   BMI(kg/m²) 
 International, the (principal) 
BMI cut-off points  
In Asia-Pacific Region, the 
BMI cut-off points 
Underweight <18.50 <18.50 
Severe thinness <16.00 <16.00 
Moderate thinness 16.00-16.99 16.00-16.99 
Mild thinness 17.00-18.49 17.00-18.49 
Normal range 18.50-24.99 18.50-22.99 
Overweight ≥25.00 ≥23.00 
Pre-obese 25.00-29.99 23.00-24.99 
Obese ≥30.00 ≥25.00 
Obese Class I 30.00-34.99 25.00-29.99 
Obese Class II 35.00-39.99 ≥30.00 
Obese Class III ≥40.00 ≥40.00 
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2.4.3 Waist circumference (WC) 
WC provides an additional indicator of BF distribution, which can identify patients 
who are at increased risk for obesity-related cardio-metabolic disease. The current 
WC cut-off points for determining health risk were derived by regression from an 
‘obese’ BMI. When the relative risk relative to normal weight and WC is calculated, 
men with a WC of 102 cm or less and women with a WC of 88 cm or less are at a 
reduced risk in the obese categorisations as compared with men and women with 
increased WC. As such, these are unlikely to affect clinical management when BMI 
and other obesity-related cardio-metabolic risk. Therefore, the clinical usefulness of 
measuring WC, when risk is based on the currently accepted guidelines, is limited 
(Misra et al., 2005).  
Despite this limitation, WC measurement provides additional information to help the 
clinician determine which patients should be evaluated for the presence of cardio-
metabolic risk factors, such as dyslipidemia, and hyperglycemia. In addition, 
measuring WC can be useful in monitoring a patient’s response to diet and exercise 
treatment, because regular aerobic exercise causes a reduction in both WC and 
cardio-metabolic risk, without a change in BMI (Lin et al., 2012). Further studies are 
needed to establish WC cut-off points that assess cardio-metabolic risk that are not 
adequately captured by BMI and routine clinical assessments. Selection of the most 
appropriate WC values will be complex because they are likely to be influenced by 
sex, race/ethnicity, age, BMI, and other factors. Nonetheless, it should be possible to 
determine more useful WC cut-off points than are currently recommended, by 
carefully reviewing published data and re-evaluating data sets available from existing 
population studies. These additional analyses will define the future role of WC 
measurement in clinical practice (Bao et al., 2008). 
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2.5 Management of obesity 
Obesity is a preventable and treatable disease (Graves, 2010). Treatment strategies 
mainly include managing obesity and its complications, as no cure has been found to 
date. It is generally understood that current pharmacotherapy approaches do not 
prevent the progression of obesity. Furthermore, pharmacotherapeutic drugs have 
been associated with significant adverse events such as potential disturbances of 
cardiac rhythm, or pharyngeal candidiasis, dryness of the mouth, nausea and 
heartburn, headache and insomnia, and skin bruising. They also precipitate the risk 
of cardiovascular diseases. Since there is no cure for obesity, symptom management, 
quality of life improvement and reducing exacerbations have become the primary 
treatment objectives (Lean, 2003). 
Treatment of obesity depends primarily on overall health. To be successful, any 
treatment must affect lifelong behavioural changes rather than short-term weight loss. 
Daily dieting, in which weight is repeatedly lost and regained, has been shown to 
increase a person’s likelihood of developing fatal health problems rather than if the 
weight had been lost gradually or not lost at all (Melin et al., 2005).  
2.5.1 Management of obesity by pharmacotherapy 
According to standards published by the US National Institute of Health and the 
European Union, the use of pharmacotherapy is indicated for patients with a BMI of 
at least 27 kg/m2 with morbidity (other medical conditions such as high blood 
pressure, diabetes, high blood cholesterol) that puts them at risk for developing heart 
disease and in people with a BMI of at least 30 kg/m2. In Asia, where the BMI is 
considerably lower than in the West, there have been concerns regarding increased 
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risk of diseases at a lower BMI. It was proposed that the BMI standards for obesity 
pharmacotherapy be reduced in Asia (Eby & Colditz, 2008). 
Medication therapy significantly improves weight loss as compared with placebo in 
most tests. In general, patients can expect a weight loss of 8% to 10% from the 
baseline via the regular intake of medications. However, the side-effects of the drugs 
have to be taken into consideration prior to the commencement of treatment. 
Medications should only be used as an adjunct to a prescribed diet modification and 
an exercise program (Dickerson & Carek, 2009). If the desire of the patient to take 
obesity medication is based on cosmetic reasons, medication should be withheld. 
The mechanism of action of weight loss drugs falls into two broad categories: those 
that affect neurotransmitter levels and those that influence fat absorption. Anti-obesity 
medications that suppress appetite do so by increasing the level of neurotransmitters 
at the junction (called a synapse) between nerve endings in the brain (Bray & 
Greenway, 2007). Appetite-suppressant drugs that work by increasing levels of 
serotonin, nor epinephrine, and dopamine, fall into the neurotransmitter category. 
These are brain chemicals that control feelings of fullness. The medications also 
decrease appetite and create a sensation of fullness. The second category works by 
inhibition of a pancreatic enzyme lipase that leads to a reduction of fat absorption in 
the intestines as shown in Figure 2.4 (Schwartz 2000). Both drug categories have 
side-effects, which will be discussed below in relation to each weight loss drug. 
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Figure 2.4: Mode of actions of pharmacotherapies: Central and peripheral functions 
associated with anti-obesity pharmacotherapies (adapted from Schwartz 2000). 
 
2.5.1.1 Anti-obesity drugs 
a) Fen/Phen 
Phentermine (Fastin, Adipex P, Ionamin, Oby-trim) (the phen of fen/phen) was the 
first class (category) of medication used for weight control that mimicked the 
sympathetic nervous system. Phentermine suppresses appetite by causing a release 
of norepinephrine. This norepinephrine increase acts to stimulate the central nervous 
system to decrease appetite. Common side-effects of phentermine include headache, 
insomnia, irritability, and nervousness. Phentermine has been on the market for 
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noted that Sibutramine was withdrawn from the market in October 2010 because 
clinical trial data indicated that it is associated with an increased risk of heart attack 
and stroke (Bray & Greenway, 2007). The available evidence from RCTs failed to 
show significant benefit from Sibutramine (Padwal & Majumdar, 2007). 
 
 
Figure 2.7: Mechanisms of action and clinical effects of Sibutramine (Scheen, 2010). 
 
d) Belviq 
In June 2012, the FDA approved Belviq (lorcaserin hydrochloride-Fig.2.8) as a weight 
loss medication. The medication works by controlling appetite via the serotonin 
activation system. The medication is approved for patients who are obese (BMI >30) 
or overweight (BMI>27) with one weight-related health issue. The predominant side-
effects were headache and dizziness, as well as fatigue. In patients with diabetes, 
low blood sugar was also a concern when taking Belviq (Bray & Greenway, 2007). 
According to the FDA data, nearly half the patients using the medication lost at least 
5% of their starting weight, which is more than double that lost by patients in the 
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g) Mazindol (Mazanor, Sanorex) 
Mazindol (Mazanor, Sanorex) is a sympathomimetic amine as shown in Fig. 2.11, 
which is similar to amphetamine.The mechanism of action of the sympathomimetic 
amine in the treatment of obesity is not fully known. Mazindol is thought to act as a 
reuptake inhibitor of norepinephrine, dopamine and serotonin. Mazindol is used in 
short-term treatment of obesity, in combination with a regimen of weight reduction 
based on caloric restriction, exercise, and behaviour modification in patients with a 
BMI of 30, or in patients with a BMI of 27 in the presence of risk factors such as 
hypertension, diabetes, or hyperlipidaemia. It stimulates the central nervous system, 
which increases heart rate and blood pressure, and decreases appetite. Side-effects 
include restlessness or tremor, nervousness or anxiety, headache or dizziness, 
insomnia, dry mouth or an unpleasant taste, diarrhoea or constipation, impotence or 
changes resulting in decreased sex drive. Sympathomimetic anorectics (appetite 
suppressants) are used in the short-term treatment of obesity. Their appetite-
reducing effect tends to decrease after a few weeks of treatment. Because of this, 
these medicines are useful only during the first few weeks of a weight-loss program. 
Although the mechanism of action of the sympathomimetic in the treatment of obesity 
is not fully known, these medications have pharmacological effects similar to those of 
amphetamines. Mazindol is not currently available as a commercially marketed and 
FDA regulated prescription agent for the treatment of obesity, its only current 
approved use in the US being treatment of Duchenne muscular dystrophy (Colon-
Gonzalez et al., 2013). 
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absorption or digestion; reduce the desire for food and prompt the body to burn 
calories more quickly; and regulate the activity of substances that control eating 
habits and stimulate overeating (Heal et al., 2013). 
2.5.2 Surgical management 
Surgical management of obesity has been increasing. For individuals who are 
severely obese, dietary changes and behaviour modification may be accompanied by 
surgery. Although obesity surgery is less risky as of 2003 because of recent 
innovations in equipment and surgical technique, it is still performed only on patients 
for whom other strategies have failed and whose obesity seriously threatens their 
health. The National Institute of Health consensus has suggested the following 
guidelines for surgery in obese patients with a BMI of greater than 40 and patients 
with a BMI of greater than 35 who have serious medical problems such as apnoea 
that would improve with weight loss. Schizophrenia, personality disorders and 
uncontrolled depression are contraindications for surgery; medical doctors have to be 
very careful in the recommendation of the use of surgical treatment for patients’ 
eating disorders (Cannon & Kumar, 2009). 
Surgical procedures of the upper gastrointestinal tract are collectively called bariatric 
surgery. The initial surgeries performed were the jejunoileal bypass (where the small 
bowel is diverted to the large bowel, bypassing much of the surface area where food 
is absorbed). These procedures were fraught with problems and are no longer 
performed. Currently, procedures used include making the stomach area smaller or 
bypassing the stomach completely (Tessier & Eagon, 2008).  
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2.5.2.1 Restrictive surgeries 
These surgeries restrict the size of the stomach and slow down digestion. In the 
cases of making the stomach smaller, vertically banded gastroplasty, where the 
esophagus is banded early in the stomach, is the most common procedure. The 
other procedure is gastric banding, where an inflatable pouch causes gastric 
constriction. Changing the volume in the ring that encircles the stomach can change 
the amount of constriction (Tessier & Eagon, 2008). 
2.5.2.2 Malabsorptive/restrictive surgeries 
Gastric bypass causes weight loss by bypassing the stomach. These surgeries 
restrict the size of the stomach, but also bypass or remove part of the digestive 
system to decrease absorption of food/calories. The most common malabsorptive 
surgery is the Roux-en-Y gastric bypass, in which the stomach is stapled to create a 
small pouch, and then part of the intestine is attached to this pouch to decrease food 
absorption (Tessier & Eagon, 2008). Although these procedures are becoming 
routine, the mortality rate for these procedures is still between 0.5%-2%, with a 
significant incidence of complications. The risks of surgery include the usual 
complications of infection, blood clots in the lower extremities (deep vein thrombosis) 
and in the lungs (pulmonary embolism), and anaesthesia risk. Specific long-term 
risks related to obesity surgery include lack of iron absorption and deficiency 
anaemia. Vitamin B12 deficiency may also develop and lead to nerve damage 
(neuropathies). Rapid weight loss may also be associated with gallstones (Baker et 
al., 2009). 
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2.5.3 Other forms of therapeutic management of obesity 
2.5.3.1 Dietary management 
Diet management plays an important role in maintaining energy balance. As stated 
previously, obesity occurs when there is a positive energy balance. That is, when 
energy input exceeds energy expenditure. Diet monitoring, using a diary to record 
weight, food intake, and cooking and eating habits provides important insights to the 
patient and management team. Dietary management should be carefully monitored, 
and advice from a nutritionist or dietician provided, as it is important to maintain diet 
quality. The habit of just maintaining a low energy diet without considering nutritional 
factors may be detrimental to health. Furthermore, low energy intake may trigger the 
drive to eat, resulting in rebound weight gain (Ortega et al., 2011).  
Recently, strict diets such as the low-carbohydrate Atkins diet have become popular. 
These have been shown to have positive influence on blood lipid concentration, 
blood pressure, and blood sugar control (Rosado et al., 2011); however, these 
effects are generally short-term. The extent of the weight loss strongly depends on 
the patient’s ability to restrict their diet and maintain self-discipline against the intense 
physical desire to eat. Meal-replacement therapy has seen some success to assist in 
weight loss, but there is a danger of malnutrition in the long-term (Kadyrova et al., 
1987). 
2.5.3.2 Cognitive behavioural therapy 
Behaviour often contributes to an overeating episode. What appears to be an 
unexpected dietary lapse can be traced to a series of small decisions and behaviours. 
The behavioural chain also reveals where the individual can intervene in the future to 
prevent unwanted eating. For most individuals who are mildly obese, behaviour 
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modifications entail lifestyle changes they are able to make independently while 
being supervised by a family physician. Behaviour-focused treatment should 
concentrate on 1) what and how much a person eats, 2) how a person responds to 
food, and 3) how a person spends their time (Van Dorsten & Lindley, 2011). 
Binge eating disorder is characterised by persistent and recurrent episodes of binge 
eating without the regular use of inappropriate compensatory behaviours seen in 
bulimia nervosa (BN).Treating this aspect may involve keeping a food diary and 
developing a better understanding of the nutritional value and fat content of foods. It 
may also involve changing grocery-shopping habits (e.g., buying only what is on a 
prepared list and only going on a certain day), timing of meals (to prevent feelings of 
hunger, a person may plan frequent, small meals), and slowing down the rate at 
which a person eats (Van Dorsten & Lindley, 2011). 
Evaluating how a person responds to food may involve understanding what 
psychological issues underlie a person’s eating habits. For example, one person may 
binge eat when under stress, while another may always use food as a reward. In 
recognising these psychological triggers, an individual can develop alternate coping 
mechanisms that do not focus on food. Thus, the individual might avoid bringing 
cookies into the house or at least store them out of sight to reduce impulse eating 
(Butryn et al., 2011). 
Mildly obese persons may seek the help of a commercial weight-loss program (e.g., 
Weight Watchers). The effectiveness of these programs is difficult to assess, since 
programs vary widely, drop-out rates are high, and few employ members of the 
medical community. Programs that emphasise realistic goals; gradual progress, 
sensible eating, and exercise are very helpful and are often recommended by doctors. 
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Programs that promise instant weight loss or feature severely restricted diets are not 
effective and in some cases are dangerous (Milne, 2008). 
2.5.3.3 Exercise 
The National Health and Examination Survey (NHANES I) reported that people who 
engage in limited recreational activity were more likely to gain weight than more 
active people. Other studies have shown that people who engage in regular 
strenuous activity gain less weight than sedentary people. Making activity and 
exercise an integrated part of everyday life is a key to achieving and maintaining 
weight loss. Starting slowly and building endurance keeps individuals from becoming 
discouraged. Varying routines and trying new activities also keeps interest high. 
Physical activity and exercise help burn calories. The amount of calories burned 
depends on the type, duration, and intensity of the activity. It also depends on the 
weight of the person. A 200-pound person will burn more calories running 1 mile than 
a 120-pound person, because the work of carrying those extra 80 pounds must be 
factored in. Exercise as a treatment for obesity is most effective when combined with 
a diet and weight-loss program. Exercise alone without dietary changes will have a 
limited effect on weight. Regular exercise is an important part of a healthy lifestyle for 
maintaining a healthy weight for the long-term. Another advantage of regular exercise 
as part of a weight-loss program is a greater loss of BF versus lean muscle 
compared to diet alone (Okay et al., 2009). 
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Other benefits of exercise include: 
 Improved blood sugar control and increased insulin sensitivity (decreased 
insulin resistance); 
 Reduced triglyceride levels and increased ‘good’ HDL cholesterol levels; 
 Lowered blood pressure; 
 Reduction in abdominal fat; 
 Reduced risk of heart disease. 
It was recommended that before commencement, the program, with regard to its type 
and intensity, should be discussed in detail with health-care professionals. (Okay et 
al., 2009). 
2.5.3.4 Nutritional therapy 
Nutrition therapy involves changing dietary patterns, rather than eating less. More 
than half of daily calorie consumption should come from carbohydrates, while less 
than a quarter should come from fat. The rest of the calories should come from 
protein. Carbohydrates and proteins provide four calories in each gram, while fat 
provides nine calories in each gram. 
Daily diet should be focused on the particular nutritional content of foods, such as 
high fibre and unrefined complex carbohydrates, low fat and reduced intake of animal 
products and sugar. The nutrition therapy treatment program also encourages the 
intake of plenty of water and exercise every day. Some nutritional supplements 
should also be prescribed such as zinc, vitamin B, and chrome. Maintaining a food 
diary can be useful for monitoring and evaluating the condition of patients. A 
nutritional approach to a strict diet is based on the control of fat intake. Furthermore, 
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a combination of cognitive-behavioural methods and nutrition education can reduce 
anxious-depressive obstacles, improve eating behaviour and promote weight loss 
(Painot et al., 2001). 
Dietary therapy and sports are the main recommendations for weight loss; however, 
introduction and maintenance of these therapies is not easy. Behaviour therapy aims 
to strengthen changes in diet and physical activity to assist in weight loss and weight 
control in the long-term. In particular, therapy focuses on developing behaviour 
strategies to help self-control, stress management, problem solving, contingency 
management, cognitive reconstruction and social support. More evidence has 
emerged to show that obesity is not a simple problem of will power, but is a complex 
disorder. Effective strategies are needed to manage combinations of weight reduction 
methods and sports activities using behaviour interventions (Lang & Froelicher, 
2006). 
For individuals who are moderately obese, medically supervised behaviour 
modification and weight loss are required. While doctors will put most moderately 
obese patients on a balanced, low-calorie diet (1200-1500 calories a day), they may 
recommend that certain individuals follow a very-low-calorie liquid protein diet (400-
700 calories) for as long as three months (Du & Feskens). This therapy, however, 
should not be confused with commercial liquid protein diets or commercial weight-
loss shakes and drinks. Doctors tailor these diets to specific patients, monitor 
patients carefully, and use them for only a short period of time. In addition to reducing 
the amount and type of calories consumed by the patient, doctors will recommend 
professional therapists or psychiatrists who can help the individual effectively change 
his or her behaviour in regard to eating (Bray & Popkin, 1998). 
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2.5.3.5 Detoxification 
Some pathogenic elements from drug treatment (or chemical pesticides) may remain 
in the body, and leave deposits in fat cells. Detoxification is the obesity treatment that 
purifies these pathogenic factors. In addition, detoxification may also help prevent 
obesity. Detoxification treatments include fasting, colon therapy and other measures. 
Several kinds of plants, such as dandelion root or burdock, can be used in 
conjunction with a detoxification and fasting plan to improve the function of the liver in 
purifying the body of pathogenic factors. Detoxification treatment can also involve 
consumption of fruit juice diluted with water (Zimniak, 2008). 
2.5.3.6 Fasting 
Fasting is a very effective way of losing weight as it can help to reduce calories to a 
major degree. Fasting requires a person to abstain from food, sometimes even water, 
resulting in weight loss. This type of fasting does improves the digestive system as it 
allows the digestive organs to have a rest. Furthermore, it helps eliminate pathogenic 
factors from the body. It also helps us lose weight in a healthy and sustainable way. 
This method is safe because it does not require any drugs to lose weight. It also does 
not require strenuous exercise. This is a simple method of exercising self-control 
(Stewart et al., 1966; van Wijk et al., 2003). At the same time, the outcome of 
supplemented fasting may be improved by giving patients  a well-supervised regimen 
of nutrition education, exercise, and behavior modification (O'Shea et al., 1994). 
2.5.3.7 Colon therapy 
Colon therapy uses water to flush out excess waste in the colon, which cleanses the 
body internally, eliminates pathogenic factors and assists in attaining total health, 
well-being and vitality. Certain pathogenic factors such as chemicals and pesticides 
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can build up in the body. These pathogenic factors need to be cleared away as part 
of a dietary and exercise treatment program for obesity. Colon therapy regimens are 
also useful in preventing obesity from returning. The human gastrointestinal tract 
contains hundreds of thousands of different types of intestinal bacteria. Intestinal 
bacteria play an important role in the digestion of food supply for nutrition absorption 
through the intestine. Colon treatment involves the use of a special mineral water 
formula to cleanse the colon to help reduce weight (Norfollia, 2002). 
2.5.3.8 Ayurvedic medicine 
Ayurveda describes a set of complex clinical disorders, collectively called prameha, 
that are characterised by frequent abnormal micturition. The clinical conditions 
associated with prameha correlate in many ways with obesity. The etiology, 
classification, pathogenesis, and management of prameha are discussed at length 
and in detail in Ayurvedic texts. The theoretical background and comprehensive set 
of strategies Ayurveda utilises to treat prameha may be valuable in managing obesity 
in an efficacious and cost-effective manner (Sharma & Chandola, 2011). 
Ayurvedic medicine treatment includes dietary changes and herbal treatment. Patki 
(et al. 1990) showed that India’s herbal treatment led to significant weight loss, 
compared to those in the placebo group. In many traditional schools of medicine it is 
claimed that a balanced modulation of several targets can provide a superior 
therapeutic effect and decrease in side-effect profile compared to a single action from 
a single selective ligand, especially in the treatment of certain chronic and complex 
diseases, such as obesity (Paranjpe et al., 1990).  
A wide array of medicinal plants and their active constituents play a role in the 
prevention and treatment of obesity. Salacia roots have been used in Ayurvedic 
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medicine since antiquity, and have been extensively consumed in Japan, the United 
States and other countries as a food supplement for the prevention of obesity. The 
evidence suggests that this unique traditional medicine fulfills a multiple-target 
strategy in the prevention and treatment of obesity. Although toxicological studies 
have suggested minimal adverse effects of the herbal medicine in rodents, a clinical 
trial is crucial to further confirm the safety of Salacia roots. In addition, further 
mechanistic studies are necessary in order to allow a better understanding of how 
use of Salacia root may interact with other therapeutic interventions (Li et al., 2008). 
2.5.3.9 Hypnotherapy 
Research on the efficacy of hypnosis in the treatment of eating disorders has 
produced mixed findings. This is due in part to the interplay between the 
characteristics of people with eating disorders and the phenomena of hypnosis 
(Sharma & Chandola, 2011). Hypnotherapy works on a subconscious level to 
regulate feelings, habits and deeply rooted behaviours. A person on a diet often fails 
in the conscious effort to change their eating habits as the problem is firmly anchored 
in the subconsciousness, which is difficult to access and change. Once the reason or 
time of overeating is identified, hypnosis can help in the treatment of obesity and 
increase personal health. Using hypnotic trance to control a person’s eating habits 
and hunger seems to be especially effective for the treatment of obesity when 
coupled with a diet and exercise program (Hinchliffe et al., 2010). 
2.5.3.10 Hydrotherapy 
Hydrotherapy is also known as spa pool therapy. It is a treatment program based on 
water. Hydrotherapy uses water buoyancy to help support the weight of the patients 
while exercising in a pool. Therefore, there is less stress on the joints and bones of 
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patients and patients are not affected by the feeling of overexertion during therapy. 
Hydrotherapy is an effective component to weight loss and is often recommended to 
patients who are overweight and suffering from the symptoms of obesity. Exercises 
performed in water alleviate the pressure that land exercises cause on the joints of 
overweight patients. An instructor will usually begin by having patients walk the pool 
floor and perform vigorous leg kicks while holding on to the pool’s wall or a kick board 
to maintain balance. As weight loss occurs and body strength increases, patients are 
usually able to increase endurance and perform a wider range of hydrotherapy 
exercises (Blake et al., 2008). 
Hydrotherapy has specific effects on body including: relief of pain, swelling & stiffness, 
muscle strengthening and maintenance, alleviating muscle spasm, increased range 
of motion in joints, improved circulation, cardio-vascular fitness (heart & lungs), 
increased tissue healing, increased speed of recovery. 
Those who are obese often struggle with exercise because excess weight places 
stress on joints and muscles; water helps avoid this problem by taking some of the 
body’s weight. Aquatic therapy is an ideal weight loss exercise program for people 
with obesity (Blake et al., 2008). 
2.6 Prognosis of long-term effects of obesity 
Obesity has a colossal impact on physical, mental, and social ill-health in many parts 
of the world. Without effective action, expanding waists in ageing populations and the 
associated health problems will present enormous financial burdens for future 
generations. The prevalence of obesity is already above the critical threshold of 15% 
set by WHO for epidemics needing intervention. The prognosis of successfully 
treating obesity may include the duration of increased weight, chances of 
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complications, probable outcomes, prospects for recovery, recovery period, survival 
rates, death rates, and other outcome possibilities.  
About 85% of dieters who do not exercise on a regular basis regain their lost weight 
within two years. In five years, the figure rises to 90%. Repeatedly losing and 
regaining weight encourages the body to store fat and may increase a patient’s risk 
of developing heart disease. The primary factor in achieving and maintaining weight 
loss is a lifelong commitment to regular exercise and sensible eating habits (Zamora 
et al., 2010). 
2.7 Obesity prevention 
Although experts agree that obesity prevention is important there is no structured 
framework. The effectiveness of different intervention strategies is not well-
documented. Obesity prevention has been integrated into community-wide programs 
preventing coronary heart disease. Although effective with respect to reduction in 
cardiovascular risk factors, these programs did not affect mean BMI of the target 
populations (Padwal & Sharma, 2010). Selective prevention directed at high-risk 
individuals (e.g. at children with obese parents) exhibited various degrees of 
effectiveness. However, at present, definitive statements cannot be made because of 
the limited number of studies as well as limits in study design. Finally, targeted 
prevention produced promising results in obese children when compared to no 
treatment; however, there are only very few long-term follow-up studies (Ells et al., 
2005). There is no clear idea about comprehensive interventions studying 
combinations of different strategies. It is tempting to speculate that predictors of 
treatment outcome (e.g. psychological and socio-demographic factors) may also 
serve as barriers to preventive strategies, but this has not yet been investigated. 
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Taken together, the prevention of obesity should become a high priority research 
goal. The early results of obesity prevention programs are promising. As well as 
health promotion and counselling, better school education and social support appear 
to be promising strategies for future interventions (Muller et al., 2001). 
It has been suggested that a key to preventing excess weight gain is monitoring fat 
consumption rather than counting calories. The National Cholesterol Education 
Program maintains that only 30% of calories should be derived from fat. Only one-
third of those calories should be contained in saturated fats (the kind of fat found in 
high concentrations in meat, poultry, and dairy products). Because most people eat 
more than they think they do, keeping a detailed food diary is a useful way to assess 
eating habits. Eating three balanced, moderate portion meals a day, with the main 
meal at midday is a more effective way to prevent obesity than fasting or crash diets. 
Exercise increases the metabolic rate by creating muscle, which burns more calories 
than fat. When regular exercise is combined with regular, healthy meals, calories 
continue to burn at an accelerated rate for several hours. Finally, encouraging 
healthy habits in children is a key to preventing childhood obesity and the health 
problems that follow in adulthood (Shimada et al., 2008). 
2.8 New directions in obesity treatment 
Obesity continues to be a major problem for global public health, affecting not only 
adults, but increasingly also adolescents and even young children. Moreover, obesity 
and diabetes are no longer limited to wealthy societies: rates are also rising in low- 
and middle-income countries (Mermel, 2004). Key issues in obesity treatment and 
prevention, require novel and interdisciplinary approaches and cutting-edge ideas 
that span child development, nutrition, behavioural sciences, economics, geography 
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and public health. Contributions suggest a sequence of steps that may result in new 
ways for addressing obesity at the personal as well as at the population level. First, a 
clear understanding of who becomes obese, where, and for what reason is needed. 
Second, the likely contributions to overeating by the brain, biology, economics and 
the environment need to be identified. Then, based on an understanding of disease 
aetiology and its distribution by geography and by social strata, targeted yet 
comprehensive strategies for obesity prevention and treatment for both individuals 
and groups need to be developed (Penny & Carryer, 2011). 
Another field of obesity research is the study of hormones, particularly leptin, which is 
produced by fat cells in the body, and ghrelin, which is secreted by cells in the lining 
of the stomach. Both hormones are known to affect appetite and the body’s energy 
balance. Leptin is also related to reproductive function, while ghrelin stimulates the 
pituitary gland to release growth hormone. Further studies of these two hormones 
may lead to the development of new medications to control appetite and food intake 
(Ruppert, 2011). 
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Chapter 3. Literature review: Chinese medicine 
perspectives 
3.1 Introduction 
This chapter will introduce the history of CM and modern research related to obesity. 
It will also discuss the theories and CM research regarding the pathogenesis, 
treatment and CM therapeutic mechanisms for the treatment of obesity. Finally, 
evidence derived from clinical trials using CM will be reviewed. 
3.2 Chinese medicine  
Chinese medicine focuses on restoring a balance of energy, body, and spirit to 
maintain health rather than treating a particular disease or medical condition. CM is 
not based on mainstream Western concepts of medical diagnosis and treatment. It 
treats patients’ main complaints or the patterns of their symptoms rather than the 
underlying causes. Practitioners attempt to prevent and treat imbalances, such as 
those caused by cancer and other diseases, with complex combinations of herbs, 
minerals, and plant extracts (Wiseman, 1996). CM originated in ancient China before 
the Christian era. It was further developed and experienced a boom between the 
12th and 18th centuries. CM was accepted and applied worldwide in the 1970s. CM 
has been modernised and industrialised over the past few decades (Cheng, 1999; 
Zhu, 2010). 
Various CM therapies are used in an effort to promote health and treat disease. The 
most commonly used approaches are CHM and acupuncture. CHM is a crucial 
modality in CM, which includes the Chinese Materia Medica, herbal formulae and the 
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applications of formulae as internal and external medicines. These formulations are a 
unique feature of CM.  
3.3 Chinese medicine in treatment of diseases 
CM has been evaluated in animal, laboratory, and human studies in both the East 
and the West with wide-ranging results. There is evidence from randomised clinical 
trials that some Chinese herbs may contribute to longer survival rates, reduction of 
side-effects, and lower risk of recurrence for some types of cancer, especially when 
combined with conventional treatment.  
CM is an important aspect of CAM practice (Moss et al., 2006). CM is used not only 
in the treatment of acute diseases such as SARS (WHO, 2003), H1N1 influenza 
(Wang, Cao, et al., 2011) and acute ischemic stroke (Huang & Guo, 2010), but also 
of chronic diseases such as diabetes (Chen et al., 2011), endometriosis (Flower et al., 
2009), chronic Kidney disease (Wang et al., 2012) and breathing disorders during 
sleep (Wu et al., 2012). Herbal medicines are used by 35% of adults with 
undiagnosed conditions; specifically, ginseng is used by 23% of herbal medicine 
consumers in the US (Mehta et al., 2008) and 6% of Victorian herb users (Zhang et 
al., 2008). 
3.4 Obesity in Chinese medicine 
3.4.1 Chinese medicine theory of obesity 
In CM, BF is considered to be the accumulation of phlegm turbidity. Phlegm is 
generated by the condensation of liquid and humour in the body. Three organs, the 
Lung, Spleen and Kidney, are said to be responsible for the regulation of liquid and 
humours in the body; however, the Spleen is the main organ responsible for the 
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development of obesity. The Spleen controls the transformation of liquid into damp 
and phlegm. Damaged Spleen function can results in a failed transformation function, 
leading to the accumulation of damp pathogens. In the long-term, the damp pathogen 
condenses into phlegm (fat) and causes obesity (Cheng, 1999; Zhu, 2010). 
3.4.1.1 Digestion in Chinese medicine 
In CM, digestion is said to be a process of heat transformation. This means that your 
body needs to digest food to produce energy. When the body fails to digest food 
properly, it leads to the accumulation of phlegm damp in the body, which is 
equivalent to adipose accumulation. This, in turn, generates heat, which is said to be 
stored in the Kidneys. Chinese scholars liken this to the fire that is lit beneath a pot to 
boil its contents. A weak digestive system is due to insufficient heat from the Kidney, 
contributing to the development of obesity (Cheng, 1999; Zhu, 2010).  
The Stomach and Spleen are responsible for digestion in CM. When food arrives in 
the Stomach, the digestion process begins. The Spleen then sorts and filters the 
nutrients and wastes. When there is weakness in digestion, it is said that the Spleen 
is weak or has a dysfunction, leading to the generation of dampness. This will then 
lead to the occurrence of various symptoms such as nausea, loss of appetite, loose 
bowels, Stomach rumbling, and a heavy sensation in the body (Cheng, 1999; Zhu, 
2010). The Spleen is weakened or damaged by stress or strong emotions. Improper 
diet with a large intake of sugary foods, saturated fat and dairy products are taxing on 
the Spleen and digestion (Cheng, 1999; Zhu, 2010). 
3.4.1.2 Chinese medical diagnosis of obesity 
From a CM perspective, good health consists of the body’s systems acting in 
harmony according to the individual’s constitution. If all is working well, there will be 
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no weight problem. CM takes a holistic approach to obesity by focussing on the 
underlying changes in the body. According to CM principles, development of obesity 
is due to the following pathological changes (Cheng, 1999; Zhu, 2010). 
a) Dyspepsia 
Dyspepsia is a cause of Stomach heat and poor Spleen functioning. Over- 
consumption of heavy, greasy and spicy foods or alcohol facilitates production of 
heat pathogenic factors in the Stomach. Meanwhile, inadequate exercise after eating 
these types of foods damages the Spleen function. The over-heated Stomach will 
ripen an excessive amount of food. Therefore, the Stomach will digest food easier 
and make an individual feel hungry, but the Spleen cannot handle an excessive food 
load making it unable to carry out its functions of transformation and transportation 
properly. As a result, the spare metabolic products turn into turbid fluid and phlegm, 
which intermix with blood and Qi (vital energy) filling up the organs, bones and 
muscles (Cheng, 1999; Zhu, 2010). 
Heat generated in the Stomach is mainly caused by excessive consumption of 
greasy and hot foods. Stomach heat tends to quickly burn off food, producing 
excessive hunger and increasing the tendency to overeat. The heat can also result in 
a dysfunction of the Spleen, leading to the generation of phlegm. Symptoms include 
a tendency to eat too much, bad breath, bitter taste, thirst and longing for cold fluids, 
and being easily angered (Bai & Fu, 2007b). 
b) Exogenous pathogenesis giving rise to obesity 
Invasion of exogenous pathogens or over-consumption of greasy foods leads to poor 
transformation and transportation of the Spleen. Dampness pathogenic factors then 
begin to accumulate in the middle burner, which is part of the triple burner (the 
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passage through which water, food and fluid are transported). When dampness and 
turbid fat enter these passages, they are further distributed by the Lungs, allowing 
penetration into all the internal organs. Additionally, exogenous pathogenic factors 
also penetrate the skin, subcutaneous tissue and muscles through the body’s surface 
giving rise to obesity (Maciocia, 2005). 
c) Qi (vital energy) stagnation as a cause of turbid phlegm accumulation 
For those who are emotionally disturbed, experience trauma, have menstrual 
problems or are elderly, the Liver often fails to regulate Qi flow, which in turn affects 
digestion and Blood flow. The resulting sluggish Qi and Blood flow tend to block the 
meridians. Therefore, in these people, dampness is likely to endure in the body. Over 
time, this will congeal into phlegm and result in obesity (Maciocia, 2005). 
d) Kidney essence exhaustion as leading to disharmony 
Lifestyles that consume Kidney essence, such as being sexually over-active can lead 
to the excitation of the internal ministerial fire. The excessive ministerial fire is a kind 
of ‘pathogenesis fire’ which makes the body produces an over-abundance of heat. 
This ‘pathogenesis fire’ affects the middle burner, leading to a malfunction of the 
Stomach and Spleen. When this persists over a long period, the vaporisation 
processes in the bladder and triple burner are impaired causing more pathogenic 
factors to accumulate and worsen the condition of obesity. 
From CM experience, the above causes of obesity can appear together or 
separately. In short, the fundamental causes of obesity are Spleen and Kidney 
deficiencies, which manifest as an overflow of body fluids, accumulation of dampness 
and phlegm pathogenic factors and stagnation in Blood flow. Sometimes Stomach 
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heat and Qi stagnation are associated. Moreover, improper vaporisation of body 
fluids by the triple burner may also appear. All of these factors play an important role 
in the development of obesity (Maciocia, 2005). 
3.4.2 Patterns of obesity in Chinese medicine 
According to CM theory, it is believed that obesity is mainly due to phlegm 
obstruction, Liver depression and Blood stasis. However, the three of them all relate 
to Qi stagnation. When the Liver fails to maintain a free flow of Qi, there results Qi 
stagnation, which will in turn, cause an obstruction in Liquid and Blood flow. 
Furthermore, the obstruction may lead to the collection and condensation of Liquid 
into phlegm. The generation of phlegm will further obstruct Qi. Qi is the moving force 
of Blood, therefore, when it is stagnant, it will fail to move Blood, leading to Blood 
stagnation and aggravating the generation of phlegm, causing the vicious cycle to 
continue (Wang, 1985; Wei & Xie, 2002). 
 
 
Figure 3.1: CM aetiology and pathogenesis of obesity (Wang, 1985; Wei & Xie, 2002) 
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3.4.2.1 Phlegm obstruction & Qi stagnation 
Phlegm damp is mostly due to excessive eating of rich foods, which generates 
dampness, in addition to lack of exercise. Symptoms include having a fat body, chest 
oppression; diarrhoea, thick, greasy tongue coating, and slippery pulse. Treatment 
principles include eliminating phlegm to move stagnation. Once the phlegm is 
eliminated, it will enable the free flow of Qi. The free flow of Qi resolves phlegm 
turbidity and reduces BW by eliminating fat (Wang, 1985). 
3.4.2.2 Excessive internal phlegm and dampness due to Spleen deficiency 
Phlegm is an important concept in CM. CM says that fat or adipose tissue is mostly 
due to phlegm and dampness pathogenic factors. The Spleen is considered to be at 
the root of all phlegm production. When the Spleen becomes damaged, such as 
through eating too many sweet foods and getting too little exercise, it will fail in its 
duty to move and transform waste fluids and foods. Instead these metabolic wastes 
will gather, collect and transform into pathogenic factors of dampness. If pathogenic 
factors of dampness endure, over time they will congeal into phlegm, and become fat 
tissue (Wang, 1985). 
Excessive internal phlegm manifests itself as excess weight, accompanied by 
tiredness, body heaviness, chest and/or stomach distension, and in some cases poor 
appetite. The tongue has a slimy covering of fur, while there is a rolling, taut pulse. 
This type of obesity is generally due to an eating disorder, or secondarily to some 
other illness. Treatment revolves around sweeping away phlegm and removing 
stagnation. Once the phlegm is swept away, the Qi can move smoothly and easily. 
This promotes the movement of phlegm and reduction of fat with the ultimate result of 
decreasing obesity (Wang, 1985). 
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3.4.2.3 Yang deficiency of Spleen and Kidney 
The Kidney plays a secondary or supplementary role in the generation of phlegm 
damp. However, its function is interdependent with the Spleen. The Spleen provides 
the Kidney with nutrients to function while the Kidney provides heat, known as yang, 
to enable the Spleen to carry out digestion. A deficiency in the Spleen and Kidney 
leads to a Yang deficiency, causing a failure in both organs to support each other 
and maintain normal function. In the case of Yang deficiency of Spleen and Kidney, 
there is not enough Qi to transform or melt the phlegm. People with Yang deficiency 
of Spleen and Kidney often feel exhausted or fatigued. They may experience lower 
back and knee weakness, shortness of breath, impotence or low libido. Abdominal 
distension after dinner, sallow complexion, impotence/infertility, tiredness, cold limbs, 
and diarrhoea are also observed. The pulse is deep and fine, the tongue is pale and 
without any fur covering. Genetic factors often play a part in Spleen and Kidney Yang 
deficiency. It may also be the result of other illnesses, stress or an unhealthy lifestyle. 
Treatment involves fortifying the Spleen and rectifying the Kidney deficiency (Wang, 
1985). 
3.4.2.4 Liver Qi stagnation 
Liver Qi stagnation is caused by prolonged strong emotions or depression which 
leads to disharmony between the Spleen and the Liver giving rise to fluid retention. 
Due to the Liver being depressed, the Gallbladder is also depressed and exhausted; 
the ebb and flow of these organs become unbalanced, and the Qi does not flow 
freely. Hence fat turbidity cannot easily be transformed and over time it leads to 
obesity (Wang, 1985). 
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People with Liver Qi stagnation tend to have excessive fatty material deposited in the 
abdomen. Individuals may also experience excess sputum secretion, dizziness, 
vertigo, retching, a dry mouth, lack of desire for food or drink and discomfort in the 
chest and abdomen. A white glossy or greasy coating usually covers their tongues. 
The pulse is rolling. Treatment involves improving Liver functioning, unblocking the 
Gallbladder and moving stagnation. 
Patients affected with this syndrome pathogenesis are usually very emotional. Most 
patients have a certain degree of chest and abdomen distension and oppression in 
the rib and shoulders, a bitter taste in the mouth and a pulse that is taut as a string. 
Due to the stagnation in the Liver, which affects the Gallbladder, patients experience 
depression and lose interest in doing anything. This lack of mobility will lead to the 
generation of fat turbidity becoming stagnant in the body. The treatment principles for 
this pattern include soothing the Liver and Gallbladder and relieving stagnation. Once 
stagnation is relieved, the body will be able to resume normal function and convert 
the food consumed into nutrients (Wang, 1985).  
3.4.2.5 Blood stasis & Qi stagnation 
Patients exhibiting stagnation of Qi and Blood may suffer from irritability, low 
motivation, chest or breast fullness, insomnia, a dreamy state, menstrual disorders or 
amenorrhea (absence of menstruation), and infertility. Some patients may complain 
of headaches. There may be dizziness and numbness of the four extremities. The 
tongue is dark red with a white thin fur, or a thin and greasy fur. The pulse is thready 
and rolling. This is because the movement of Blood is not smooth. Stasis obstructs 
the vessels and inhibits the Qi mechanism. Therefore, fat and dampness collect and 
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accumulate within the vessels, making the Blood more viscous. If this continues over 
time, obesity and arteriosclerosis (thickening and hardening of the arteries) will result.  
In addition to having a fat body, these patients experience dizziness, limb numbness, 
and have a dark tongue with red spots. The stagnation of Qi and Blood flow results in 
the accumulation and storage of fat and turbidity in the Blood vessels. The treatment 
principles for treating this pattern include promoting Qi and Blood flow to relieve 
stagnation (Wiseman, 1995). 
3.4.3 Differentiation of obesity by CM syndrome  
Currently there is no uniform differentiation of obesity in CM. Most commonly, obesity 
is classified as an imbalance in Qi, Blood or phlegm damp. These general areas are 
further divided into five types. Table 3.1 lists the five types of obesity and the major 
symptoms associated with each syndrome. For each syndrome, there are at least 2-3 
diagnostic symptoms including the basic condition of the person, tongue appearance, 
and pulse quality (Maciocia, 2005). 
 
 
 
 
 
Table 3.1: Differentiation of obesity (Cheng, 1999; Wei & Xie, 2002) 
Types of obesity Syndrome 
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Spleen wet resistance 
Swelling, oedema, fatigue, weakness, decreased urine 
output, poor appetite, full sensation in the stomach, 
deep and thready pulse, pink tongue with thin greasy 
coating . 
Stomach damp heat resistance 
Headache, vertigo, increased hunger, heavy limbs, 
lethargy, an increased thirst and fluid intake, wiry and 
smooth pulse, red tongue and yellow and greasy 
coating. 
Qi stagnation and blood stasis 
Chest distress and hypochondriac distension, irregular 
menstruation, insomnia, constipation, taut pulse, dark 
red tongue with white coating. 
Spleen Kidney Yang deficiency 
Larger physique, listlessness, somnolence, lumbago, 
and cold limbs, deep and thready pulse, pale and 
swollen tongue with white coating. 
Internal Yin deficiency 
Restlessness, dream disturbed sleep, burning sensation 
of the palms, soles and chest, night sweating, dryness 
of the mouth and throat, red and dry tongue, thready 
and rapid pulse. 
Internal retention of phlegm 
Body heaviness, lassitude of limbs, dizziness, vomiting 
and lack of appetite, listlessness, somnolence, smooth 
pulse, white and greasy tongue coating. 
 
3.4.4 Chinese herbal medicine in the management of obesity 
Obesity is primarily caused by a combination of excessive food energy intake, lack of 
physical activity, and genetic susceptibility. Although excess food (calories) in any 
form are converted into fat and stored, the amount of fat in a person’s diet may have 
a greater impact on weight than the number of calories it contains. A sedentary 
lifestyle contributes to positive energy balance and the spared calories are stored as 
fat (adipose) tissue. Eating habits and patterns of physical activity also play a 
significant role in the amount of weight a person gains. Genetic factors can influence 
how the body regulates the appetite and the rate at which it turns food into energy 
(metabolic rate). Psychological factors such as depression and low self-esteem may, 
in some cases, also play a role in weight gain (Rippe et al., 1998). 
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The molecular biology of obesity is only partially understood. This is likely due to the 
heterogeneity of ‘garden variety‘ obesity and the fact that it is caused, like other 
complex diseases, not by a single genetic mutation but by multiple allelic defects, 
which determine susceptibility to environmental factors. Individuals who carry only 
one or some of these alleles may still not develop the disease, because they either 
lack another allele (gene-gene interaction) or are not exposed to the precipitating 
environment (gene-environment interaction). Furthermore, there is controversial 
evidence for a direct association between genotypes and lifestyle or anatomical 
phenotypes of obesity (McPherson, 2007).  
CM research has shown that green tea assists metabolism and weight reduction. 
Aloe vera is used to cleanse the digestive tract. It helps to improve digestion and the 
absorption of nutrients, and increases of the rate of metabolism. The herb, 
Astragalus, has been shown to help the absorption of nutrition as well as increase 
energy levels. This herb is able to help in the breakdown of fat in the liver. Goji 
berries have also been shown to assist in controlling obesity. Guarana, an effective 
obesity treatment, contains caffeine, which can suppress appetite, increase a low 
metabolism rate, and has a mild diuretic effect. Yohimbe is able to improve 
metabolism and suppress appetite (Bensky et al., 2004). 
In the management of metabolic syndrome, CM is a good representative of 
alternative and complementary medicine as it comprises a complete theoretical 
system, based on herbal remedy. (Luk et al., 2008) reported that three herbs – 
ginseng, Rhizomacoptidis (which consists of berberine as the main active compound) 
and bitter melon – are useful in the treatment of metabolic syndrome/obesity. The 
roots, essence, berries, leaves and rootlets of American ginseng and Asian ginseng 
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have been proven to have anti-hyperglycemic and antioxidant properties and have 
functions in improving islet cell protection and reducing BF content. Through ginseng, 
the energy consumption in the ginseng transplants saponins as the main bioactive 
substances in metabolic activity of ginseng. 
Berberine, the main active compound found in Rhizomacoptidis, is an oral glucose-
lowering agent. It also has the ability to reduce BF content and regulates dyslipidemic 
activities. By inhibiting mitochondrial function, the stimulation of AMPK activation 
inhibits the adipogenesis pathway and induces low-density lipoprotein (LDL) receptor 
expression (Luk et al., 2008). Bitter melon or Charantia (balsam pear) was shown to 
be able to reduce glucose and lipids in two normal and diabetic animals (Luk et al., 
2008). It is also able to protect beta cells, improve insulin sensitivity, and reduce 
oxidative stress. Despite the evidence obtained from animal and human studies 
regarding the treatment of metabolic syndrome/obesity with ginseng, berberine and 
balsam pear, there have been no clinical trials evaluating the clinical curative effect 
and safety of these herbal medicines (Bensky et al., 2004; Luk et al., 2008). 
Management of obesity with CM is considered safe (Zhou et al., 2004) and effective 
as a treatment when application is based on the individual’s condition and syndrome 
differentiation according to CM diagnosis. Using a combination of acupuncture, CHM, 
dietary and lifestyle advice, and other CM therapies, personalised treatments are 
prescribed to target each patient’s underlying cause of obesity. CM treatment aims to 
return the systemic dynamic balance of the body to bring patients back to a state of 
health. The following are common treatment principles associated with CM obesity-
related syndromes: 
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Table 3.2: Treatment principles for obesity syndromes (Cheng, 1999; Wei & Xie, 
2002) 
Syndrome Treatment Principle Acupuncture points CHM 
Spleen 
deficiency 
Invigorate spleen, 
promote diuresis and 
eliminate dampness 
Tianshu (ST25), Sanyinjiao (SP6), 
Zhongwan (CV12), Zusanli (ST36) 
Gui Pi Tang
Stomach 
damp heat 
resistance 
Purge stomach heat 
and promote digestion
Hegu (LI4), Shenmen (HT7), Zusanli 
(ST36), Neiting (ST44), Sanyinjiao 
(SP6)  
Qing Wei 
San 
Liver Qi 
stagnation  
Activate Qi and blood 
circulation and 
dissipate blood stasis 
Liangqiu (ST34), Xuehai (Sp10), Zhigou 
(SJ6), Waiguan (SJ5), Sanyinjiao 
(SP6),  Zusanli (ST36)Fujue (SP14), 
Daimai (GB26),Tainshu (ST25),Wailing 
(ST26), Guanyuan (CV4), Taixi (KI3), 
Shangjuxu (ST37) 
Xiao Yao 
San 
Kidney 
YinYang 
deficiency 
Warm and tonify 
Kidney and Spleen , 
induce diuresis and 
relieve fluid retention 
Shangjuxu (ST37), Sanyinjiao (SP6), 
Yinlingquan (SP9), Pishu (SP20), 
Xinshu (BL15), Taixi (KI3),Guanyuan 
(CV4) 
Jing Gui 
Sheng Qi 
Tang 
Internal Yin  
deficiency 
and 
deficient 
heat 
Nourish Yin and clear 
away heat 
Quchi (LI11),Neiting (ST44), Shangjuxu 
(ST37), Pishu(BL20),Xuehai (SP10), 
Fenglong (ST40), Zhongwan  (CV12), 
Suifen (CV9), Qihaishu (BL24), 
Shuidao (ST28),Tianshu (ST25), 
Zusanli (ST36 ), Sanyinjiao (SP6) 
Zhi Bai Di 
Huag Tang 
Internal 
retention of 
phlegm 
Dry dampness, 
resolve phlegm and 
eliminate mass 
Gongsun (SP4),Neiting (St44), 
Fenglong (ST40), Neiguan (PC6), 
Yinlingquan (SP9), Zusanli (ST36), 
Shuifen (CV9), Zhongwan (CV12), Daju 
(ST27), Shuidao (ST28), Guanyuan 
(CV4), Taichong (LR3), Quchi ( LI11), 
Xiajuxu (ST39) 
Er Chen 
Tang 
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3.4.5 Acupuncture in management of obesity 
This section provides a comprehensive review of the most recent basic and clinical 
advances relating to acupuncture in the treatment of obesity. 
Management of obesity with acupuncture is considered effective (Cho et al., 2009). 
Acupuncture has been practised for several thousand years in China as a 
monotherapy or complementary therapy that is safe and inexpensive. It is 
increasingly used worldwide in the treatment of a wide spectrum of clinical symptoms 
and diseases. Acupuncture has been found to be effective in weight control since the 
1980s. An increasing body of evidence demonstrates that acupuncture produces 
good effects for weight loss without causing adverse reactions. Acupuncture therapy 
for obesity is increasingly accepted by more and more people around the world. In 
addition, acupuncture can help with the treatment of obesity-related diseases (Liu, 
Sun, Hu, et al., 2004). Extensive research on acupuncture weight loss has been 
conducted in both basic and clinical areas in recent years.  
Acupuncture is performed by inserting needles into acupuncture points on meridians. 
As early as the 1990s, China began to use acupuncture for the treatment of obesity. 
This is a comprehensive treatment of weight control using the application of 
traditional Chinese acupuncture, coordinated with the principles of modern nutrition. 
Acupuncture for weight loss does not involve drugs and has fewer side-effects. It is 
said that acupuncture has an effect on metabolism and endocrine function, which 
plays a role in the development of obesity. Acupuncture speeds up the body’s energy 
metabolism for increasing energy consumption and aids in the decomposition of BF, 
thus leading to weight reduction (Yao et al., 2012). Acupuncture improves 
accompanying symptoms of obesity by reducing blood pressure and improving bowel 
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function. Despite these benefits, diet control and regular exercise should be 
maintained during acupuncture treatment to achieve the desired effect in weight loss. 
While acupuncture is being utilised to treat various important health problems, its 
efficacy in obesity management has not yet been fully evaluated. Studies have been 
done to evaluate the efficacy of acupuncture treatment for obesity (Yao et al., 2012). 
However, most of these studies are of short duration (less than or equal to 12 
weeks). Further studies on the potential of acupuncture as an adjunct treatment in 
weight management are required (Cheng, 1999). 
3.4.5.1 Treatments 
There are fourteen major meridians, corresponding (loosely) to the Western definition 
of ‘organs’. Acupuncture points are specific locations on the body are connected to 
these energy meridians. During illness Qi is thought to be out of balance, and 
stimulation of acupuncture points corrects this imbalance. Theoretically speaking, an 
‘excess’ or ‘deficiency’ of Qi can be ‘normalised’ by the specific manner of point 
stimulation. Using this paradigm, obesity and/or excess appetite has been 
conceptualised in a variety of ways, such as ‘heat’ in the stomach and intestine. A 
deficiency of Qi in the Spleen and Stomach or a deficiency of primary Qi syndromes 
manifest in tiredness and loose bowel (Maciocia, 2005). Based on these beliefs 
about the causes of obesity, a variety of acupoints are targeted in the treatment of 
obesity, including: Neiguan (PC 6), Fenglong (St 40), Liangmen (St 21), Guanyuan 
(CV 4), Zusanli (St 36), Tianshu (St 25), Quchi (LI 11). 
Liu & Vian believed that acupuncture works to alter central nervous system 
neurotransmitter’s levels by stimulating peripheral nerves at acupoints. These 
stimulated nerves then carry the signals centrally, including to the spinal cord, 
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pituitary, and midbrain. Activated centres then release neurochemicals, endorphins, 
monoamines and cortisol (Liu & Vian, 1998). 
3.4.5.2 Basic acupuncture points 
From a CM perspective, acupuncture points to treat obesity are chosen based on 
their function to regulate the body’s Yin and yang, vitalised Qi, remove phlegm and 
damp to reduce the BW (Liu & Vian, 1998). When treating simple obesity, there are 
thirty common acupuncture points used to treat the different syndromes. In terms of 
meridian-based theory for acupuncture point selection, foot meridians (Stomach 
Yangming and Spleen Taiyin) acupuncture points are selected most frequently. The 
most frequently occurring points used are found on the abdomen and include: 
Zhongwan (CV12), Xiawan (CV10), Qihai (CV 6), Guanyuan (CV 4), Tianshu (St 25), 
Daheng (SP 15) (Lacey et al., 2003). 
CM concepts prescribe the use of intersection points such as: Daimai (GB 26), 
Wushu (GB 27), Weidao (GB 28), Zulinqi (GB 41) for treatment of central obesity (Yu, 
2008b). On the rest of the body, the following points are often used: Fengchi (GB 20), 
Zusanli (St 36), Sanyinjiao (SP 6) (Yu, 2008b). 
Conclusion 
Acupuncture has been practised effectively for many centuries in China and all over 
the world. In recent times acupuncture has been popular in Western countries for the 
treatment of many diseases including obesity. However, from a research 
methodological point of view, more scientific evidence-based investigation is needed 
to substantiate the claim for clinical benefit. Therefore, more quality clinical trial as 
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well as systematic reviews is needed in order to obtain a clearer picture and public 
confidence in scientific and public communities. 
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Chapter 4. General Methodology 
4.1 Introduction 
To address the research questions, this thesis is divided into two sections: literature 
reviews and a clinical study. This chapter describes the methods used for performing 
the following in these sections: 
Systematic reviews: 
 SRs on RCTs of acupuncture and CHM for the management of obesity and  
Clinical studies: 
 A randomised controlled clinical trial of CHM formula (RCM-104) in the 
management of obesity.  
4.2 Systematic reviews 
The reviews presented in this thesis were conducted according to the instructions 
specified in the Cochrane Handbook for SRs of Interventions 5.1 (Higgins, 2011).  
4.2.1 Search strategy 
A total of fifteen electronic English and three Chinese databases were searched from 
their respective inceptions to February 2006 and updated in January 2014 to identify 
relevant studies. The list of databases is provided in Table 4.1.  
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Table 4.1: Databases searched for SRs on acupuncture and CHM for obesity 
English databases Chinese databases 
 Cochrane Central Register of 
Controlled Trials 
 PubMed 
 EMBASE 
 CINAHL 
 Science Direct 
 ProQuest 
 Web of Science  
 Informit 
 LILACS (Latin American and 
Caribbean Health Sciences) 
 PSYCINFO 
 Blackwell Synergy 
 KoreaMed 
 INDMED 
 Ingenta 
 mRCT 
 VIP Information (www.cqvip.com) 
 China National Knowledge 
Infrastructure (www.cnki.net) 
 Wanfang Data 
(www.wanfangdata.com) 
 
4.2.1.1 Key words in acupuncture review 
Key words used for searching these databases to identify acupuncture trials for 
obesity included the combination of acupuncture, electro acupuncture, obesity, 
weight loss, randomised trial and their synonyms. The strategy used for searching 
PubMed is provided in Table 4.2 as an example. Similar search strategies were 
applied to other databases. 
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Table 4.2: Search strategy for the acupuncture systematic review for obesity used for 
PubMed 
#1 acupuncture or electro-acupuncture 
#2 obesity or obese 
#3  lose weight or weight reduction 
#4 Overweight 
#5  body weight or body mass 
#6 #2 or #3 or #4 or #5 
#7 clinical trial or clinical study 
#8 random* 
#9 #7 and #8 
#10 #1 and #6 and #9 
 
4.2.1.2 Key words in CHM review 
The following key words were used for searching these databases to identify CHM 
trials for obesity, including the combination of Chinese herbs, obesity, weight loss, 
randomised trial and their synonyms. The search strategy for PubMed is provided in 
Table 4.3 as an example. Similar search strategies were applied to other databases. 
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Table 4.3: Search strategy for the CHM systematic review for obesity used for 
PubMed 
#1 Chinese herbs 
#2 obesity or obese 
#3  lose weight or weight reduction 
#4 Overweight 
#5  Body weight or body mass 
#6 #2 or #3 or #4 or #5 
#7 clinical trial or clinical study 
#8 random* 
#9 #7 and #8 
#10 #1 and #6 and #9 
 
4.2.2 Study selection 
After identifying all the potential records by searching the electronic databases, two 
independent reviewers (KL and WY) initially screened their titles and abstracts. When 
the titles and abstracts did not provide sufficient information, the full texts of the 
articles were obtained for further assessment. Any discrepancy between two 
reviewers was resolved by discussion with a third party researcher (GL). 
All the potential records were examined according to the following inclusion and 
exclusion criteria. 
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4.2.2.1 Inclusion criteria 
 RCTs with or without blinding. If randomised cross-over trials were included, 
only data from the first phase were used. 
 Adult patients, male or female, with overweight or obesity. Overweight or 
obesity must be determined by weight or BMI. 
 Intervention:  
o For acupuncture review: acupuncture (either traditional Chinese 
acupuncture or EA);  
o For CHM review: any form (eg. decoction, capsule, tablet, pill or powder) 
of single herb or Chinese medicinal formulae. 
 Co-intervention was allowed as long as the same co-intervention was involved 
in both arms; 
 Control: sham/placebo, no intervention, WM, or other therapy (such as dietary 
therapy and exercise); 
 Outcome measures: any type of outcome measure; 
 Any type of publication published in English and Chinese. 
4.2.2.2 Exclusion criteria 
 For acupuncture review: other types of acupuncture, such as ear-acupuncture, 
acupressure, laser acupuncture, dry needling, Western acupuncture, and 
transcutaneous electrical nerve stimulation (TENS); 
 For CHM review: chemical compound of CHMs or green tea used as 
interventions; 
For all the included studies, full texts were obtained for data extraction and evaluation. 
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4.2.3 Data extraction 
Two independent reviewers (KL and WY) extracted the data of each included study 
using the data extraction forms. The extracted data consisted of the characteristics of 
study design, participants, interventions and outcome measures. Characteristics of 
study design were the country of origin, study setting and risk of bias. Characteristics 
of participants referred to age, inclusion and exclusion criteria, sample size, and the 
number and reasons for dropouts and/or withdrawals. Characteristics of interventions 
included treatment and control therapies, needling techniques (for acupuncture 
review) or herbal ingredients (for CHM review), dosage and duration of treatment and 
follow-up. Characteristics of outcome measures referred to primary and/or secondary 
outcomes where applicable. Any inconsistency between the two reviewers was 
discussed with a third party (GL). 
4.2.4 Assessment of risk of bias in included studies 
Two reviewers (KL and WY) independently assessed the risk of bias in the included 
studies. Any disagreement between the two authors was judged by the third party 
(GL). The domains of risk of bias and their assessment criteria are listed in Table 4.4.  
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Table 4.4: Domains of risk of bias and their assessment criteria (Higgins 2011) 
Domain Assessment criteria 
Random sequence 
generation 
Low risk (computer generated random numbers, or random number 
table, or similar), unclear risk (not reported), or high risk (other 
methods) 
Allocation 
concealment 
Low risk (central allocation, or serially numbered, opaque, sealed 
envelopes, or similar), unclear risk (not reported), or high risk (open 
allocation or similar) 
Blinding of 
participants 
Low risk (sham acupuncture or placebo CHM or similar), Unclear risk 
(not performed), or high risk (acupuncture or CHM versus dietary 
therapy or similar) 
Blinding of outcome 
assessors 
Low risk (blinding performed, or similar), unclear risk (not performed), 
or high risk (no blinding performed, or blinding unlikely performed, or 
similar) 
Incomplete outcome 
data 
Low risk (incomplete outcome adequately addressed), unclear risk 
(difficult to determine), or high risk (incomplete outcome not 
adequately addressed) 
Selective reporting Low risk (the trial protocol available and outcome not selectively 
reported), Unclear risk (difficult to determine), or High risk (outcomes 
selectively reported) 
Other bias Low risk (baseline imbalance not existed, selection criteria valid and 
feasible), unclear risk (difficult to determine), or high risk (baseline 
imbalance existed, selection criteria not valid or feasible) 
 
4.2.5 Data analysis 
Meta-analyses were processed using the Cochrane software RevMan 5.2 (RevMan 
2011). 
4.2.5.1 Data synthesis 
The data synthesis was performed quantitatively and qualitatively. The dichotomous 
data was presented as risk ratio (RR) and continuous data was presented as mean 
difference (MD) with 95% confidence intervals (CI) using inverse variance with 
random effects methods due to the diversity of the interventions. When the same 
100 
 
outcome measure was assessed by different scales, standardised mean difference 
(SMD) was used to replace MD. The intention-to-treat analysis (ITT) was applied to 
this review where possible. The ‘worst-case scenario’ method was used to address 
missing data.  
For the acupuncture review, both traditional Chinese manual acupuncture and EA for 
the same outcome measure were included in the same meta-analysis as their 
techniques were similar at the pre-stimulation stage, including diagnosis and 
selection of acupoints and needles. The only difference between them is the 
stimulation method: the former stimulates needles manually whilst the latter applies 
the instruments to the needles for electric stimulation. Their heterogeneity was 
assessed when applicable. 
For the CHM review, as different CHMs were applied across all the included studies, 
all the CHMs for the same outcome measure were included in the same meta-
analysis and their heterogeneity was examined when applicable. 
4.2.5.2 Assessment of heterogeneity 
The heterogeneity was estimated by I2. This review considered I2 from 0 to 30% 
(exclusive) as low heterogeneity; 30% to 50% (exclusive) as moderate heterogeneity; 
and 50% to 100% as substantial heterogeneity. When substantial heterogeneity 
existed, subgroup analysis was conducted to further identify the potential factors if 
possible.  
4.2.5.3 Assessment of reporting bias 
If the number of included trials was sufficient, potential publication bias was planned 
to be assessed using a funnel plot.  
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4.3 Clinical study: Randomised placebo-controlled clinical trial of 
CHM for obesity (RCM-104) 
This trial was to evaluate the safety and efficacy of CHM formula (RCM-104) in the 
management of obesity.  
4.3.1 Statement of compliance 
This clinical trial was designed following the requirements specified in Australia’s 
National Statement on the Ethical Conduct Human Research (2007). Its protocol was 
approved by the RMIT Human Research Ethics Committee (HREC) (0407 Lenon) 
prior to being conducted. The trial was registered on Clinical Trial Notification (CTN) 
at TGA (TGA-2007/313) and the Australian New Zealand Clinical Trials Registry 
(ANZCTR) at the NHMRC Clinical Trials Centre (ACTRN12607000255482). This trial 
was conducted strictly in compliance with the protocol, the principles of Good Clinical 
Practice (GCP) and the Australian Code for the Responsible Conduct of Research as 
well as other relevant requirements.  
4.3.2 Recruitment of subjects (Appendix 1)   
The subjects were recruited through an advertising campaign in Leader newspapers, 
internal advertisement and media release in June 2007 and September 2008 in 
Metropolitan Melbourne (Appendix 1-1). After brief information screening at the initial 
telephone enquiry, potential participants (PP) were sent the Clinical Trial for Obesity 
2007 General Information Booklet containing Plain Language Statement (PLS) form 
and Screening Questionnaire (Appendix 1-2,3) with a prepaid self-addressed 
returned envelope. Based on the information returned,  PPs were invited to the initial 
interview and assessment for eligibility of participation.  
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4.3.3 Trial design 
This trial was to evaluate the efficacy and safety of RCM-104. It was conducted over 
a period of 24 weeks and subjects were required to attend a research clinic for 4 
visits during which subjects were asked to take trial capsules and fill out the 
evaluation forms.  
Subjects and personnel who were involved in the clinical trial were blind to the 
participants’ group allocation. A pharmacist was responsible for re-packing and 
dispensing the RCM-104 and matched placebo capsules into identical packages. The 
pharmacist was the only person having access to the randomisation allocation codes. 
The trial was conducted as described in Figure 4.1. 
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Figure 4.1: Clinical trial procedure 
END OF TRIAL
Data collection and analysis
Visit 4 (Week 12) - Placebo group 
anthropometric measurements. Collect forms.
Blood collection
Advertising: Media release, 
RMIT website, trial website, local 
Leaders newspapers, posters 
Potential 
participants 
(PP) contact PI 
Visit 1(Week 0) - Placebo group 
ID, 4 week’s supply of placebo capsules 
anthropometric measurements, WRSM, OWLQOL, 
RMR, BP and Food record.
Telephone 
interview with 
PP
INITIAL ASSESSMENT AT RESEARCH CLINIC
Interview, Inclusion and exclusion, PLS, Informed consent 
Anthropometric measurements and  3-day food record, WRSM, OWLQOL & 
Blood collection for baseline data. 
Eligible PP invited to 
clinic for initial 
assessment
2 week run-in period, Completing food record
Visit 1 (Week 0)- RCM-104 group 
ID, 4 week’s supply of RCM-104 capsules 
anthropometric measurements, WRSM, OWLQOL, 
RMR, BP and Food record.
Visit 2 (Week 4)- RCM-104 group 
Give 4 week’s supply of RCM-104 capsules
anthropometric measurements, WRSM, OWLQOL, 
RMR, BP and Food record. Collect forms.
Visit 3 (Week 8)- RCM-104 group 
Give 4 week’s supply of RCM-104 capsules 
anthropometric measurements, WRSM, OWLQOL, 
RMR, BP and Food record. Collect forms.
Visit 4 (Week 12)- RCM-104 group 
anthropometric measurements. Collect forms.
Blood collection
Visit 2 (Week 4) - Placebo group 
Give 4 week’s supply of placebo capsules   
anthropometric measurements, WRSM, OWLQOL, 
RMR, BP and  Food record. Collect forms.
Visit 3 (Week 8) - Placebo group 
Give 4 week’s supply of placebo capsules 
anthropometric measurements, WRSM, OWLQOL, 
RMR, BP and  Food record. Collect forms.
Participants randomised to placebo and RCM-104 groups at the start of trial 
Week 0- RCM-104 group 
Self-assessment of anthropometric measurements, 
WRSM, OWLQOL and Food record.
. 
End of treatment period and star t of follow‐up period
Week 4 - RCM-104 group 
Self-assessment of anthropometric measurements, 
WRSM, OWLQOL and Food record.
. 
Week 12 - RCM-104 group 
Self-assessment of anthropometric measurements, 
WRSM,OWLQOL and  Food record.
. 
Week 8 - RCM-104 group 
Self-assessment of anthropometric measurements, 
WRSM, OWLQOL and Food record.
. 
Week 0- Placebo  group 
Self-assessment of anthropometric measurements, 
WRSM, OWLQOL and Food record.
. 
Week 4 - Placebo  group 
Self-assessment of anthropometric measurements, 
WRSM, OWLQOL and Food record.
. 
Week 8 - Placebo  group 
Self-assessment of anthropometric measurements, 
WRSM, OWLQOL and Food record.
.
. 
Week 12 - Placebo  group 
Self-assessment of anthropometric measurements, 
WRSM, OWLQOL and Food record.
.
. 
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4.3.3.1 Sample size calculation 
Sample size for this study was estimated using a study by Hioki et al., (2004). From 
the data, the effect size was calculated to be 0.85 for weight reduction using a 
significance level of 5% and power of 90%, the estimated sample size was 45 per 
group. The calculation also accounted for 10% drop-out. 
4.3.3.2 Initial assessment and baseline (Appendix 2) 
During the initial visit, the eligibility of participants was assessed and their informed 
consent was obtained. Once the consent forms were signed and the participants 
were found to have satisfied the selection criteria, blood samples for full blood 
examination (FBE), liver function, and kidney function were collected. Finally, a 
number test was also performed and the subjects were given IDs for record-keeping 
and baseline self-administered forms for evaluation. 
Subjects were given written information and a verbal explanation concerning the 
study prior to obtaining consent for their participation. After the two-week baseline 
assessment, the subjects were randomly assigned into either the RCM-104 treatment 
or placebo groups using treatment allocation codes generated by a statistician and 
designed to ensure balance of gender, age, and severity of obesity between groups.  
4.3.3.3 Informed consent forms (Appendix 2-1)  
Informed consent was obtained during the first visit to the clinic prior to entering into 
the run-in period and randomisation process. Subjects were given written information 
and verbal explanation concerning the study. Full explanations were given to any 
questions that arose prior to the signing of the informed consent forms. The 
investigator who conducted this process recorded the details, including date, time, 
and location of the provision of informed consent forms. 
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4.3.3.4 Inclusion and exclusion criteria (Appendix 2-2) 
a) Inclusion criteria: Subjects were included in the study if they met the following 
criteria were 
 Aged between 18 to 65 years and have a BMI greater than 30 kg/m2;  
 Not involved in other clinical trials for the treatment of obesity; Agree to avail 
themselves for the period of the study;  
 Provide written consent for participation.  
b) Exclusion criteria: Subject with one or more of the followings was excluded from 
the study 
 Losing more than 5 kg in the past three months;  
 Endocrine disorders other than T2D mellitus;  
 Uncontrolled hypertension;  
 Autoimmune or cardiovascular diseases or carrying a pace-maker;  
 Lactating or pregnant women; 
 Those using drugs affecting the central nervous system or lipid lowering drugs;  
 Obesity known to be caused by pharmacotherapy;  
 Therapy for weight control in the last six months;  
 Renal or hepatic disease;  
 Unable to read or understand English.  
The subjects were not allowed to receive other obesity management and were asked 
to keep their existing diet and life style during the study period. All subjects were free 
to withdraw at any time during the course of the study. 
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The study was advertised in the local newspapers and websites. Flyers advertising 
the study were displayed in the local medical centre and university campuses. After a 
brief telephone screening interview, subjects were invited to a face-to-face interview 
to ensure they understood the aims of the trial and satisfied the inclusion and 
exclusion criteria. 
4.3.3.5 Withdrawal policy 
A subject was withdrawn from the trial if: 
 a severe adverse reaction to treatment occurred, in which case other medical 
care was recommended immediately; 
 the subject failed to attend the clinic for assessment; 
All withdrawn cases were contacted and details were recorded on a weekly 
basis for 4 weeks following the withdrawal. 
4.3.3.6 Randomisation and blinding  
Randomisation was handled by an independent statistician to ensure a balance of 
gender, age and severity of obesity between treatment and CGs. This process was 
carried out after the two-week baseline period when each subject was given an ID 
code. Blinding was achieved by using subject codes and treatment codes, and pre-
packing of placebo and RCM-104 capsules with identical presentation and smell. To 
ensure blinding, the random allocation of subjects to active and placebo groups was 
handled independently by a staff member from an external department. The codes 
and labeling were recorded in a password-protected computer program.  
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4.3.3.7 Treatment protocol 
Subjects were required to attend the trial clinic every four weeks for assessment and 
medication collection.Subject was given a four-week supply of either RCM-104 or 
placebo capsules packed in identical plastic bottles. All bottles were labelled 
according to Committee for Proprietary Medicinal Products (CPMP)/ International 
Conference of Harmonisation (ICH), Note for Guidance on Good Clinical Practice 
(CPMP/ICH-135/95) and coded so that emergency identification of actual treatment 
received by patient was possible. Each subject was required to take 4 capsules per 
time, three times daily, for period of 12 weeks. 
Patients were supplied with full instructions and written information on how to take 
the capsules. Patients were asked to return the bottles during their one monthly visits 
and left-over capsules were counted for monitoring medication adherence. Subjects 
were given another bottle of capsules (one month supply) during each visit to the 
clinic.  
4.3.3.8 Treatment period  
The treatment period lasted 12 weeks consisting of four consecutive visits. At each 
visit, the subjects were given four-week supplies of medication and they handed in 
evaluation forms (Appendix 3). In addition, the severity of symptoms was also 
assessed by a CM practitioner four-weekly. At the end of trial period (visit 4), final 
blood tests were performed to monitor kidney and liver functions. 
4.3.4 Trial medication 
Subjects were required to take four capsules per time, three times daily for a period 
of 12 weeks. Each capsule contained 500 mg of either herbal granules or placebo 
ingredient (herbal starch) and was encapsulated in a standard capsule by Sun Ten 
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Pharmaceuticals Co Ltd in Taiwan. The two types of capsules were identical in 
weight and appearance. Both placebo and real CHM capsules were bottled in 185 
HDPE tablet bottles with a sealed cap. All bottles were labeled according to 
CPMP/ICH, Note for Guidance on Good Clinical Practice (CPMP/ICH-135/95). They 
were also coded so that in an emergency, identification of treatment types could be 
done. The trial medication compliance was monitored by counting left-over capsules 
to determine the number of capsules taken by subjects and checking on the 
completeness of the data on forms returned to the trial team. 
 
 
Figure 4.2: Sample of clinical trial medications 
 
4.3.4.1 Real Chinese herbal medicine capsules 
All ingredients of RCM-104 are Therapeutic Goods Administration (TGA) approved 
listed substances for human consumption.  
To comply with the Australian Guidelines for Good Research Practice (1991), the 
content of the capsules and potential side-effects (Table 4.5) of each individual 
ingredient were disclosed to all participants in the information booklet.  
109 
 
The individual herbal granules of formula were supplied by Sun Ten Pharmaceuticals 
Co Ltd Taiwan which complies with the Australian Code of Good Manufacturing 
Practice (GMP) for therapeutic goods.  
 
Table 4.5: Reported therapeutic effects and side effects of RCM-104’s ingredients 
Active ingredients Indications in 
Chinese 
medicine 
Therapeutic effects in Western 
Medicine 
Reported side- 
effects 
Camellia sinenis (Lu 
Cha Ye) 40% 
Cools down the 
body's exterior 
and interior 
ability to nourish 
yin. Regulating 
action on the 
intestines. 
Contains caffeine may produce 
diuretic effects. Increase blood 
pressure. 
Powerful antioxidant because of 
its high levels of catechins. 
Anti-cancer properties, reducing 
effects on cholesterol levels and 
weight. 
1. Nausea and an 
upset stomach. 
2. Heart 
palpitations and 
nervousness 
3. May lead to 
iron deficiency 
(K.C. Huang, 
1999; Y. P. Zhu, 
1998) 
Cassiaobtusifolia 
(Jue Ming Zi) 40% 
 
clears heat, 
moistens and 
lubricates the 
intestines and 
therefore acts 
as a mild 
laxative 
Anodyne, Anti-inflammatory, 
Cardio tonic, laxative, nervine, 
stimulant. 
Improving Liver, Kidney, and 
intestine function .Can help vision 
and conjunctival congestion. 
No side-effects 
reported (K.C. 
Huang, 1999; Y. 
P. Zhu, 1998) 
 Sophora Japonica 
(Huai Hua). 20% 
  
Cools blood and 
stop bleeding, 
which is similar 
to an anti-
inflammatory 
effect. 
Diuretic and 
laxative actions 
attributed to it. 
It has abortifacient, antibacterial, 
anticholesterolemic, 
antiinflammatory, antispasmodic, 
diuretic, emetic, emollient, 
febrifuge, hypotensive, purgative, 
styptic, and tonic properties 
It also has anti-oxidative, anti-
inflammatory, anti-platelet 
aggregation, anti-hemorrhagic, 
anti-haemostatic (due to 
increased capillary permeability 
and reduced platelet aggregation. 
No side-effects 
reported (K. C. 
Huang, 1999; Y. 
P. Zhu, 1998) 
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4.3.4.2 Placebo capsules 
Each placebo capsule contained 500 mg of herbal starch powder supplied by Sun 
Ten Pharmaceuticals Co Ltd Taiwan which complied with the Australian Code of 
GMP for therapeutic goods.  
4.3.4.3 Outcome measures and data management (Appendix 3) 
Eight self-administered instruments and three practitioner-administered instruments 
were used in this clinical trial for recruitment process and data collection. An overall 
evaluation for all symptoms was also carried out four-weekly.  
a) Anthropometric measurements (Appendix 3-1) 
All anthropometric measurements were carried out using standardised methods and 
performed at the beginning of each four-weekly visit. Height was measured with a 
wall-mounted stationmaster without wearing shoes to the nearest 0.1 cm; BW was 
measured while wearing light clothes without shoes on a calibrated balance beam 
scaled to the nearest 0.1 kg. BMI was calculated according to the formula: BMI = 
BW/squared height (kg/m2). WC was measured mid-way between the lateral lower rib 
margin and the iliac crest, and HC was measured at the levels of the prominence of 
greater trochanters.  
b) Body fat composition 
A standard Bioimpedance Analyser (Omron, Kyoto, Japan) was used to 
determine BF composition which calculated lean mass and fat mass using an 
algorithm based on electrical resistance, weight, age, height, and gender. The  
test was performed at the CM research clinic BIA, Model HBF-522 as shown in 
Figure. 4.3. 
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Figure 4.3: Bioimpedance Analyser BIA, Model HBF-522(Omron, Kyoto, Japan) 
 
c) Resting metabolic rate 
Fitmate (Biomedex Pty. Ltd. 1/1 Pioneer Drive, Bellambi, NSW, Australia) was used 
to determine the resting metabolic rate. The machine was performed at the CM 
research clinic as Figure.4.4.  
 
 
Figure 4.4: Fitmate (Biomedex Pty. Ltd. 1/1 Pioneer Drive, Bellambi, NSW, Australia) 
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Subjects were instructed not to exercise or consume stimulants such as alcohol, tea, 
or coffee at least two hours prior to the test. Blood pressure and heart rate were 
measured three times in a resting seated position with the rest period of one minute 
between the measurements using ITO blood pressure monitor, and the average of all 
three measurements was recorded. 
d) Weight-Related Symptom Measure (WRSM) and Obesity & Weight-Loss 
Quality of Life measure (OWLQOL) (Appendix 3-2 and 3-3) 
WRSM and OWLQOL are validated instruments for which a permit was obtained 
from the University of Washington, USA. These instruments comprised twenty and 
seventeen items respectively and were used to assess specific obesity symptoms to 
determine the effects of CHM on the subjects’ quality of life. Assessment was based 
on a seven-point scale from not troubled (0) to extremely troubled (6). The mean 
scores of each domain were used for statistical analysis. 
e) Adverse events questionnaire (Appendix 3-5) 
An adverse events questionnaire was also handed out to subjects and collected after 
four weeks with other evaluation instruments to document side effects during the 
treatment period. 
f) Food intake records (Appendix 3-7) 
Subjects were asked to maintain their normal diet and routine activities. They were 
instructed to record their diet in the dietary record form. The forms include day-by-
day, meal-by-meal records of all food and liquids consumed over three days at the 
beginning of the trial and a further random three days in each treatment period. The 
food intake records were subsequently analysed using a standard dietary software 
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package (Food Works, Xyris, Brisbane, Australia) incorporating the latest Australian 
database of food composition (NUTTAB 2006, FSANZ, Canberra, Australia). Nutrient 
intake was averaged over the initial three-day period to determine the daily intake of 
macro- and micro-nutrient, fat subtypes, and total energy as the subject's baseline 
diet. Dietary data collected during study periods were compared to baseline to 
determine any change in dietary intake. 
g) Chinese medicine diagnosis questionnaire (Appendix 3-8) 
The CM diagnosis questionnaire was used by a CM practitioner to assess syndromes 
from a CM perspective: Damp, Damp-heat, Lung Qi deficiency, Lung and Spleen 
deficiency and Kidney Yang deficiency. This instrument was used in the first and last 
visit. This is in a FPS format where a higher score means a high level of deficiency . 
(h) Serological data 
Blood collections for serological data were conducted only at the first and the last 
visit. The serological data included cholesterol, LDL, HDL, triglycerides, fasting 
insulin and glucose for calculation of homeostasis model assessment of insulin 
resistance (HOMA-IR), and renal and liver function tests. 
4.3.5 Source data entry 
All data were entered onto the Case Record Form by authorised personnel involved 
in this project. All personnel received a training session on how to enter data prior to 
the commencement of the study. All data entries were dated and initialled by the 
responsible individuals. Assessors or data collectors were blinded to the treatment 
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assignment from the randomisation process to the decision of breaking codes until 
the study was completed.  
Standard operation procedure for data entry onto the CRF was developed to guide all 
individuals involved in the study and were used as a training tool. Any corrections or 
changes of data were recorded and data entry into the database was performed 
continuously throughout the study. Double-checking was performed to ensure 
accuracy of the data. Descriptive statistics on each important variable in the database 
was performed without unmasking the codes to detect doubtful data. 
4.3.6 Data analysis 
Data were summarised as means and standard error of mean (SEM). The data were 
analysed using the Statistical Package for the Social Sciences (SPSS, Windows 
Version 11.5). The statistical procedure employed was repeated measures analysis 
of variance utilising the General Linear Model (GLM). The data from non-repeated 
measures including blood tests were analysed by t-tests. All P values were 2-tailed at 
a significant level of  = 0.05.  
All data were analysed using the SPSS, version 18 for Windows. ITT analysis 
included all randomised patients with baseline data with at least one outcome after 
the interventions were determined using the last-value-carried-forward method. 
Outcomes were evaluated by comparing baseline data with data after 12 weeks of 
intervention for the variables BW, BMI, WC, HC, hip-to-waist ratio (HWR), and BF. 
The data from non-repeated measures including blood tests were analysed using t-
tests. Ordinal data variables involving baseline and end of study within each 
treatment group (TG) were analysed using the Wilcoxon signed-rank test. Gender 
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balance in the two groups was assessed using the Chi-square test. Analysis of 
covariance (ANCOVA) was used to assess whether the treatment and placebo 
groups were significantly different on variables assessed at the end of the study 
using baseline as covariate. All statistical tests were assessed at α = 0.05 with 
adjustments to α where necessary to accommodate testing involving multiple 
outcomes. 
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Chapter 5. Systematic review of acupuncture in the 
management of obesity 
5.1 Introduction 
This chapter reports the results of the systematic review of RCTs using acupuncture 
for the treatment of obesity using the method described in Chapter 4. 
5.2 Results of search 
Following the established search strategies, there were a total of 2,610 records 
(846 from English databases and 1,764 from Chinese databases) retrieved from 
electronic databases and no references through hand searching until 15 November 
2013. Initially, 874 duplicated references were removed. The remaining 1,736 studies 
were screened by their titles and abstracts. Among them, 1,548 records were 
excluded. Full texts were obtained for the remaining 188 studies and 165 were 
excluded. As a result, 23 of them met the inclusion criteria and they were included in 
the current review. The study selection process with detailed exclusion reasons is 
illustrated in the Figure 5.1. 
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Figure 5.1: Flow chart of study selection process of RCTs of acupuncture for obesity 
 
  
Records identified 
through English 
database searching  
(n = 846) 
Records identified through 
Chinese database searching
(n = 1,764) 
Records before 
duplicates removed 
(n = 2,610) 
Records after duplicates 
removed (n = 1,736) 
Records excluded, with reasons (n = 1,548) 
‐ Animal studies (n = 179) 
‐ Non-RCT (n = 828) 
‐ Not for assessing effects of obesity  
(n = 218) 
‐ Not for assessing effects of acupuncture  
(n = 48) 
‐ Inappropriate comparators (n = 274) 
‐ Non-adult study (n = 1) 
Full-text articles 
assessed for eligibility   
(n = 188) 
Full-text articles excluded with reasons (n = 
165) 
‐ Non-RCT (n = 64) 
‐ Not for assessing effects of obesity (n = 6) 
‐ Not for assessing effects of acupuncture (n 
= 6) 
‐ Inappropriate comparators (n = 69) 
‐ Non-adult studies (n = 10) 
‐ Non-English/Chinese (n = 4) 
‐ Duplicated publication (n = 6) 
 RCTs included in 
qualitative synthesis (n = 
23)
RCTs included in quantitative 
synthesis (meta-analysis)  
(n = 15) 
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5.3 Description of studies 
Among the 23 included RCTs, four trials were published in English (Abdi et al., 2012; 
Darbandi et al., 2013; Gucel et al., 2012; Xu et al., 2013) and the rest of the 19 
studies were published in Chinese. The summary of characteristics of the included 
RCTs is provided in Table 5.1.
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Table 5.1: Characteristics of 23 included studies 
 Author, 
Year 
Setting Randomised 
sample size 
Intervention Outcome 
measure 
Adverse 
events 
T (n, 
age) 
C (n, 
age) 
T C 
Acu vs 
Sham 
acu 
Gucel 
2012 
Clinic, 
outpatient
s 
20, NS 
M/F: 
0/20 
20, NS 
M/F: 
0/20 
Acupoints:  
Hegu (LI4), Shenmen (HT7), 
Zusanli (ST36), Neiting (ST44), 
Sanyinjiao (SP6)  
Tech: manual acupuncture 
Duration: 5 wks 
Sessions: 10 
Frequency: 2/wk 
Insertion depth: 5-10 mm 
Retention time: 20 mins 
Follow-up: NS 
Acupoints:  
Sham acupuncture near: 
Hegu (LI4), Shenmen 
(HT7), Zusanli (ST36), 
Neiting (ST44), 
Sanyinjiao (SP6) 
Tech: sham 
acupuncture 
Duration: 5 wks 
Sessions: 10 
Frequency: 2/wk 
Retention time: 20 mins 
Follow-up: NS 
BMI  
Plasma 
ghrelin 
CCK 
NS 
Zhang 
2012 
NS 15, 20-
66 yrs 
M/F: 
NS 
15, 20-
66 yrs 
M/F: 
NS 
Acupoints:  
Tianshu (ST25), Sanyinjiao (SP6), 
Zhongwan (CV12),  Zusanli (ST36)
Tech: after Deqi, connect electro 
Acupoints: Sham 
acupuncture, sham-
electro stimulate 
1.0~1.5cm near: Tianshu 
(ST25), Sanyinjiao 
(SP6), Zhongwan 
BMI  WHR 
BF % 
mild 
ecchymosis 
(T group) 
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 Author, 
Year 
Setting Randomised 
sample size 
Intervention Outcome 
measure 
Adverse 
events 
T (n, 
age) 
C (n, 
age) 
T C 
machine (LH202H) 50/100Hz 
Duration: 1 mth 
Sessions: 20 
Frequency: 5/wk 
Insertion depth: NS 
Retention time: 30 mins 
Follow-up: NS 
(CV12), Zusanli (ST36)  
Tech: sham acu 
Duration: 1 months  
Sessions: 20  
Frequency: 5/wk 
Retention time: 30 mins 
Follow-up: NS 
Acu vs 
No 
treatmen
t 
Luo 
2007 
NS T1: 20, 
21-48 
yrs 
M/F: 
8/12. 
T2: 20, 
21-48 
yrs; 
M/F: 
10/10 
20, 21-
48 yrs 
M/F: 
6/14 
Acupoints:  
(1) Liangqiu (ST34), Xuehai 
(Sp10), Zhigou (SJ6), Waiguan 
(SJ5), Sanyinjiao (SP6), Zusanli 
(ST36), Fujue (SP14), Daimai 
(GB26), Tainshu (ST25),Wailing 
(ST26), Guanyuan (CV4),Taixi 
(KI3), Shangjuxu (ST37) 
 (2) Gongsun (SP4), Neiting 
(St44), Fenglong (ST40), Neiguan 
(PC6), Yinlingquan (SP9), Zusanli 
(ST36), Shuifen (CV9), Zhongwan 
(CV12), Daju (ST27), Shuidao 
(ST28), Guanyuan (CV4), 
Taichong (LR3), Quchi (LI11), 
No treatment BMI, WHR   
Serum 
cholesterol 
NS 
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 Author, 
Year 
Setting Randomised 
sample size 
Intervention Outcome 
measure 
Adverse 
events 
T (n, 
age) 
C (n, 
age) 
T C 
Xiajuxu (ST39) 
Tech: After Deqi, Electro group 
use electro machine (G6805-B), 2-
5mA, 0.8~3Hz at Tianshu (ST25), 
Fujue (SP14), Zhigou (SJ6), 
Fenglong (ST40), Shuifen (CV9), 
Zhongwan (CV12), Inseriton 
depth: NS 
Duration: 65 days 
Sessions: 27 
Frequency: once every other day 
Retention time: 30 min 
Follow-up: NS 
Wang 
2006b 
NS 18, 20-
55 yrs 
M/F: 
NS 
18, 20-
55 yrs 
M/F: 
NS 
Acupoints:  
(1) ST heat:10 abdomen points+ 
Quchi (LI11), Neiting ST44), 
Shangjuxu (ST37), Pishu 
(BL20),Xuehai (SP10), Fenglong 
(ST40) 
(2) Qi deficiency: 10 abdomen 
points+ Shangjuxu (ST37), 
Sanyinjiao (SP6),Yinlingquan 
(SP9), Pishu (BL20), Xinshu 
Duration: 30days 
No treatment for 30days  
And take an 
electrogastrography 
before and after 30 days. 
BW 
BF%, BMI 
NS 
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 Author, 
Year 
Setting Randomised 
sample size 
Intervention Outcome 
measure 
Adverse 
events 
T (n, 
age) 
C (n, 
age) 
T C 
(BL15), Taixi (KI3), Guanyuan 
(CV4) 
Tech:manual acupuncture 
Duration: 30 days 
Insertion Depth:NS 
Sessions: 30 
Frequency: 1/day 
Retention time: 50 mins 
Follow-up: NS 
Xu 2013 Hospital, 
outpatient
s 
T1: 15, 
29-63 
yrs; 
M/F: 
0/15. 
T2: 15, 
29-63 
yrs; 
M/F: 
0/15 
15, 29-
63 yrs 
M/F: 
0/15 
Acupoints:  
Zhongwan (CV12),Suifen (CV9), 
Qihaishu (BL24),Shuidao (ST28), 
Tianshu (ST25),Zusanli (ST36 ), 
Sanyinjiao (SP6) 
Tech: manual acupuncture 
Duration: 40 days 
Insertion Depth:1.5 inch 
Sessions: 20 
Frequency: once every other day 
Duration: 40 days 
No treatment  
BMI  
Gut 
microbiota 
NS 
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 Author, 
Year 
Setting Randomised 
sample size 
Intervention Outcome 
measure 
Adverse 
events 
T (n, 
age) 
C (n, 
age) 
T C 
Retention time: 30 mins 
Follow-up: NS 
Acu vs 
Diet 
Chen 
2008 
Hospital, 
outpatient
s 
112, 
18-49 
yrs 
M/F: 
14/98 
C1: 
112, 
20-50; 
M/F: 
12/100. 
C2: 
110, 
19-47 
yo; M/F: 
11/99 
Acupoints: 
Zhongwan (CV12),Tianshu 
(ST25), Zusanli (ST36),Guanyuan 
(CV4), Shangjuxu 
(ST37),Fenglong 
(ST40),Yinlingquan (SP9), 
Sanyinjiao (SP6)+Pishu 
(BL20) ,Weishu (BL21), 
Dachangshu (BL25) 
Tech: manual acu+diet control 
Duration: 2months 
Insertion depth: NS 
Sessions:30 times 
Frequency:1/2 days 
Retention time: 30 mins 
Follow-up: 1 year 
Control 1 group:  
Simple acupuncture+ 
Diet control 
Control 2 group  
No acupuncture+ Diet 
control   
Duration: 2 months 
Sessions:30 times 
Insertion depth: NS 
Frequency: 1/2days 
Retention time: 30 min 
Follow-up: 1 year 
BW 
BF% 
NS 
Fan 
2005 
Hospital, 
outpatient
50, NS 
M/F: 
50, NS 
M/F: 
Acupoints:  
Xuehai (SP10), Sanyinjiao (SP6), 
Diet  
 
BMI   TC NS 
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 Author, 
Year 
Setting Randomised 
sample size 
Intervention Outcome 
measure 
Adverse 
events 
T (n, 
age) 
C (n, 
age) 
T C 
s 11/39 10/40 Tianshu (ST25),  Zusanli (ST36), 
Hegu (LI4) 
+ Fenlong (ST40)  
+ Quchi (LI11) 
+ Taixi (KI3) 
+ Taichong (LR3) 
+ Qihai (CV6) 
Tech: Manual acupuncture  
Duration: 50 days 
Sessions: 30 
Insertion depth: NS 
Frequency: 1/day for the first 10 
sessions; then once every other 
day for the last 20 sessions 
Retention time: 30 mins 
Follow-up: NS 
 
Shen 
2000 
NS 30, 18-
52 yrs; 
M/F: 
30, 18-
52 yrs; 
M/F: 
Acupoints: 
Huatuojiaji (HTJI) T3~L5 
Tech: Manual Acupuncture 
Use tea for weight loss 
or diet 
Duration 15 days 
Not 
specified 
NS 
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 Author, 
Year 
Setting Randomised 
sample size 
Intervention Outcome 
measure 
Adverse 
events 
T (n, 
age) 
C (n, 
age) 
T C 
1/29 1/29 Duration: 30 days 
Sessions: 30 
Insertion depth: 1-1.5 cun 
Frequency: 1/day 
Retention time: 30 min 
Follow-up: 6months 
Session: 30  
Frequency: 2 times/day 
 
Acu + 
diet vs 
Sham 
acu + 
same 
diet 
Abdi 
2012 
Hospital, 
outpatient
s 
98, 18-
55 yrs 
M/F: 
NS 
98, 18-
55 yrs 
M/F: 
NS 
Acupoints:  
Tianshu (ST25), Weidao (GB28), 
Zhongwan (CV12),Guanyuan 
(CV4), Sanyinjiao (SP6) 
+ Quchi (LI11), Fenglong (ST40) 
+ Yinlingquan (SP9), Qihai (CV6) 
+ Electrical stimulation 
(ST25,GB28) 
Tech: Manual Acupuncture+ 
Electro 30-40Hz dense-disperse 
wave, 12-23 V  
Duration: 6 wks 
Sessions: 12 
Acupoints:  
Laterally and up the real 
position 0.3~0.5 cm 
Tech: sham acu 
Duration: 6 wks 
Sessions: 12 
Frequency: 2/wk 
Retention time: 20 mins 
Follow-up: NS 
BW, BMI, 
BF% ,TG, 
TC, LDL-C, 
HDL-C 
NS 
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 Author, 
Year 
Setting Randomised 
sample size 
Intervention Outcome 
measure 
Adverse 
events 
T (n, 
age) 
C (n, 
age) 
T C 
Insertion depth: 2.5cm 
Frequency: 2/wk 
Retention time: 20 min 
Follow-up: NS 
Darband
i 2013 
Hospital, 
outpatient
s 
42, 18-
55 yrs 
M/F: 
10/32 
44, 18-
55 yrs 
M/F: 
10/34 
Acupoints:  
Tianshu (ST25), Weidao (GB28), 
Zhongwan (CV12), Guanyuan 
(CV4), Sanyinjiao (SP6), Shuifen 
(CV9) 
+ Quchi (LI11), Fenglong (ST40) 
+ Yinlingquan (SP9), Qihai (CV6) 
Tech: EA 30-40 Hz dense-
disperse wave 12-23v 
Duration: 6 wks 
Sessions: 12 
Insertion depth:  
Frequency: 2/wk 
Retention time: 20 mins 
Follow-up: 2 months 
Acupoints:  
Laterally and up the real 
position 0.3~0.5 Cm  
Tech: sham acu 
Retention time: 20min 
Follow-up: 2 mths 
BW 
BMI 
BF% 
No adverse 
events 
observed 
127 
 
 Author, 
Year 
Setting Randomised 
sample size 
Intervention Outcome 
measure 
Adverse 
events 
T (n, 
age) 
C (n, 
age) 
T C 
Tong 
2010 
Hospital, 
outpatient
s 
76, 18-
60 yrs 
M/F: 
18/58 
42, 18-
60 yrs 
M/F: 
12/30 
Acupoints:  
Zhongwan (CV12), Zhongji (CV3), 
Daheng (SP12), Xiawan (CV10), 
Shimen (CV5), Tianshu (ST25), 
Liangqiu (ST34), Zusanli 
(ST36),Yinlingquan (SP9) 
Tech: manual acu 
Duration: 24 days 
Insertion depth: NS 
Sessions: 12 
Frequency: once every other day 
Retention time: 30 mins 
Follow-up: NS 
Acupoints:  
Tech: sham acu 
 
BMI  
 
NS 
Acu + 
OT vs 
same 
OT 
Chen 
2008 
(same 
trial 6) 
Hospital, 
outpatient
s 
112, 
18-49 
yrs 
M/F: 
14/98 
C1: 
112, 
20-50; 
M/F: 
12/100. 
C2: 
110, 
19-47 
Acupoints: 
Zhongwan (CV12),Tianshu 
(ST25), Zusanli (ST36), Guanyuan 
(CV4), Shangjuxu (ST37), 
Fenglong (ST40),Yinlingquan 
(SP9), SanYinjiao (SP6) + Pishu 
(BL20), Weishu (BL21), 
Dachangshu (BL25) 
Control 1 group:  
Simple acupuncture + 
Diet 
Control 2 group  
No acupuncture + Diet   
Duration: 2 months 
BW 
BF% 
NS 
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 Author, 
Year 
Setting Randomised 
sample size 
Intervention Outcome 
measure 
Adverse 
events 
T (n, 
age) 
C (n, 
age) 
T C 
yrs; 
M/F: 
11/99 
Tech: manual acu + diet 
Duration: 2 months 
Insertion depth: NS 
Sessions:30 times 
Frequency: ½ days 
Retention time: 30 mins 
Follow-up: 1 year 
Sessions: 30 times 
Insertion depth: NS 
Frequency: ½ days 
Retention time: 30 mins 
Follow-up: 1 year 
Chen 
2013 
Hospital, 
outpatient
s 
52, 19-
50 yrs 
M/F: 
19/33 
51, 18-
51 yrs 
M/F: 
16/35 
Acupoints:  
Zhongwan (CV12), Qi hai (CV6), 
Huoroumen (ST24),Daheng 
(SP12), Zhigou (SJ6),Zusanli 
(ST36), Liangqiu 
(ST34),Sanyinjiao (SP6) 
+Yinlingquan (SP9),Gongsun 
(SP4) 
+Hegu (LI4),Quchi (LI11), 
Fenglong (ST40),Neiting (ST44) 
+Yanglingquan (GB34),Taichong 
(LR3) 
+Neiguan (PC6),Taixi (KI3) 
Diet   
 
Carbamazepine 0.1g, 
3/day 
Standard 
BW 
NS 
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 Author, 
Year 
Setting Randomised 
sample size 
Intervention Outcome 
measure 
Adverse 
events 
T (n, 
age) 
C (n, 
age) 
T C 
+Shangwan (CV13),Xiajuxu 
(ST39),Shousanli (LI10) 
Tech: EA+diet control  
Duration: 30 days 
Sessions: 30 
Insertion depth:NS 
Frequency: 1/day 
Retention time: 30 min 
Follow-up: NS 
Dai 
2006 
Hospital, 
outpatient
s 
48, 19-
53 yrs 
M/F: 
10/38 
48, 20-
53 yrs 
M/F: 
11/37 
Acupoints:  
Zhongwan (CV12), Tianshu 
(ST25) Neiting (ST44), Shangjuxu 
(ST37) 
+Zusanli (ST36),Qihai (CV6) 
+ Fenglong (ST40), Shuidao 
(ST28), Yinlingquan (SP9) 
+Shangwan (CV13),Neiguan 
(PC6), Sanyinjiao (SP6) 
Tech: Manual Acupuncture+ 
Electro G6805-2  
Diet 
(F<6276KJ/D 
M<7531KJ/D) 
 
BMI 
 TG, TC, 
LDL-C, 
HDL-C 
NS 
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 Author, 
Year 
Setting Randomised 
sample size 
Intervention Outcome 
measure 
Adverse 
events 
T (n, 
age) 
C (n, 
age) 
T C 
Duration: 2 months 
Insertion depth:NS 
Sessions: 30 
Frequency: once every other day 
Retention time: 25 mins 
Follow-up: NS 
He 2011 Hospital, 
outpatient
s 
60, 25-
45 yrs 
M/F: 
NS 
60, 25-
45 yrs 
M/F: 
NS 
Acupoints:  
Zhongwan (CV12), Jianli (CV11), 
Qihai (CV6), Guanyuan (CV4), 
Huoroumen (ST24), Tianshu 
(ST25), Shuidao (ST28), Guilai 
(ST29) 
+ Zusanli (ST36), Neiting 
(ST44),Quchi (LI11), Hegu (LI4) 
+ Shangjuxu (ST37), Xiajuxu 
(ST39) 
+ Yinlingquan (SP9), Gongsun 
(SP4), 
Neiguan (PC6), Zusanli (ST36), 
Zangmen (LR13) 
+ Taichong (LR3), Ququan (LR8), 
Exercise and diet BW,BMI 
Blood lipid 
FBG 
NS 
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 Author, 
Year 
Setting Randomised 
sample size 
Intervention Outcome 
measure 
Adverse 
events 
T (n, 
age) 
C (n, 
age) 
T C 
Ganshu (BL18), Zusanli (ST36) 
+ Sanyinjiao (SP6) 
+ Zusanli (ST36),Yinlingquan 
(SP9), Zhigou (SJ6), Zhaohai (KI6) 
Daimai (GB26), Sanyinjiao (SP6) 
Tech: manual Acu + Electro + 
Exercise + diet 
Duration: 74 days 
Sessions: 30 
Insertion depth:NS 
Frequency: once every other day 
Retention time: 30-40 min 
Follow-up: NS 
Li 2005 Clinic, 
outpatient
s 
35, NS 
M/F: 
0/35 
33, NS 
M/F: 
0/33 
Acupoints:  
Zhongwan (CV12), Qihai (CV6), 
Tianshu (ST25), Daheng (SP12) 
Daimai (GB26), Mangshu (KI16) 
Futonggu (KI20), Chengman 
(ST20) 
Tech: manual Acupuncture + diet 
 
diet (X<1200K cal/day)  
aerobic exercise 
(burning 250K cal/day) 
BW 
Lean body 
mass 
Soft lean 
mass 
Obesity 
degree 
NS 
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 Author, 
Year 
Setting Randomised 
sample size 
Intervention Outcome 
measure 
Adverse 
events 
T (n, 
age) 
C (n, 
age) 
T C 
+ Aerobic exercise 
Duration: 4 wks 
Sessions: 12 
Insertion depth: NS 
Frequency: 3/wk 
Retention time: 50 mins 
Follow-up: NS 
WC  HC TC 
Tao 
2009 
NS, 
outpatient
s 
20, 20-
27 yrs 
M/F: 
NS 
20, 20-
27 yrs 
M/F: 
NS 
Acupoints:  
Zhongwan (CV12), Qihai (CV6), 
Tianshu (ST25), Zhigou (SJ6), 
Fenglong (ST40), Liangqiu (ST34) 
Yinlingquan (SP9), Zusanli (ST36), 
Sanyinjiao (SP6), Neiting (ST44) 
Tech: Manual Acupuncture + 
Control Diet 
Duration: 20 days 
Insertion depth: NS 
Sessions: 20 
Frequency: 1/day 
Diet  BW 
BMI   
 TG, TC, 
LDL-C, 
HDL-C 
NS 
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 Author, 
Year 
Setting Randomised 
sample size 
Intervention Outcome 
measure 
Adverse 
events 
T (n, 
age) 
C (n, 
age) 
T C 
Retention time: 30 mins 
Follow-up: NS 
Wang 
2006a      
NS, 
outpatient
s 
30, 25-
60 yrs 
M/F: 
NS 
29, 25-
60 yrs 
M/F: 
NS 
Acupoints:  
Baihui (CV 20), Quchi 
(LI11),Taichong (LR3), Zusanli 
(ST36) 
Tech: Manu acupuncture+ 
Exercise + dietary therapy 
Lotensin 
Duration: 2 months 
Sessions: 31 
Insertion depth: NS 
Frequency: 1/day in the first wk; 
then once every other day for the 
rest wks 
Retention time: 30 mins 
Follow-up: NS 
Exercise and diet 
Lotensin 
BP,   BW, 
BMI, WC, 
WHR, FPG,   
TC, TG, 
HDL-C,    
LDL-C, 
FINS 
NS 
Yang 
2010 
Hospital, 
outpatient
31, 18-
42 yrs 
30, 18-
48 yrs 
Acupoints:  
Zhongwan (CV12), Guanyuan 
Diet 
Aerobic exercise 
BW, BMI 
 TG, TC, 
NS 
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 Author, 
Year 
Setting Randomised 
sample size 
Intervention Outcome 
measure 
Adverse 
events 
T (n, 
age) 
C (n, 
age) 
T C 
s M/F: 
4/27 
M/F: 
3/27 
(CV4), Tianshu (ST25), Zhigou 
(SJ6), Fenglong (ST40), 
Yinlingquan (SP9), Sanyinjiao 
(SP6), Pishu (BL20), Weishu 
(BL21) 
Tech: Acupuncture + Diet therapy 
Aerobic exercise 
Duration: 51 days 
Insertion depth:NS 
Sessions: 45 
Frequency: 1/day 
Retention time: 30 mins 
Follow-up: NS 
LDL-C,  
HDL-C 
Ye 2010 Hospital, 
outpatient
s 
48,18-
50 yrs  
M/F: 
20/28 
48,18-
50 yrs  
M/F: 
21/27 
Acupoints:  
Tianshu (ST25), Guanyuan (CV4), 
Sanyinjiao (ST36), Fenglong 
(ST40), Zusanli (ST36) 
+ Quchi (LI11), Neiting (ST44), 
Sangjuxu (ST37) 
+ Yinlingquan (SP9), Qihai (CV6), 
Diet and exercise BW, BMI NS 
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 Author, 
Year 
Setting Randomised 
sample size 
Intervention Outcome 
measure 
Adverse 
events 
T (n, 
age) 
C (n, 
age) 
T C 
Pishu (BL20) 
Tech: After Deqi, use G6805-II 
50/100Hz  
Insertion depth NS 
Duration: 90 days 
Sessions: 45 
Frequency: once every other day 
Retention time: 30 mins 
Follow-up: NS 
Zhang 
2007 
NS, 
outpatient
s 
32, 18-
60 yrs 
M/F: 
12/20 
32, 19-
57 yrs 
M/F: 
10/22 
Acupoints:  
Zhongwan (CV12), Guanyuan 
(CV4), Tianshu (ST25), Shuifen 
(CV9), Yinjiao (CV7), KI16, Zusanli 
(ST36), Xuehai (SP10), Xinshu 
(BL15), Geshu (BL17), Pishu 
(BL20) 
+ Quchi (LI11), Fengshi (GB20), 
Liangqiu (ST34), Tianzong (SI11), 
Weiguanxiashu, Danshu (BL19) 
Dachangshu (BL25), Fenglong 
(ST40) 
Diet and exercise BW NS 
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 Author, 
Year 
Setting Randomised 
sample size 
Intervention Outcome 
measure 
Adverse 
events 
T (n, 
age) 
C (n, 
age) 
T C 
Tech: Electro KWD-8081 
(SI11,GB31,ST34,ST25), 
Exercise, simple diet control 
Duration: 2 mths 
Insertion depth:  
(1) 25~75mm (CV12,CV4,ST25) 
(2) 15~20mm (CV9,CV7,KI16) 
(3) 25~75mm (acu-points on the 
four limb) 
Sessions: 40 
Frequency: 5/wk 
Retention time: 20 min 
Follow-up: NS 
Zhang 
2011 
Hospital, 
outpatient
s 
T1: 26, 
18-50 
yo; 
M/F: 
NS. 
T2: 26, 
18-50 
yo; 
26, 18-
50 yo 
M/F: 
NS 
Acupoints:  
Zhongwan (CV12), Shuifen (CV9), 
Qihai (CV6), Tianshu (ST25), 
Daimai (GB26), Daheng (SP15), 
Zhigou (SJ6), Zusanli (ST36), 
Fenglong (ST40),Yinlingquan 
(SP9) 
Tech: Group A (conventional 
Diet control and  
Exercise (3~5/wk) 
BW 
BMI 
BF% 
NS 
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 Author, 
Year 
Setting Randomised 
sample size 
Intervention Outcome 
measure 
Adverse 
events 
T (n, 
age) 
C (n, 
age) 
T C 
M/F: 
NS 
intervention + electroacupunture), 
Group B (conventional intervention 
+ electoacu + intermediate 
frequency) 
G6805 2-15Hz  
Duration: 2 months 
Insertion depth: all points inner 
2.5cun  
Sessions: 30 
Frequency: 1/day in the first 3 
days; then once every other day 
for the rest days 
Retention time: 30 mins  
Follow-up:  
Zhao 
2010 
Hospital, 
outpatient
s 
35, 18-
60 yrs 
M/F: 
5/25 
(A) 
37, 18-
60 yrs 
M/F: 
6/24 (A)
Acupoints:  
Tianshu (ST25), Huroumen 
(ST24), Wailing (ST26), Futu 
(ST32), Zusanli (ST36), Shangjuxu 
(ST37), Xiajuxu (ST39), Neiting 
(ST44)  
Sanyinjiao (SP6), Daheng (SP15) 
Fujie (SP14), Zhongwan (CV12), 
Diet and exercise  BMI   FPG  
FINS 
HOMA-IR     
HbA1C % 
BP 
NS 
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 Author, 
Year 
Setting Randomised 
sample size 
Intervention Outcome 
measure 
Adverse 
events 
T (n, 
age) 
C (n, 
age) 
T C 
Xiawan (CV10), Guanyuan (LR8) 
Tech: Manu acupuncture+Diet-
therapy+Aerobic exercise 
Duration: 2 months 
Insertion depth: NS 
Sessions: 24 
Frequency: 4/wk for the first 4 
wks; then 2/wk for the rest 4 wks 
Retention time:  
Follow-up:  
Acu + 
OT vs 
WM + 
same 
OT 
24Dong 
2005 
Hospital, 
outpatient
s 
30, 18-
65 yrs 
M/F: 
NS 
30, 18-
65 yrs 
M/F: 
NS 
Acupoints:  
Xuehai (SP10), Pishu (BL20), 
Weishu (BL21), Zhongwan 
(CV12), Guanmen (ST22) 
Tech: Manual Acupuncture + 
control Diet + exercising (walking 
30 mins after having meal)    
Duration: 40 days 
Insertion depth: NS 
Sessions: 40 
WM: Sibutramine 
Hydrochloride 10mg/D + 
control diet + exercising 
(walking 30 mins after 
having meal)    
Duration: 40 days  
 
 
BW 
BF% 
T: 16.67% 
C: 42.86% 
appeared 
constipation, 
dizziness, 
insomnia, 
palpitation, 
high blood 
pressure 
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 Author, 
Year 
Setting Randomised 
sample size 
Intervention Outcome 
measure 
Adverse 
events 
T (n, 
age) 
C (n, 
age) 
T C 
Frequency: 1/day 
Retention time: 30 mins  
Follow-up: NS 
Note:  A: analysed number; Acu: acupuncture; BF%: body fat composition; BMI: body mass index; BP: blood pressure; BW: body weight; 
C: control group; CCK: cholecystokinin; Diet: dietary therapy; FBG: fasting blood glucose;  FPG: fasting plasma glucose;  GTT: glucose 
tolerance test; HbA1c: hemoglobin A1c;  HC: hip circumference; HDL-C: High density lipoprotein cholesterol;  HOMA-IR: homeostasis 
model assessment-estimated insulin resistance; LDL-C: low-density lipoprotein cholesterol ; mth: month;  NS: not stated;  OT: other 
therapy; TC: total cholesterol; Tech: technique; TG: triglyceride ; T: treatment group;  vs: versus;  WC: waist circumference;  WHR: waist 
and hip ratio;  wk: week; WM: Western medicine. 
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5.3.1 Design of studies 
Four studies were three-arm RCTs (Chen, 2008c; Luo & Li, 2007; Xu et al., 2013; 
Zhang, 2011). The rest of RCTs employed two arms. There were no cross-over trials 
among included studies. In the multi-arm studies only the groups meeting the 
inclusion criteria were included for data analysis in this review. 
Sixteen studies were single-centre trials (Abdi et al., 2012; Chen 2013; Chen, 2008c; 
Dai, 2006; Darbandi et al., 2013; Dong, 2005; Fan et al., 2005; Gucel et al., 2012; He 
et al., 2011; Li 2005; Tao, 2009; Tong et al., 2010; Xu et al., 2013; Zhang, 2011; 
Zhang & Ya, 2007; Zhao & Shi, 2010). Only one study was a multi-centre trial (Yang 
et al., 2010b).The rest six trials did not provide clear information on it (Luo & Li, 2007; 
Shen Jie 2000; Wang & Cheng 2006a; Wang & Li, 2006b; Ye & Yao 2010; Zhang et 
al., 2012). 
5.3.2 Sample sizes 
The sample sizes of the included studies varied from30 to 334, with an average of 86 
per trial. Two trials had sample sizes below 40 (Wang & Li, 2006b; Zhang et al., 
2012). The sample sizes of 16 trials were between 40 and 99 (Chen 2013; Dai, 2006; 
Darbandi et al., 2013; Dong, 2005; Gucel et al., 2012; Li 2005; Luo & Li, 2007; Shen 
Jie 2000; Tao, 2009; Wang & Cheng 2006a; Xu et al., 2013; Yang et al., 2010b; Ye & 
Yao 2010; Zhang, 2011; Zhang & Ya, 2007; Zhao & Shi, 2010).Four trials had 
sample sizes between 100 and 199 (Abdi et al., 2012; Fan et al., 2005; He et al., 
2011; Tong et al., 2010). Only one study had a sample size of over 200 (Chen, 
2008c). 
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5.3.3 Setting 
In the 23 included trials, 20 trials were conducted in mainland China (Chen 2013; 
Chen, 2008c; Dai, 2006; Dong, 2005; Fan et al., 2005; He et al., 2011; Li 2005; Luo 
& Li, 2007; Shen Jie 2000; Tao, 2009; Tong et al., 2010; Wang & Cheng 2006a; 
Wang & Li, 2006b; Xu et al., 2013; Yang et al., 2010b; Ye & Yao 2010; Zhang, 2011; 
Zhang et al., 2012; Zhang & Ya, 2007; Zhao & Shi, 2010) and three trials were 
performed outside mainland China, including two in Iran (Abdi et al., 2012; Darbandi 
et al., 2013), and one in Turkey (Gucel et al., 2012). 
Nineteen trials clearly stated that only out-patients were recruited in the studies (Abdi 
et al., 2012; Chen 2013; Chen, 2008c; Dai, 2006; Darbandi et al., 2013; Dong, 2005; 
Fan et al., 2005; Gucel et al., 2012; He et al., 2011; Li 2005; Tao, 2009; Tong et al., 
2010; Wang & Cheng 2006a; Xu et al., 2013; Yang et al., 2010b; Ye & Yao 2010; 
Zhang, 2011; Zhang & Ya, 2007; Zhao & Shi, 2010). The other four trials did not 
mention whether participants were in-patients or out-patients (Luo & Li, 2007; Shen 
Jie 2000; Wang & Li, 2006b; Zhang et al., 2012). 
Over two-thirds of the trials (16 out of 23) were conducted in hospitals (Abdi et al., 
2012; Chen 2013; Chen, 2008c; Dai, 2006; Darbandi et al., 2013; Dong, 2005; Fan et 
al., 2005; He et al., 2011; Tong et al., 2010; Wang & Cheng 2006a; Xu et al., 2013; 
Yang et al., 2010b; Ye & Yao 2010; Zhang, 2011; Zhang & Ya, 2007; Zhao & Shi, 
2010), and two trials were performed in a clinic (Gucel et al., 2012; Li 2005). The 
remaining five studies did not provide any information on the setting of the study (Luo 
& Li, 2007; Shen Jie 2000; Tao, 2009; Wang & Li, 2006b; Zhang et al., 2012). 
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5.3.4 Types of participants 
A total of 1968 participants were randomised in the included studies. They were aged 
from 18 to 66 years old. Seventeen studies clearly reported the range and mean of 
participants’ ages (Abdi et al., 2012; Chen 2013; Chen, 2008c; Dai, 2006; Darbandi 
et al., 2013; Dong, 2005; Li 2005; Luo & Li, 2007; Shen Jie 2000; Tao, 2009; Tong et 
al., 2010; Wang & Li, 2006b; Xu et al., 2013; Zhang, 2011; Zhang et al., 2012; Zhang 
& Ya, 2007; Zhao & Shi, 2010). Two studies did not report the range of ages but only 
indicated the mean of participants’ ages (Fan et al., 2005; Gucel et al., 2012). Four 
studies only indicated the range of ages without reporting the mean value of ages 
(He et al., 2011; Wang & Cheng 2006a; Yang et al., 2010b; Ye & Yao 2010). Among 
the studies which provided the range and mean value of the age, eight trials reported 
the range of ages for all participants without detailed information for each group (Abdi 
et al., 2012; Darbandi et al., 2013; Dong, 2005; Wang & Li, 2006b; Xu et al., 2013; 
Zhang, 2011; Zhang et al., 2012; Zhao & Shi, 2010). Four studies only stated the 
mean without providing the standard deviation (SD) (Chen, 2008c; Dai, 2006; Dong, 
2005; Wang & Li, 2006b). Two studies only listed the total mean of ages, but did not 
specify the mean of ages in the different groups (Wang & Li, 2006b; Xu et al., 2013). 
Just three studies did not indicate the gender of the participants (Abdi et al., 2012; He 
et al., 2011; Tao, 2009); the remaining 20 studies involved 1,284 females and 375 
males. All the participants in the RCTs were clearly diagnosed as having obesity 
according to its diagnostic criteria. All the studies provide diagnostic criteria for 
overweight and/or obesity. 
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5.3.5 Types of interventions 
All the studies involved acupuncture in the TGs. The CGs included sham 
acupuncture, no treatment, and dietary therapy or community activities (consisting of 
health education, dietary therapy and exercise). Four studies compared acupuncture 
with sham acupuncture (Abdi et al., 2012; Darbandi et al., 2013; Gucel et al., 2012; 
Zhang et al., 2012). Three trials compared acupuncture with no treatment (Luo & Li, 
2007; Wang & Li, 2006b; Xu et al., 2013), and two trials (Fan et al., 2005; Shen Jie 
2000) plus one arm of the Chen 2008 and Yang 2010 study compared acupuncture 
with dietary therapy. Over two-thirds of the trials (16 out of 23) involved co-
interventions in both groups and acupuncture was assessed as an adjunct therapy to 
the co-intervention. Three trials compared acupuncture plus dietary therapy with 
sham acupuncture plus the same dietary therapy (Abdi et al., 2012; Darbandi et al., 
2013; Tong et al., 2010). Nearly half of the trials (11 out of 23) and one arm of the 
Chen 2008 study compared acupuncture plus other therapy with the same other 
therapy alone (Chen 2013; Dai, 2006; He et al., 2011; Li 2005; Tao, 2009; Wang & 
Cheng 2006a; Yang et al., 2010b; Ye & Yao 2010; Zhang, 2011; Zhang & Ya, 2007; 
Zhao & Shi, 2010). Three trials evaluated the adjunct effects of acupuncture with WM 
when using other dietary therapy and exercise as co-intervention (Chen 2013; Dong, 
2005; Wang & Cheng 2006a). 
Among the 23 RCTs, the forms of acupuncture were traditional Chinese acupuncture 
and EA. Ten studies used traditional Chinese acupuncture (Chen, 2008c; Dong, 
2005; Fan et al., 2005; Gucel et al., 2012; He et al., 2011; Shen Jie 2000; Tao, 2009; 
Tong et al., 2010; Wang & Li, 2006b; Xu et al., 2013). One trial involved both 
traditional Chinese acupuncture and EA (Luo & Li, 2007). The remaining 12 studies 
applied EA (Abdi et al., 2012; Chen 2013; Dai, 2006; Darbandi et al., 2013; Li 2005; 
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Wang & Cheng 2006a; Yang et al., 2010b; Ye & Yao 2010; Zhang, 2011; Zhang et 
al., 2012; Zhang & Ya, 2007; Zhao & Shi, 2010). 
All the included RCTs employed multiple points. However, all the acupuncture 
formulas used were different. However, less than half of the studies (10 out of 23) 
employed the differentiation of syndromes (Abdi et al., 2012; Chen 2013; Dai, 2006; 
Darbandi et al., 2013; Dong, 2005; Fan et al., 2005; He et al., 2011; Wang & Li, 
2006b; Ye & Yao 2010; Zhang, 2011). 
The top ten most frequently used acupuncture points were: 
Zusanli (ST36; in 30 trials), Tianshu (ST25; in 26 trials), Sanyinjiao (SP6; in 25 trials), 
Fenglong (ST40 in 24 trials), Zhongwan (CV12 in 20 trials), Yinlingquan (SP9 in 20 
trials), Quchi (LI11 in 18 trials), Qihai (CV6 in 18 trials), Guanyuan (CV4 in 16 trials), 
Shangjuxu (ST37 in 13 trials). Only nine included RCTs reported the depth of needle 
insertion (Abdi et al., 2012; Chen, 2008c; Gucel et al., 2012; He et al., 2011; Li 2005; 
Shen Jie 2000; Xu et al., 2013; Zhang, 2011; Zhang & Ya, 2007). The other 14 
studies did not provide the relevant information. 
The duration of treatments in the included studies varied from 20 days to three 
months. The treatment duration of two studies was from 20 days (inclusive) to one 
month (30 days) (exclusive) (Tao, 2009; Tong et al., 2010).Twelve studies treated 
patients from one month (30 days) (inclusive) to two months (60 days) (exclusive) 
(Abdi et al., 2012; Chen 2013; Darbandi et al., 2013; Dong, 2005; Fan et al., 2005; 
Gucel et al., 2012; Li 2005; Shen Jie 2000; Wang & Li, 2006b; Xu et al., 2013; Yang 
et al., 2010b; Zhang et al., 2012).Treatment periods of eight studies were from two 
months (60 days) (inclusive) to three months (90 days) (exclusive) (Chen, 2008c; Dai, 
2006; He et al., 2011; Luo & Li, 2007; Wang & Cheng 2006a; Zhang, 2011; Zhang & 
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Ya, 2007; Zhao & Shi, 2010). Only one study treated patients for three months (Ye & 
Yao 2010). 
Only two trials indicated follow-up periods after the last treatment, one for two months 
(Darbandi et al., 2013) and the other for one year (Chen, 2008c). The remaining trials 
did not provide any information on follow-up.  
Treatment sessions were varied across all the studies. Five studies conducted 10 
(inclusive) to 20 (exclusive) sessions of treatment (Abdi et al., 2012; Darbandi et al., 
2013; Gucel et al., 2012; Li 2005; Tong et al., 2010). Treatment sessions of another 
five studies were between 20 sessions (inclusive) and 30 sessions (exclusive) (Luo & 
Li, 2007; Tao, 2009; Xu et al., 2013; Zhang et al., 2012; Zhao & Shi, 2010). Nine 
studies delivered 30 (inclusive) to 40 sessions (exclusive) of treatment (Chen 2013; 
Chen, 2008c; Dai, 2006; Fan et al., 2005; He et al., 2011; Shen Jie 2000; Wang & 
Cheng 2006a; Wang & Li, 2006b; Zhang, 2011). Another four trials provided over 40 
treatment sessions (inclusive) (Dong, 2005; Yang et al., 2010b; Ye & Yao 2010; 
Zhang & Ya, 2007). 
All the included studies indicated the frequency of treatment. Five studies provided 
acupuncture treatment once a day (Chen 2013; Dong, 2005; Shen Jie 2000; Wang & 
Li, 2006b; Yang et al., 2010b). Seven studies had treatment once every other day 
(Chen, 2008c; Dai, 2006; He et al., 2011; Luo & Li, 2007; Tong et al., 2010; Xu et al., 
2013; Ye & Yao 2010). Four studies had treatment once a day followed by once 
every other day (Fan et al., 2005; Tao, 2009; Wang & Cheng 2006a; Zhang, 
2011).Three studies had treatment twice a week (Abdi et al., 2012; Darbandi et al., 
2013; Gucel et al., 2012). One study offered the treatment three times per week (Li 
2005). Two trials treated participants five times per week (Zhang et al., 2012; Zhang 
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& Ya, 2007). The Zhao 2010 study provided treatment four times a week for the first 
four weeks followed by twice a week for another four weeks (Zhao & Shi, 2010). 
Except four trials which did not describe whether De Qi sensation was achieved 
(Darbandi et al., 2013; Li 2005; Wang & Li, 2006b; Xu et al., 2013), the remaining 19 
studies indicated that De Qi sensation was obtained during the acupuncture 
treatment. 
All the studies indicated the retention time of needling during the acupuncture 
treatment. The majority of RCTs needled the points for 20 minutes ([in four trials: 
(Abdi et al., 2012; Darbandi et al., 2013; Gucel et al., 2012; Zhang & Ya, 2007) or 30 
minutes (in 15 studies: Chen 2013; Chen, 2008c; Dong, 2005; Fan et al., 2005; Luo 
& Li, 2007; Shen Jie 2000; Tao, 2009; Tong et al., 2010; Wang & Li, 2006b; Xu et al., 
2013; Yang et al., 2010b; Ye & Yao 2010; Zhang, 2011; Zhang et al., 2012; Zhao & 
Shi, 2010). One trial retained the needles for 25 minutes (Dai, 2006). One study 
inserted needles for 30 to 40 minutes (He et al., 2011). Two trials did needle retention 
for 50 minutes (Li 2005; Wang & Li, 2006b). 
The intervention in the CG consisted of sham acupuncture (six trials), no treatment 
(three trials), WM (three trials), and dietary therapy, exercise or education (19 trials). 
When co-intervention was not involved in the trials, with acupuncture in the active 
intervention group, four studies compared acupuncture with sham acupuncture (Abdi 
et al., 2012; Darbandi et al., 2013; Gucel et al., 2012; Zhang et al., 2012); and three 
trials (Fan et al., 2005; Shen Jie 2000; Yang et al., 2010b) while one arm of a three-
arm trial (Chen, 2008c) used dietary therapy. Three studies did not provide any 
treatment in the CGs (Luo & Li, 2007; Wang & Li, 2006b; Xu et al., 2013); the Yang 
2010 study compared acupuncture with dietary therapy. 
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Co-intervention with acupuncture was applied in 16 studies. Three studies compared 
acupuncture plus dietary therapy with sham acupuncture plus dietary therapy (Abdi et 
al., 2012; Darbandi et al., 2013; Tong et al., 2010). Acupuncture plus other therapy 
was compared to the same other therapy alone in 11 studies (Chen 2013; Dai, 2006; 
He et al., 2011; Li 2005; Tao, 2009; Wang & Cheng 2006a; Yang et al., 2010b; Ye & 
Yao 2010; Zhang, 2011; Zhang & Ya, 2007; Zhao & Shi, 2010) and one arm of a 3-
arm trial (Chen, 2008c). One trial compared acupuncture plus dietary therapy and 
exercise with WM plus same dietary therapy and exercise (Dong, 2005).  
5.3.6 Types of outcome measures 
5.3.6.1 Body weight 
Ten studies assessed BW (Abdi et al., 2012; Darbandi et al., 2013; Dong, 2005; 
Gucel et al., 2012; Li 2005; Tao, 2009; Wang & Cheng 2006a; Yang et al., 2010b; 
Zhang, 2011; Zhao & Shi, 2010) at the end of treatment period. 
5.3.6.2 Body mass index 
Thirteen RCTs evaluated BMI: (Abdi et al., 2012; Darbandi et al., 2013; Gucel et al., 
2012; He et al., 2011; Luo & Li, 2007; Tao, 2009; Tong et al., 2010; Wang & Cheng 
2006a; Xu et al., 2013; Yang et al., 2010b; Zhang, 2011; Zhang et al., 2012; Zhao & 
Shi, 2010) 
5.3.6.3 Body fat composition 
Six trials assessed the BF composition (Abdi et al., 2012; Dong, 2005; Li 2005; Wang 
& Li, 2006b; Zhang, 2011; Zhang et al., 2012). 
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5.3.6.4 Waist circumference 
Five studies measured the WC (Abdi et al., 2012; Li 2005; Tao, 2009; Wang & Cheng 
2006a; Zhao & Shi, 2010).  
5.3.6.5 Hip circumference 
Three trials measured the HC (Abdi et al., 2012; Li 2005; Tao, 2009).  
5.3.6.6 Adverse events 
Two included studies monitored adverse events (Dong, 2005; Zhang et al., 2012). 
Dong 2005 has reported constipation, dizziness, insomnia, palpitations and high 
blood pressure (treatment group 16.67%, CG 42.86%); Zhang 2012 reported mild 
ecchymosis in the TG. None of the other 21 included studies reported adverse events. 
Chen et al. 2008 observed three (out of 112) drop-outs from acupuncture plus the 
dietary therapy group, five (out of 110) drop-outs from the acupuncture alone group 
and 58 drop-outs from dietary therapy alone group. However, reasons for drop-outs 
were not provided. It was unclear if any drop-outs were associated with adverse 
events.  
5.4  Risk of bias in included studies 
The graph and summary of ‘Risk of bias’ assessment are provided in Figures 5.2 and 
5.3. Each domain of the assessment of risk of bias is described as below. 
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Figure 5.2: Risk of bias graph of included RCTs of acupuncture for obesity 
 
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other bias
0% 25% 50% 75% 100%
Low risk of bias Unclear risk of bias High risk of bias
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Figure 5.3: Risk of bias summary of included RCTs of acupuncture for obesity 
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5.4.1 Random sequence generation (selection bias) 
All included trials stated that participants were randomly assigned into treatment and 
CGs. Eleven included trials provided the methods used for randomisation, including 
random number tables in seven studies (Darbandi et al., 2013; Tao, 2009; Tong et al., 
2010; Yang et al., 2010b; Zhang, 2011; Zhang & Ya, 2007; Zhao & Shi, 2010), 
computer-generated random table in two studies (Gucel et al., 2012; Zhang et al., 
2012), draw in one study (Ye & Yao 2010), and three-colour cards in one study (Luo 
& Li, 2007). The other 12 trials did not describe the methods used for randomisation. 
5.4.2 Allocation concealment (selection bias) 
Among 23 included studies, only three trials reported the methods for allocation of 
randomisation. Two studies used sealed opaque envelopes to allocate random 
numbers to participants (Zhang et al., 2012; Zhao & Shi, 2010). One trial used an urn 
to allocate random numbers to participants (Gucel et al., 2012). The rest of the 20 
studies did not describe the methods used for allocation concealment. 
5.4.3 Blinding (performance bias and detection bias) 
As it is impossible to blind an acupuncturist to perform treatment, double-blinding was 
defined as blinding of both participants and outcome assessors. Only one trial 
employed double-blinding (Zhang et al., 2012). Four trials employed single-blinding of 
participants (Abdi et al., 2012; Darbandi et al., 2013; Gucel et al., 2012; Tong et al., 
2010). 
5.4.3.1 Blinding of participants 
Five studies employed sham acupuncture as control interventions to blind 
participants (Abdi et al., 2012; Darbandi et al., 2013; Gucel et al., 2012; Tong et al., 
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2010; Zhang et al., 2012). Another 13 trials used different forms of treatments in two 
groups which made the blinding of participants unlikely (Fan et al., 2005; He et al., 
2011; Li 2005; Luo & Li, 2007; Shen Jie 2000; Wang & Cheng 2006a; Wang & Li, 
2006b; Xu et al., 2013; Yang et al., 2010b; Ye & Yao 2010; Zhang, 2011; Zhang & Ya, 
2007) Zhao 2010. The rest of the five studies did not provide adequate information 
on blinding.  
5.4.3.2 Blinding of outcome assessors 
Only one trial blinded outcome assessors (Zhang et al., 2012). The blinding of 
outcome assessors was unlikely in six studies as only one author conducted the trial 
(Chen 2013; Chen, 2008c; Dai, 2006; Dong, 2005; Tao, 2009; Zhang, 2011). The 
remaining 16 studies did not provide sufficient information on blinding. 
5.4.4 Incomplete outcome data (attrition bias) 
The attrition bias was only assessed for the effects immediately after the last 
treatment. More than two thirds of included studies (18 out of 23) had the identical 
number of participants randomised and reported in the results for the outcomes 
(Chen 2013; Dai, 2006; Fan et al., 2005; Gucel et al., 2012; He et al., 2011; Li 2005; 
Luo & Li, 2007; Shen Jie 2000; Tao, 2009; Tong et al., 2010; Wang & Cheng 2006a; 
Wang & Li, 2006b; Xu et al., 2013; Ye & Yao 2010; Zhang, 2011; Zhang et al., 2012; 
Zhang & Ya, 2007, Yang 2010). Among them, only one study clearly stated that all 
participants completed the trials which implied that there were no withdrawals/drop-
outs at the end of treatment period (Gucel et al., 2012). Five studies reported a total 
of 117 withdrawals/drop-outs (Abdi et al., 2012; Chen, 2008c; Darbandi et al., 2013; 
Dong, 2005; Zhao & Shi, 2010). Two of them indicated that those withdrawals/drop-
outs did not comply with the treatment protocol (Chen, 2008c; Zhao & Shi, 2010). 
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One of them mentioned that those withdrawals/drop-outs were due to side-effects 
(Dong, 2005). However, no further details were provided in these three studies. The 
other two studies did not provide any reasons for the withdrawals/drop-outs. None of 
these five trials applied the ITT method to their data analysis.  
5.4.5 Selective reporting (reporting bias) 
To determine whether the studies selectively reported their results, published papers 
were supposed to be compared with their protocol. However, none of the included 
studies reported their protocol prior to publishing the final results. Therefore, in the 
current review, the selective reporting was assessed by comparing the results with 
the outcome measures listed in the methods section in the same published papers. 
Five studies did not report results for all the outcome measures (Dai, 2006; Darbandi 
et al., 2013; Dong, 2005; Wang & Li, 2006b; Zhang, 2011). Among them, the Dai 
(2006) trial did not report the results for CG (Dai, 2006). The Darbandi (2013) trial 
mentioned a 2-month follow-up but it did not report any results for the follow-up 
period. The Dong 2005 study did not present the follow-up effects (Dong, 2005). The 
Wang (2006b) trial did not report the outcomes of BW and BMI in the CG (Wang & Li, 
2006b). The Zhang (2011) study did not describe the WC after the treatment (Zhang, 
2011).  
5.4.6 Other bias 
Except for four RCTs (Dong, 2005; He et al., 2011; Wang & Li, 2006b; Xu et al., 2013) 
which did not provide any information on the baseline, the majority of included 
studies (19 out of 23) reported that the demographic data at the baseline were 
comparable. 
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Apart from four trials (Chen 2013; Chen, 2008c; Shen Jie 2000; Wang & Li, 2006b) 
which did not provide any selection criteria, the rest of the nineteen studies described 
valid and feasible inclusion and exclusion criteria which can be implemented into 
practice.  
5.5 Effects of interventions 
The effects of acupuncture compared to sham acupuncture, no treatment, Western 
medication and other therapy, with or without co-intervention, are reported as below. 
5.5.1 Real acupuncture versus sham acupuncture 
Two studies compared real acupuncture with sham acupuncture (Gucel et al., 2012; 
Zhang et al., 2012). 
5.5.1.1 Body weight 
Only one trial reported the results of BW at the end of treatment period (Gucel et al., 
2012). It showed that there was no significant difference between the real and sham 
acupuncture groups for the BW after five weeks’ treatment (MD -4.40, 95% CI -11.21 
to 2.41). 
5.5.1.2 Body mass index 
Both RCTs reported the results of BMI at the end of treatment period. The extracted 
data showed that real acupuncture was more effective for BMI than sham 
acupuncture (MD -1.88, 95% CI -3.68 to -0.07) (Figure 5.4). No heterogeneity existed 
in these two studies (I2 = 0%). 
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Figure 5.4: Comparison of real and sham acupuncture for BMI. 
 
5.5.1.3 Body fat composition 
Only one study presented the findings of BF composition (Zhang et al., 2012). The 
effect size analysis did not show any difference between the two groups (MD -2.80, 
95% CI -6.39 to 0.79). 
5.5.2 Acupuncture versus no treatment 
Three RCTs compared acupuncture with no treatment (Luo & Li, 2007; Wang & Li, 
2006b; Xu et al., 2013). Only two studies (Luo & Li, 2007; Xu et al., 2013) reported 
the results of BMI and thus they are included in the meta-analysis. 
5.5.2.1 Body mass index 
The extracted data from these two studies showed acupuncture was more effective 
for BMI than no treatment (MD -1.88, 95% CI -2.67 to -1.08) (Figure 5.5). There was 
no heterogeneity existed (I2 = 0%) 
 
Figure 5.5: Comparison of acupuncture and no treatment for BMI. 
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5.5.3 Acupuncture versus dietary therapy 
There were two RCTs (Fan et al., 2005; Shen Jie 2000) and one arm of a three-arm 
trial (Chen, 2008c) comparing acupuncture with dietary therapy. However, none of 
them reported the results for primary or secondary outcome measures. Thus, these 
studies were not included in meta-analysis. 
5.5.4 Real acupuncture plus dietary therapy versus sham acupuncture 
plus dietary therapy 
Three trials compared real acupuncture plus dietary therapy with sham acupuncture 
plus same dietary therapy (Abdi et al., 2012; Darbandi et al., 2013; Tong et al., 2010).  
5.5.4.1 Body weight 
Two trials measured and compared BW between two groups (Abdi et al., 2012; 
Darbandi et al., 2013). Their extracted data indicated that real acupuncture was more 
effective for BW than sham acupuncture as an adjunct therapy to dietary therapy (MD 
-1.58, 95% CI -2.22 to -0.95) (Figure 5.6). No heterogeneity existed (I2=0%). 
 
 
Figure 5.6: Comparison of real acupuncture plus dietary therapy and sham 
acupuncture plus dietary therapy for BW. 
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5.5.4.2 Body mass index 
All three studies assessed BMI and the extracted data demonstrated that real 
acupuncture was superior to sham acupuncture for BMI in addition to dietary therapy 
(MD -0.95, 95% CI -1.87 to -0.03) (Figure 5.7). The heterogeneity was 59%. 
 
 
Figure 5.7: Comparison of real acupuncture plus dietary therapy and sham 
acupuncture plus dietary therapy for BMI. 
 
5.5.4.3 Body fat composition 
Only one trial measured BF composition (Abdi et al., 2012). It showed the combined 
real acupuncture group was more effective than the combined sham acupuncture 
group (MD -0.51, 95% CI -0.74 to -0.28).  
5.5.4.4 Waist circumference 
The Abdi 2012 trial reported the WC at the end of treatment period. It indicated the 
real TG was superior to the sham-controlled group (MD -1.54, 95% CI -1.91 to -1.17). 
5.5.4.5 Hip circumference 
The Abdi (2012) study also reported HC. The results showed that the combined real 
acupuncture group was more effective than the combined sham acupuncture group 
(MD -4.51, 95% CI -4.82 to -4.20). 
Study or Subgroup
Abdi 2012
Darbandi 2013
Tong 2010
Total (95% CI)
Heterogeneity: Tau² = 0.40; Chi² = 4.91, df = 2 (P = 0.09); I² = 59%
Test for overall effect: Z = 2.02 (P = 0.04)
Mean
31.17
31.05
29.38
SD
0.53
5.18
2.92
Total
85
42
76
203
Mean
31.87
31.02
31.35
SD
0.61
3.85
3.26
Total
87
44
42
173
Weight
54.8%
16.1%
29.0%
100.0%
IV, Random, 95% CI
-0.70 [-0.87, -0.53]
0.03 [-1.91, 1.97]
-1.97 [-3.15, -0.79]
-0.95 [-1.87, -0.03]
Real acup + diet Sham acup + diet Mean Difference Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Favours Real acup + diet Favours Sham acup + diet
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5.5.5 Acupuncture plus other therapy versus the same other therapy 
Eleven studies (Chen 2013; Dai, 2006; He et al., 2011; Li 2005; Tao, 2009; Wang & 
Cheng 2006a; Yang et al., 2010b; Ye & Yao 2010; Zhang, 2011; Zhang & Ya, 2007; 
Zhao & Shi, 2010) and one arm of a three-arm trial (Chen, 2008c) compared 
acupuncture plus other therapy with same other therapy alone. Other therapy refers 
to dietary therapy alone or dietary therapy together with exercise. 
5.5.5.1 Body weight 
Six RCTs reported BW at the end of the treatment period (Li 2005; Tao, 2009; Wang 
& Cheng 2006a; Yang et al., 2010b; Zhang, 2011; Zhao & Shi, 2010). The extracted 
data showed that the combined acupuncture group was more effective for BW than 
by other therapy alone group (MD -2.90, 95% CI -4.22 to -1.59) (Figure 5.8). The 
heterogeneity was as low as 6%. 
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Figure 5.8: Comparison of acupuncture plus other therapy and same other therapy 
for BW. 
 
5.5.5.2 Body mass index 
Six trials presented BMI after the last treatment (He et al., 2011; Tao, 2009; Wang & 
Cheng 2006a; Yang et al., 2010b; Zhang, 2011; Zhao & Shi, 2010). The synthesised 
data demonstrated that the combination of acupuncture with other therapy was 
superior to other therapy alone for BMI (MD -1.30, 95% CI -1.93 to -0.67) (Figure 5.9). 
However their heterogeneity was substantial (I2=64%) 
Study or Subgroup
4.1.1 Diet
Tao 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
4.1.2 Diet and exercise
Li 2005
Wang 2006a
Yang 2010
Zhang 2011
Zhao 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 2.99, df = 4 (P = 0.56); I² = 0%
Test for overall effect: Z = 4.74 (P < 0.00001)
Total (95% CI)
Heterogeneity: Tau² = 0.18; Chi² = 5.34, df = 5 (P = 0.38); I² = 6%
Test for overall effect: Z = 4.32 (P < 0.0001)
Test for subgroup differences: Chi² = 2.35, df = 1 (P = 0.12), I² = 57.5%
Mean
62
58.87
71.78
65.68
71.36
71.93
SD
4.81
7.91
9.3
6.07
3.67
10.56
Total
20
20
35
30
31
26
30
152
172
Mean
62.93
60.48
77.91
69.38
74.73
74.32
SD
4.27
6.35
6.26
7.53
3.8
11.01
Total
20
20
33
29
30
26
30
148
168
Weight
20.1%
20.1%
14.2%
10.2%
13.9%
36.0%
5.7%
79.9%
100.0%
IV, Random, 95% CI
-0.93 [-3.75, 1.89]
-0.93 [-3.75, 1.89]
-1.61 [-5.01, 1.79]
-6.13 [-10.16, -2.10]
-3.70 [-7.14, -0.26]
-3.37 [-5.40, -1.34]
-2.39 [-7.85, 3.07]
-3.39 [-4.80, -1.99]
-2.90 [-4.22, -1.59]
Acupuncture + OT Same OT Mean Difference Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Favours Acup + OT Favours same OT
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Figure 5.9: Comparison of acupuncture plus other therapy and the same other 
therapy for BMI. 
 
5.5.5.3 Body fat composition 
Only two trials assessed BF composition (Li 2005; Zhang, 2011). There was no 
significant difference between two groups at the end of treatment period (MD 0.90, 95% 
CI -0.70 to 2.49) (Figure 5.10). 
  
Study or Subgroup
4.2.1 Diet
Tao 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.26 (P = 0.02)
4.2.2 Diet and exercise
He 2011
Wang 2006a
Yang 2010
Zhang 2011
Zhao 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 0.17; Chi² = 6.24, df = 4 (P = 0.18); I² = 36%
Test for overall effect: Z = 5.00 (P < 0.00001)
Total (95% CI)
Heterogeneity: Tau² = 0.36; Chi² = 13.97, df = 5 (P = 0.02); I² = 64%
Test for overall effect: Z = 4.05 (P < 0.0001)
Test for subgroup differences: Chi² = 6.35, df = 1 (P = 0.01), I² = 84.3%
Mean
24.75
26.29
26.08
24.51
24.95
25.93
SD
0.81
4.43
1.59
1.3
1.92
3.14
Total
20
20
60
30
31
26
30
177
197
Mean
25.3
27.83
28.56
25.6
26.8
26.59
SD
0.73
3.81
2.49
1.31
1.94
3.08
Total
20
20
60
29
30
26
30
175
195
Weight
24.7%
24.7%
11.2%
15.8%
22.0%
16.0%
10.3%
75.3%
100.0%
IV, Random, 95% CI
-0.55 [-1.03, -0.07]
-0.55 [-1.03, -0.07]
-1.54 [-3.02, -0.06]
-2.48 [-3.55, -1.41]
-1.09 [-1.75, -0.43]
-1.85 [-2.90, -0.80]
-0.66 [-2.23, 0.91]
-1.54 [-2.14, -0.94]
-1.30 [-1.93, -0.67]
Acupuncture + OT Same OT Mean Difference Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Favours Acup + OT Favours same OT
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Figure 5.10: Comparison of acupuncture plus other therapy and the same other 
therapy for body fat composition. 
 
5.5.5.4 Waist circumference 
Four studies reported the measurement of WC upon the completion of treatment. 
However, no significant difference was observed between two groups (MD -1.62, 95% 
CI -4.24 to 1.00) (Figure 5.11). 
  
Study or Subgroup
4.3.1 Diet and exercise
Li 2005
Zhang 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.11; Chi² = 1.09, df = 1 (P = 0.30); I² = 8%
Test for overall effect: Z = 1.10 (P = 0.27)
Total (95% CI)
Heterogeneity: Tau² = 0.11; Chi² = 1.09, df = 1 (P = 0.30); I² = 8%
Test for overall effect: Z = 1.10 (P = 0.27)
Test for subgroup differences: Not applicable
Mean
30.62
32.42
SD
4.81
3.56
Total
35
26
61
61
Mean
30.64
30.8
SD
4.9
3.9
Total
33
26
59
59
Weight
44.1%
55.9%
100.0%
100.0%
IV, Random, 95% CI
-0.02 [-2.33, 2.29]
1.62 [-0.41, 3.65]
0.90 [-0.70, 2.49]
0.90 [-0.70, 2.49]
Acupuncture plus OT Other therapy Mean Difference Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Favours Acup + OT Favours Same OT
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Figure 5.11: Comparison of acupuncture plus other therapy and same other therapy 
for waist circumference. 
 
5.5.5.5 Hip circumference 
Only two studies (Li 2005; Tao, 2009) observed HC at the end of treatment period. 
There was no significant difference in HC between the two groups (MD -0.01, 95% CI 
-0.96 to 0.95) (Figure 5.12). 
 
Study or Subgroup
4.4.1 Diet
Tao 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
4.4.2 Diet & exercise
Li 2005
Wang 2006a
Zhao 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 6.26; Chi² = 6.01, df = 2 (P = 0.05); I² = 67%
Test for overall effect: Z = 1.27 (P = 0.21)
Total (95% CI)
Heterogeneity: Tau² = 4.43; Chi² = 7.97, df = 3 (P = 0.05); I² = 62%
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Chi² = 0.98, df = 1 (P = 0.32), I² = 0%
Mean
77.75
83.1
90.27
92.7
SD
4.36
6.98
5.91
6.27
Total
20
20
35
30
30
95
115
Mean
77.8
83.21
95.79
93.57
SD
4.03
7.17
6.64
8.73
Total
20
20
33
29
30
92
112
Weight
28.9%
28.9%
24.3%
25.2%
21.6%
71.1%
100.0%
IV, Random, 95% CI
-0.05 [-2.65, 2.55]
-0.05 [-2.65, 2.55]
-0.11 [-3.48, 3.26]
-5.52 [-8.73, -2.31]
-0.87 [-4.72, 2.98]
-2.24 [-5.71, 1.23]
-1.62 [-4.24, 1.00]
Acu + other therapy Other therapy Mean Difference Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Favours Acup + OT Favours Same OT
163 
 
 
Figure 5.12: Comparison of acupuncture plus other therapy and the same other 
therapy for hip circumference. 
 
5.5.6 Acupuncture plus other therapy versus Western medication plus 
same other therapy 
Only one trial compared acupuncture plus other therapy (dietary therapy and 
exercise) with Western medication plus same other therapy (Dong, 2005). 
5.5.6.1 Body weight 
The results showed that there was no significant difference in BW between two 
groups after 40 treatment sessions (MD -2.44, 95% CI -10.57 to 5.69).  
5.5.6.2 Body fat composition 
No significant difference in BF composition was observed between two groups at the 
end of 40 daily treatments (MD -1.53, 95% CI -6.99 to 3.93). 
  
Study or Subgroup
4.5.1 Diet
Tao 2009
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
4.5.2 Diet & exercise
Li 2005
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.96); I² = 0%
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Chi² = 0.00, df = 1 (P = 0.96), I² = 0%
Mean
95.03
28.12
SD
6.71
2.06
Total
20
20
35
35
55
Mean
95.13
28.12
SD
4.91
2.1
Total
20
20
33
33
53
Weight
6.9%
6.9%
93.1%
93.1%
100.0%
IV, Random, 95% CI
-0.10 [-3.74, 3.54]
-0.10 [-3.74, 3.54]
0.00 [-0.99, 0.99]
0.00 [-0.99, 0.99]
-0.01 [-0.96, 0.95]
Acu+OT OT Mean Difference Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Favours Acu+OT Favours OT
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5.6 Discussion 
5.6.1 Summary of main results 
The current review identified 23 RCTs comparing acupuncture with sham 
acupuncture, no treatment, Western medication or other therapy (dietary therapy 
and/or exercise), with or without co-intervention. All the trials focused on BW, BMI 
and/or BF composition.  
When used alone, acupuncture was more effective than sham acupuncture or no 
treatment for reducing BMI at the end of treatment period. However, no significant 
difference was observed in BW or BF composition when compared to sham 
acupuncture. No data were available for meta-analysis for other comparisons.  
When combined with other treatment (i.e. Diet therapy and/or exercise), acupuncture 
showed more benefits for BW, BMI and BF composition when compared to sham 
acupuncture. Acupuncture also demonstrated better effects on reduction of BW and 
BMI when used as an adjunct therapy to other therapy. However, acupuncture did 
not show better effects on BW or BF composition than WM. 
The assessment of risk of bias demonstrated that majority of included RCTs had high 
risk in performance bias (blinding of participants), as well as unclear risk in selection 
bias (allocation concealment), detection bias (blinding of outcome assessment) and 
attrition bias (incomplete outcome data). These findings implied that the quality of 
included trials was low.  
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5.6.2 Overall completeness and applicability of the evidence 
The current review identified the currently available RCTs to be included by 
searching fifteen English and three Chinese databases. Both traditional Chinese 
manual acupuncture and EA for treating adult patients with obesity were considered.  
Although the included studies adopted different acupuncture prescriptions, some 
acupoints were popularly used across RCTs. The top ten most frequently used 
acupoints were Zusanli (ST 36), Tianshu (ST 25), Sanyinjiao (SP 6), Fenglong (ST 
40), Zhongwan (CV 12), Yinlingquan (SP 9), Quchi (LI 11), Qihai (CV 6), Guanyuan 
(CV 4), and Shangjuxu (ST 37). These acupoints are widely used in Chinese 
medicine clinical practice to regulate the digestive system, tonify Qi and eliminate 
dampness-heat (Yu, 2008a). More than half of them are on the ST/SP meridians. 
Another three points on the Conception Vessel meridian also provide benefit for 
ST/SP Qi deficiency. In CM, obesity is considered to be a result of excessive 
consumption of high-energy nutrition, which in the long-term weakens the digestive 
system (Spleen and Stomach QI) and causes an accumulation of dampness and 
heat in the body. Thus, the above-mentioned acupoints are to strengthen the Spleen 
and Stomach which leads to transforming dampness and phlegm (reducing body 
fat/weight). 
In addition, nearly two-thirds of included RCTs involved co-intervention (dietary 
therapy and/or exercise). In particular, 12 trials compared acupuncture plus other 
therapy with the same other therapy alone. This reflects the fact that patients with 
obesity tend to use a combination of different therapies for weight loss (Mulhisen & 
Rogers, 1999).  
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The trials performed outside mainland China always reported acupuncture’s effects 
with measurable outcomes (such as BW, BMI, WC and HC). However, the trials 
conducted in mainland China did not report the detailed results of individual 
outcomes but tended to use the ‘effectiveness rate’ to indicate acupuncture’s effects. 
Such expression makes data synthesis and comparison of different studies 
impossible due to lack of detailed data. Future study should report each outcome 
measure separately. Apart from comparison with other studies, it will provide detailed 
and reliable evidence for clinical practice.  
It is worth pointing out that none of the included studies assessed the quality of life of 
the obese. Chinese medicine is a holistic paradigm which focuses on the 
maintenance of the Yin-Yang balance of the entire body rather than symptomatic 
relief to improve the quality of life. Thus, assessment of quality of life is critical and 
essential for Chinese medicine research (Wong & Leung, 2008). Therefore, it is 
critical to use a validated questionnaire to assess quality of life in future obesity 
research. 
In summary, acupuncture seems an effective and safe method for the management 
of obesity. Findings from the current review reflect the up-to-date management of 
obesity treated by acupuncture. However, this review did not identify an ideal 
treatment regime for treating obesity because there were numerous confounding 
variables existing in the included studies, such as age (18 to 66), sample size (30 to 
334), number of acupoints (3 to 30), treatment period (20 days to three months), and 
low quality of studies.  
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5.6.3 Quality of the evidence 
Generally speaking, most included studies were of poor quality due to methodological 
defects, small sample sizes and unexplained heterogeneity. 
Methodological defects refer to high or unclear risk of bias in selection (random 
sequence generation and/or allocation concealment), performance, detection and 
attrition. All the included studies claimed that randomisation was used. However, less 
than half (11 out of 23) provided appropriate methods used for randomisation and 
only three of them reported the methods for allocation of randomisation. 
It seems unfeasible to blind the acupuncturists to perform treatment. It is critical to 
blind participants and outcome assessors as the results of RCTs without blinding 
tend to generate more bias towards beneficial effects (Wood et al., 2008). In the 
current review, only five trials blinded participants and one RCT blinded the outcome 
assessors. The high ratio of positive results from the included studies needs to be 
interpreted with caution. 
Substantial heterogeneity existed in BMI (real acupuncture plus dietary therapy 
compared to sham acupuncture plus dietary therapy, and acupuncture plus other 
therapy compared to the same other therapy). The substantial heterogeneity may be 
attributed to a number of factors, including study factors (e.g. quality of reporting), 
participant factors (e.g. age, gender, and diagnosis) and treatment factors (e.g. co-
intervention, formulation). However, due to the limited number of trials involved, 
subgroup analysis was not performed to identify the confounding variables. 
5.6.4  Agreements and disagreements with other studies or reviews 
A number of systematic reviews of RCTs using acupuncture for the management of 
obesity have been published (Cho et al., 2009; Ernst, 1997; Lin et al., 2009; Liu, Sun, 
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Hu, et al., 2004; Sui et al., 2012b; Sun, 2008; Yu, 2008a). There are some similarities 
and differences between this current review and those published papers. 
Firstly, this systematic review performed more comprehensive literature searches on 
15 English databases and three Chinese databases compare to previous reviews. 
Cho’s review searched nine English databases, five Korean databases, one 
Japanese database and one Chinese database (Cho et al., 2009); Ernst (1997) 
review searched two databases; Lin’s review searched four English databases and 
four Chinese databases (Lin et al., 2009); Liu’s review searched two English 
databases and one Chinese database (Liu, Zhang, et al., 2004); Sui’s review 
searched four English databases, two Korean databases, one Japanese database 
and one Chinese database (Sui et al., 2012b); Sun (2010) review searched four 
Chinese databases;  Yu’s review only searched three Chinese databases (Yu, 
2008a).  
Secondly, the current review included 23 RCTs to assess the efficacy and safety of 
acupuncture for the treatment of obesity. Others’ reviews included various RCTs 
ranging from 18 to 49. Interestingly, there were only 10 duplicated RCTs in those 
reviews although all of them focused on the obesity to the present review.  
Thirdly, the current review followed the Cochrane Handbook’s instructions and 
assessed the risk of bias of each study. However, the other reviews assessed the 
methodological quality using risk of bias and Jadad’s scores. This review has shown 
that the quality of included RCTs was low which is consistent with previous reviews 
(Hasani-Ranjbar et al., 2009; Sui et al., 2012b).  
Finally, similar to others’ reviews, the current review also found some potential 
promising results of acupuncture for treating obesity by acupuncture. However, due 
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to the high/unclear risks of bias and substantial heterogeneity across all the included 
studies, large scale RCTs with rigorous design are required to confirm the findings. 
5.7 Conclusions 
In conclusion, this review investigated the effectiveness and safety of acupuncture for 
the management of adult patients with obesity by systematically reviewing 23 RCTs. 
The findings have identified some positive results of acupuncture for treating obesity. 
However, there were a few methodological shortcomings in these studies, including: 
 Poor method of control 
 Methods used for randomisation and allocation concealment were not 
provided; 
 Blinding of assessors was not involved; 
 Validated quality of life questionnaires for obesity were not used; 
 Clinical effectiveness was presented as an effective rate without using 
measurable criteria; 
 ITT analysis method was not applied. 
Therefore, due to the low methodological quality of included studies, the positive 
results need to be interpreted with caution. A more rigorously designed RCT is 
required to overcome all the identified weaknesses. 
 
 
. 
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Chapter 6. Systematic review of Chinese herbal 
medicine in the management of obesity 
6.1 Introduction 
This chapter presents the results of the systematic review on RCTs of CHM for the 
treatment of obesity using the methods described in Chapter 4. 
6.2 Results of search 
Following the established search strategies, there were a total of 4,319 records 
(1,498 from English databases and 2,821 from Chinese databases) retrieved from 
electronic databases and no reference through hand searching until 18th November 
2013. Initially, 2,138 duplicated references were removed. The remaining 2,181 
studies were screened by their titles and abstracts. Among them, 2,021 records were 
excluded. Full texts were obtained for the remaining 160 studies and 146 were 
excluded. As a result, 14 of them met the inclusion criteria and they were included in 
the current review. The study selection process with detailed exclusion reasons is 
illustrated in Figure 6.1.  
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Figure 6.1: Flow chart of study selection process of RCTs of CHM for obesity 
 
Records identified 
through English 
database searching  
Records identified through 
Chinese database searching 
(n=2,821) 
Records before duplicates 
removed (n = 4,319) 
Records after duplicates 
removed (n = 2,181) Records excluded, with reasons (n = 2,021) 
‐ Animal studies (n = 43) 
‐ Non-RCT (n = 411) 
‐ Not for assessing effects of obesity (n = 723) 
‐ Not for assessing effects of CHM (n = 749) 
‐ Inappropriate comparators (n = 29) 
‐ Non-adult studies (n = 66) 
Full-text articles 
assessed for eligibility  
(n = 160) Full-text articles excluded with reasons (n = 146) 
‐ Non-RCT (n = 78) 
‐ Not for assessing effects of obesity (n = 41) 
‐ Not for assessing effects of CHM (n = 20) 
‐ Inappropriate comparators (n = 5) 
‐ Duplicated publication (n = 2) 
RCTs included in 
qualitative synthesis  
(n = 14)
RCTs included in quantitative 
synthesis (meta-analysis)  
(n = 8) 
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6.3 Description of studies 
Among the 14 included RCTs, four trials were published in English (Greenway et al., 
2006; Hioki et al., 2004; Ignjatovic et al., 2000; Lenon et al., 2012) and the rest of the 
10 studies were published in Chinese. The summary of characteristics of the included 
RCTs is provided in Table 6.1.  
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Table 6.1: Characteristics of 14 included studies 
 Author, 
Year 
Setting Randomised sample 
size 
Intervention Outcome 
measures 
Adverse 
events 
   T (n, age) C (n, age) T C   
CH
M vs 
plac
ebo 
Greenw
ay 2006 
Hospital, 
outpatient
s 
18 
M/F: 0/18 
Age: 
T1: 40.75 
T2: 44.50 
T3: 44.00 
6 
M/F: 0/6 
Age:33.67 
Number Ten (NT) extract  
Ingredients & dosage:  
Radix et Rhizomarhei (Da Huang) 
40%, Radix Astragali (Huang Qi) 
13.3%, Radix Salviae miltiorrhizae 
(Dan Shen) 13.3%, Rhizoma 
curcumae longae (Jiang Huang) 26–
27%, Rhizoma zingiberis officinalis 
(Gan Jiang) 6–7%. 
Dosage: T1: 6 g/ day;T2: 6 g/ day; T3: 
12 g/ day. 
Route of administration: Oral 
Duration: 11 wks 
Follow-up: 1 wk 
CHM placebo:  
Duration: 11 wks 
Follow-up: 1 wk 
BW 
BMI 
T: 
dermatologic 
(1), 
gastrointestin
al symptoms 
(32), 
gynaecologic 
(1), 
musculoskele
tal (11), 
headache/ 
migraine (1), 
oral 
symptoms 
(6), 
respiratory 
symptoms 
(4); 
C: 
gastrointestin
al symptoms 
(8), 
musculoskele
tal (1), oral 
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 Author, 
Year 
Setting Randomised sample 
size 
Intervention Outcome 
measures 
Adverse 
events 
   T (n, age) C (n, age) T C   
symptoms 
(1), 
respiratory 
symptoms (2) 
 Ignjatovi
c 2000 
 70 
M/F: 15/55
Age:47±1 
70 
M/F: 11/59
Age:45±1 
Slimax extract 
Ingredients & dosage:  
Hordeum vulgare L. (Da Mai), 
Polygonatum multiflorum (L.) All. 
(Huang Jing), Dimocarpus longan 
Lour (Li Zhi), Ligusticum sinense Oliv 
(Gao Ben), Lilium brownii F.R.Br.ex 
Miellez (Bai He), Gynurapinnatifida 
(San Qi), Coreopsis lanceolata (Jin Ju 
Hua),Juniperus communis (Du Song 
Zi), Zingiberi officinale Roscoe (Sheng 
Jiang Pi)  
Ratio of 
750:50:100:250:500:500:50:50:25  were 
extracted in 6.5 mM of ethanol at 
100°C for 75 min. 
Dosage: 10 drops, 3/day 
Route of administration: Oral 
Duration: 6 wks 
CHM placebo:  
Ingredients & 
dosage:  
water mixed with 
the ‘Green Apple 
powder’  
10 drops, 3/ day 
Route of 
administration:  
Oral 
Duration: 6 wks 
Follow-up: NS 
BW, BMI 
WC, HC  
BF % 
NS 
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 Author, 
Year 
Setting Randomised sample 
size 
Intervention Outcome 
measures 
Adverse 
events 
   T (n, age) C (n, age) T C   
Follow-up: NS 
 Lenon 
2012 
NS 59 
M/F: 10/49
Age: 
39.3±13.2 
58 
M/F: 10/48
Age:40.4±
10.2 
RCM-104 
Ingredients & dosage:  
Camellia Sinensis (Lu Cha Ye: 40%), 
Cassia Obtusifolia (Jue Ming Zi: 40%), 
Sophora Japonica (Huai Hua : 20%). 
Dosage: 4 capsules, 3/day. 
Route of administration: Oral. 
Duration: 12 wks 
Follow-up: 2 mths 
CHM placebo:  
Ingredients & 
dosage:  
herbal starch 
capsules that 
contained no 
active 
substances, with 
an identical 
appearance to 
the RCM-104 
capsules 
4 capsules, 3/day 
Route of 
administration: 
Oral. 
Duration: 12wks 
Follow-up: 2 mths 
BW,BMI 
Heart rate    
BP, 
HbA1c   
TC    TG 
LDL-C    
HDL-C 
Insulin   
Glucose 
Homa-
index % 
T: nausea 
(4), 
headache (9) 
C: decrease 
in appetite 
(2) 
 Wang 
2007 
Outpatien
ts 
60 
Age: 
49.69 
60 
Age:52.23 
Jian Fei He Ji extract 
Ingredients & dosage:  
Crataegus cuneata (ShanZha), 
CHM placebo:  
Ingredients & 
dosage: dextrin 
BMI   TC  
TG 
HDL-C   
T: None; 
C: None 
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 Author, 
Year 
Setting Randomised sample 
size 
Intervention Outcome 
measures 
Adverse 
events 
   T (n, age) C (n, age) T C   
 Mentha aplocalyx (Bo He),  Rhizoma 
alismatis (Ze Xie) 
Ratio (1:2:1),  
Dosage: 6g, 3/ day 
Route of administration: Oral 
Duration: 6 months 
Follow-up: NS 
6g, 3/ day 
Route of 
administration: 
Oral. 
Duration: 6 
months 
Follow-up: NS 
LDL-C 
CH
M vs 
WM 
Shi 2005 Inpatient 
Outpatien
t 
32 
M/F: 17/15
Age: 65.3 
30 
M/F:15/15 
Age: 66.1 
Fu Fang Cang Zhu decoction 
Ingredients & dosage:  
Rhizoma atractylodis (Cang Zhu)  
15g, Coix lacryma-jobi L. var. meyuan 
(Yi Yi Ren) 24g, Moraceae (Sang 
Shen) 20g, Rhizoma Dioscoreae 
(Shan Yao) 30g, Cortex Phellodendri 
(Huang Bai) 10g, Citrus Aurantium 
(Zhi Ke) 20g, Pheretimaas pergilum 
(Di Long) 10g 
Dosage: 150ml, 2/ day 
Route of administration: Oral 
Duration: 8 wks 
Follow-up: NS 
Deltamine 
Ingredients & 
dosage:  
0.25g, 3/ day 
Route of 
administration: 
Oral 
Duration: 8 wks 
Follow-up: NS 
BW, WC   
HC ,WH, 
GTT, 
FINS,TC  
TG 
NS 
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 Author, 
Year 
Setting Randomised sample 
size 
Intervention Outcome 
measures 
Adverse 
events 
   T (n, age) C (n, age) T C   
CH
M + 
diet 
+ 
exer
cise 
vs 
Plac
ebo 
+ 
sam
e 
diet 
+ 
exer
cise 
Hioki 
2004 
Outpatien
ts 
44 
M/F: 0/44 
Age: 
52.6±14.0 
41 
M/F: 0/41 
Age: 
54.8±12.5 
Bofu-Tsusho-San 
Ingredients & dosage:  
Scutellariae Radix (Huang Qin) 44.4g, 
Glycyrrhizae Radix (Gan Cao) 44.4g, 
Platycodi Radix (Jie Geng) 44.4g, 
Gypsum Fibrosum (Shi Gao) 44.4g, 
Atractylodis Rhizoma (Chuang Zhu) 
44.4g, Rhei Rhizoma (Da Huang) 
33.3g, Schizonepetae Spica (Jing Jie) 
26.7g, Gardeniae Fructus (Zhi Zi) 
26.7g, Paeoniae Radix (Bai Shao)  
26.7g, Cnidium Rhizoma (She 
Chuang Zi) 26.7g, Angelicae Radix 
(Dang Gui) 26.7g, Menthae Herba (Bo 
He) 26.7g, Ledebouriellae Radix 
(Fang Feng) 26.7g, Ephedrae Herba 
(Ma Huang) 26.7g, Forsythiae Fructus 
(Lian Qiao) 26.7g, Zingiberis Rhizoma 
(Gan Jiang) 6.7g,Talcum (Hu Shi) 
66.7g, Natrium lphuricum (Salt) 15.6g 
Route of administration: Oral 
Before drug 
Diet therapy (1200kcal/day) and 
Exercise (5000 steps/day) for 2 
CHM placebo:  
Route of 
administration: 
oral 
Diet therapy 
(1200kcal/ day)   
Exercise (5000 
step/ day)  for 2 
months 
Progressing:  
Placebo  
Duration: 24 wks 
Follow-up: NS 
BW, BMI 
BF %     
Abdominal 
visceral fat
BP      
Heart rate 
TG   TC 
LDL-C     
HDL-C 
Uric acid     
HbA1c 
Fasting 
glucose 
OGTT 2h 
glucose 
Glucose 
AUC 
FINS   
HOMA-IR 
 
NS 
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 Author, 
Year 
Setting Randomised sample 
size 
Intervention Outcome 
measures 
Adverse 
events 
   T (n, age) C (n, age) T C   
months 
Duration: 24wks 
Follow-up: NS 
CH
M + 
OT 
vs 
Sam
e 
OT 
Li 2004 Inpatient 24 
M/F: 15/9 
Age: 
57.2±9.1 
21 
M/F: 14/7 
Age: 
58.6±9.2 
Deng’s Formula 
Ingredients & dosage:  
Tangerin (Ju Hong)1.8g, Pinellia 
ternata (Fa Ban Xia), 1.8g, Poria 
cocos (Fu Ling) 1.8g, Glycyrrhizae 
Radix (Gan Cao)1.8g, Citrus 
Aurantium (Zhi Ke) 1.8g, Caulis 
bambusae in taeniam (Zhu Ru) 1.8g, 
Codonopsis Radix (Dang Shen) 1.8g, 
Salviae miltiorrhizae (Dan Shen) 1.8g, 
Siegesbeckia orientalis  (Xi Xian Cao) 
1.8g 
Dosage:1.8g, 3/day 
Route of administration: Oral. 
Duration: 6 months 
Follow-up: NS 
Before: 
Enteric coated 
Aspirin 150mg 
Caudaline  
250mg 
Processing : 
Heparin 1000U 
After: 
Enteric coated 
aspirin 100mg 
Caudaline 250mg 
Zocor 20mg 
nitrates 
 
Route of 
administration: 
oral 
BMI, BF% 
WC, HC 
T: None; 
C: weakness, 
drowsiness, 
mild 
gastrointestin
al symptoms 
(1) 
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 Author, 
Year 
Setting Randomised sample 
size 
Intervention Outcome 
measures 
Adverse 
events 
   T (n, age) C (n, age) T C   
Duration: 6 
months 
Follow-up: NS 
 Li 2007  25 
M/F: 11/14
Age:  
42.76±9.7
9 
25 
M/F: 10/15
Age: 
43.44±14.
02 
Jian Fei Tiao Zhi capsule 
Ingredients & dosage:  
Fresh Rhei Rhizoma (Sheng Da 
Huang)  0.5g, Polygonum mult, (He 
Shou Wu) 0.5g, Scutellaria 
baicalensis (Huang Qin) 0.5g, 
Rhizoma alismatis (Ze Xie) 0.5g, 
Folium Nelumbinis (He Ye) 0.5g, 
Crataegus pinnatifida Bunge (Shan 
Zha) 0.5g 
Dosage: 4 capsules, 3/day 
Route of administration: Oral 
Diet therapy: Carbohydrate 
50~60%/day 
Protein 15%/day, Fat <30%/day, 
Fiber<30g/day 
Exercise therapy  
Duration: 60 days 
Follow-up: NS 
Diet therapy: 
Carbohydrate 
50~60%/ day 
Protein 15%/ day 
Fat <30%/ day 
Fiber<30g/ day 
Route of 
administration:  
Exercise therapy 
Duration: 60 days 
Follow-up: NS 
 
BW    BMI 
BF % 
WC,HC   
WHR 
FBG   TG   
INS  
Leptin 
T: mild 
gastrointestin
al symptoms 
(2) 
C: NS 
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 Author, 
Year 
Setting Randomised sample 
size 
Intervention Outcome 
measures 
Adverse 
events 
   T (n, age) C (n, age) T C   
 Wei 
2008 
Inpatients 
Outpatien
ts 
30 
Age: 
65.06 
30 
Age: 
66.40 
Wei Ke Xiao decoction 
Ingredients & dosage:  
Epimedium brevicornu Maxim  (Yin 
Yang Ye) 30g, Astragalus 
mongholicus (Huang Qi)15g, Lycium 
barbarum (Gou Qi Zi) 15g, Crataegus 
pinnatifida Bunge (Shan Zha)15g, 
Salviae miltiorrhizae (Dan Shen) 15g, 
Pericarpium citri reticulatae (Chen Pi) 
5g, Fresh Rhei Rhizoma (Sheng Da 
Huang) 5g 
Dosage:NS, 2/ day. 
Route of administration: Oral 
Diet: (5000~6300kJ/day) 
Protein<15~20%, 
Fat<20~25%,Carbohydrate<45%~60
% 
Exercise: Fast walking 30 min, 2 times 
(morning/evening) per day  
Duration: 12 wks 
Follow-up: NS 
Diet:  
(5000~6300kJ/ 
day) 
Protein<15~20% 
Fat<20~25% 
Carbohydrate<45
%~60% 
Exercise: 
Fast walking 30 
min  
2  times 
(morning/evening
) 
per day  
Duration: 12 wks 
Follow-up: NS 
TG   TC  
LDL-C    
HDL-C 
NS 
 Xie 2008 Outpatien 40 40 Qing Shen Jian Zhi decoction Fenfluramine BMI T: diarrhoea, 
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 Author, 
Year 
Setting Randomised sample 
size 
Intervention Outcome 
measures 
Adverse 
events 
   T (n, age) C (n, age) T C   
ts M/F: 12/28
Age:18-56 
M/F: 11/29
Age:18-63 
Ingredients & dosage:  
Capillary artemisia (Yin Chen) 30g, 
Rhizoma atractylodis (Chuang Zhu) 
20g, Polygonum cuspidatum (Gu 
Zhang) 20g, Semen Cassiae (Jue 
Ming Zi) 20g, Rheum offici (Da 
Huang) 10g, Rhizoma alismatis (Ze 
Xie) 20g, Rhizoma polygonati (Huang 
Jing ) 20g, Crataegus pinnatifida 
Bunge Sheng (Shan Zha) 30g, Folium 
Nelumbinis (Gan He Ye) 15g, Cattail 
pollen (Pu Huang) 20g, Radix 
Polygoni multiflori Preparata (Zhi 
Shou Wu) 20g, Lycium barbarum 
(Gou Qi Zi) 15g 
Dosage: 150ml, 2/ day. 
Route of administration: Oral.  
Diet and exercise  
Duration: 8 wks 
Follow-up: NS 
Ingredients & 
dosage:  
Fenfluramine 10g 
Route of 
administration: 
Oral  
Diet and exercise 
Duration: 8 wks 
Follow-up: NS 
FPG, TC, 
TG, LDL- 
C, HDL-C 
abdominal 
distension (3) 
C: dry mouth, 
anorexia, 
constipation 
(11); 
headache, 
insomnia (2) 
 
 Zhang 
2011 
Outpatien
ts 
38 
M/F: 19/19
Age: 
38 
M/F: 18/20
Age: 
Jian Pi Hua Zhuo and Li Qi Hua Shi 
decoction 
Ingredients & dosage:  
Control diet  
Route of 
administration: 
BMI 
WC 
BP 
NS 
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 Author, 
Year 
Setting Randomised sample 
size 
Intervention Outcome 
measures 
Adverse 
events 
   T (n, age) C (n, age) T C   
62.42±1.7
0 
61.18±3.4
4 
Rhizoma atractylodis (Chuang Bai 
Zhu) each 15g, Agastache rugosus 
(Huo Xiang),  15g, Amomum 
cardamomum (Bai Dou Kou) 6g, 
Mangnolia officinalis (Hou Po) 9g, 
Poria cocos (Fu Ling) 30g, Rhizoma 
alisma (Ze Xie) 12g, Semen Raphani 
(Lai Fu Zhi) 15g, Cassie semen (Jue 
Ming Zi) 30g, Salviae miltiorrhizae 
(Dan Shen) 15g , Radix curcumae (Yu 
Jin) 15g 
Dosage: 200ml, 2/ day 
Route of administration: Oral 
Diet: 3 meals/day  
Duration: 12 wks 
Follow-up: NS 
oral 
Duration: 12 wks 
Follow-up: NS 
 TC, TG, 
LDL-C, 
HDL-C 
CH
M + 
OT 
vs 
WM 
+ 
sam
e 
Mi 1998 Outpatien
ts 
40 
M/F:13/27 
Age:35 
40 
M/F:15/25 
Age:37 
Da Huang pill 
Ingredients & dosage:  
Rheum offici (Da Huang)  
Dosage: 2g, 2/ day 
Route of administration: Oral. 
Diet  and exercise  
Amfepramone 
Ingredients & 
dosage:  
1 tablet, 3/ day. 
Route of 
administration: 
Oral. 
BW Abdominal 
distension 
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 Author, 
Year 
Setting Randomised sample 
size 
Intervention Outcome 
measures 
Adverse 
events 
   T (n, age) C (n, age) T C   
OT Duration: 3 mths 
Follow-up: NS 
Diet therapy and 
exercise  
Duration: 3 mths 
Follow-up: NS 
 Tang 
2013 
Outpatien
ts 
75 
M/F:28/47 
Age:37.24
±8.12 
75 
M/F:24/51 
Age:38.35
±9.31 
Tang Qi Chang Long decoction 
Ingredients & dosage:   
Milk and Rhizoma smilacis glabrae 
(Tu Fu Ling) 30g, Talinum 
crassifolium (Tu Ren Shen), Mountain 
pineapple (San Bo Lou) 20g, Polygala 
aureocauda Dunn (Huang Hua Dao 
Shui Lian), Momordica grosvenori 
(Lou Han Guo) 15g, Juncus 
articulatus (Deng Xin Cao) 12g, 
Dioscorea japonica (Ye Shan Yao) 
10g, Carica papaya (Fan Mu Gua) 
50g 
(1) Sp deficiency: Codonopsis 
pilosula (Dang Shen) 20g, Rhizoma 
Atractylodis (Bai Zhu) 12g, Coix 
lacryma-jobi L.(Yi Yi Ren) 30g, 
Rhizoma Atractylodis (Chuang Zhu) 
15g  
(2) Congested chest with 
Orlistat capsules 
Ingredients & 
dosage:  
Orlistat capsules 
Nitric Esters 
120 mg, 3/day. 
Route of 
administration: 
Oral 
Duration: 67 days 
incl. 7-day break 
Follow-up: NS 
BMI   TC  
TG 
HDL-C   
LDL-C 
NS 
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 Author, 
Year 
Setting Randomised sample 
size 
Intervention Outcome 
measures 
Adverse 
events 
   T (n, age) C (n, age) T C   
dampness :  Trichosanthes kirilowii 
Maxim (Gua Lou) 15g, Agastache 
rugosus (Huo Xiang) 10g, Prunus 
armeniaca L (Xing Ren) 10g  
(3) LR Qi  stagnation: Paeonia 
lactiflora (Bai Shao) 15g,  Citrus 
Aurantium (Zhi Ke) 10g  
(4) ST heat excess: Rhizoma 
anemarrhenae (Zhi Mu) 10g 
Dosage: 2/ day,  
Route of administration: Oral  
Duration: 67 days incl. 7-day break 
Follow-up: NS 
 Yin 2007 Outpatien
ts 
40 
M/F:11/29 
Age:39.24
±9.04 
39 
M/F:10/29 
Age:39.45
±8.56 
Shou ShenTiao Zhi capsule 
Ingredients & dosage:  
Angelicae Radix (Dang Gui), Radix 
Rehmanniae (Sheng Di), Paeonia 
suffruticosa Andr (Dan Pi), 
Ligusticum chuanxiong Hort (Chuan 
Xiong), Astragalus (Huang Qi), 
Paeonia lactiflora (Bai Shao), Coix 
lacryma-jobi (Yi Yi Ren), Poria cocos 
(Fu Ling), Rhizoma Dioscoreae 
( (Shan Yao), Crataegus pinnatifida 
Qumei capsules 
Ingredients & 
dosage: 5g 
2 capsules, 1/ 
day. 
Route of 
administration: 
Oral. 
Duration: 2 
months 
BW 
BMI 
BF% 
NS 
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 Author, 
Year 
Setting Randomised sample 
size 
Intervention Outcome 
measures 
Adverse 
events 
   T (n, age) C (n, age) T C   
Bunge (Shan Zha), Folium Nelumbinis 
(He Ye), phaseolus calcaratus (Chi 
Xiao Dou), Semen Cassiae  (Jue Ming 
Zi), Glycyrrhizae Radix (Sheng Gan 
Cao)  
Dosage: 2 capsules, 3/day 
Route of administration: Oral.  
Duration: 2 months 
Follow-up: NS 
Follow-up: NS 
 
Note:  A: analysed number;  AUC: area under the curve; BF%: body fat composition; BMI: body mass index; BP: blood pressure; BW: 
body weight; C: control group;  CHM: Chinese herbal medicine;  Diet: dietary therapy; FBG: fasting blood glucose; FINS:fasting insulin; 
FPG: fasting plasma glucose; GTT: glucose tolerance test; HbA1c: hemoglobin A1c;  HC: hip circumference ; HDL-C: High density 
lipoprotein cholesterol;  HOMA-IR: homeostasis model assessment-estimated insulin resistance; IGT: impaired glucose tolerance; INS: 
insulin;  LDL-C: low-density lipoprotein cholesterol; NS: not stated; OGTT: oral glucose tolerance test; OT: other therapy; TC: total 
cholesterol; TG: triglycerid; T: treatment group; vs: versus; WC: waist circumference;  WHR: waist and hip ratio;  wk: week;  WM: 
Western medicine. 
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The characteristics of the included RCTs including design, sample sizes, participants, 
interventions and outcomes are summarised as below.  
6.3.1 Design of studies 
One study was a four-arm RCT (Chen, 2008a; Greenway et al., 2006). The rest of 
the 13 RCTs employed two arms. There were no cross-over trials among included 
studies. In the multi-arm studies only the groups meeting the inclusion criteria were 
included for data analysis in this review. 
Twelve studies were single-centre trials (Hioki et al., 2004; Ignjatovic et al., 2000; Li 
et al., 2007; Li et al., 2004; Mi, 1998; Shi, Hu, et al., 2005; Tang et al., 2013; Wang  
et al., 2007; Wei et al., 2008; Xie 2008; Yin et al., 2007; Zhang 2011).The other two 
trials did not provide clear information on it (Greenway et al., 2006; Lenon et al., 
2012). 
6.3.2 Sample sizes 
The sample sizes of the included studies varied from 21 to 150, with an average of 
83 per trial. One trial had a sample size below 21 (Greenway et al., 2006). The 
sample sizes of nine trials were between 20 and 100 (Hioki et al., 2004; Li et al., 
2007; Li et al., 2004; Mi, 1998; Shi, Hu, et al., 2005; Wei et al., 2008; Xie 2008; Yin et 
al., 2007; Zhang 2011).Three trials had sample sizes between 100 and 150 
(Ignjatovic et al., 2000; Lenon et al., 2012; Wang et al., 2007). Only one study had a 
sample size of over 150 (Tang et al., 2013). 
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6.3.3 Setting 
In the 14 included trials, 10 trials were conducted in mainland China (Li et al., 2007; 
Li et al., 2004; Mi, 1998; Shi, Hu, et al., 2005; Tang et al., 2013; Wang et al., 2007; 
Wei et al., 2008; Xie 2008; Yin et al., 2007; Zhang 2011) and four trials were 
performed outside mainland China, including two in Australia (Ignjatovic et al., 2000; 
Lenon et al., 2012), one in Japan (Hioki et al., 2004) and one in USA (Greenway et 
al., 2006). 
Six trials clearly stated that only outpatients were recruited in the studies (Hioki et al., 
2004; Tang et al., 2013; Wang et al., 2007; Xie 2008; Yin et al., 2007; Zhang 2011). 
One study indicated that only inpatients were involved (Li et al., 2004). Another two 
described that both out-patients and inpatients were included (Shi, Hu, et al., 2005; 
Wei et al., 2008). The other five trials did not mention whether participants were 
inpatients or outpatients (Greenway et al., 2006; Ignjatovic et al., 2000; Lenon et al., 
2012; Li et al., 2007; Mi, 1998). 
Over two-thirds of trials (9 out of 14) were conducted in hospitals (Li et al., 2007; Li et 
al., 2004; Mi, 1998; Shi, Hu, et al., 2005; Tang et al., 2013; Wang et al., 2007; Wei et 
al., 2008; Xie 2008; Yin et al., 2007), and three trials were performed in a clinic 
(Greenway et al., 2006; Hioki et al., 2004; Ignjatovic et al., 2000). The remaining two 
studies did not provide any information on the setting of the study (Lenon et al., 2012; 
Zhang 2011). 
6.3.4 Types of participants 
A total of 1,168 participants were randomised in the included studies, aged from 18 
to 78 years old. Eight studies only indicated the range and mean of ages (Greenway 
et al., 2006; Lenon et al., 2012; Shi, Hu, et al., 2005; Tang et al., 2013; Wei et al., 
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2008; Xie 2008; Yin et al., 2007; Zhang 2011). Six studies did not report the range of 
ages but only indicated the mean of participants’ ages (Hioki et al., 2004; Ignjatovic 
et al., 2000; Li et al., 2007; Li et al., 2004; Mi, 1998; Wang et al., 2007). Among them, 
only four studies only stated the mean without providing the standard deviation 
(Greenway et al., 2006; Lenon et al., 2012; Xie 2008; Yin et al., 2007). Two studies 
only listed the total mean of ages, but did not specify the mean of ages in the 
different groups (Greenway et al., 2006; Lenon et al., 2012). 
Apart from two studies did not indicate the gender of the participants (Wang et al., 
2007; Wei et al., 2008), the remaining 12 studies involved 699 females and 289 
males. All the participants in the RCTs were clearly diagnosed as having obesity 
according to diagnostic criteria.  
6.3.5 Types of interventions 
All the studies involved CHM in the TGs. The CGs included placebo, no treatment, 
WM, and diet therapy and/or exercise. Four studies compared real CHM with placebo 
(Greenway et al., 2006; Ignjatovic et al., 2000; Lenon et al., 2012; Wang et al., 2007). 
No trial compared CHM with no treatment. One trial compared CHM with WM (Shi, 
Hu, et al., 2005). Over half of the trials (nine out of 14) involved co-interventions in 
both groups and CHM was assessed as an adjunct therapy to co-intervention. One 
trial compared CHM plus dietary therapy and exercise with placebo plus the same 
dietary therapy and exercise (Hioki et al., 2004). Five trials compared CHM plus other 
therapy with the same other therapy (Li et al., 2007; Li et al., 2004; Wei et al., 2008; 
Xie 2008; Zhang 2011). Three trials evaluated the adjunct effects of CHM comparing 
to WM when using dietary therapy and/or exercise as co-intervention (Mi, 1998; Tang 
et al., 2013; Yin et al., 2007). 
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Among the 14 RCTs, the forms of CHM were various, including decoction (Shi, Hu, et 
al., 2005; Tang et al., 2013; Wei et al., 2008; Xie 2008; Zhang 2011), capsules 
(Greenway et al., 2006; Lenon et al., 2012; Li et al., 2007; Yin et al., 2007), 
powder/granules (Li et al., 2004; Wang et al., 2007), liquid (Ignjatovic et al., 2000), 
and pills (Mi, 1998). One trial did not describe the form of CHM (Hioki et al., 2004).  
All the included RCTs but one (Mi, 1998) employed more than one herb. However, all 
the CHM formulas used were different. Only two studies employed the differentiation 
of syndromes (Li et al., 2007; Wei et al., 2008). 
The top 10 most frequently used Chinese herbs were Radix et Rhizoma Rhei (Da 
Huang, in six studies), Fructus Crataegi (Shan Zha, in six studies), Rhizoma 
Atractylodis (Cang Zhu, in five studies), Radix Salviae Miltiorrhizae (Dan Shen, in five 
studies), Folium Nelumbinis (He Ye, in four studies), Rhizoma Alismatis (Ze Xie, in 
four studies), Semen Cassiae (Jue Ming Zi, in four studies), Poria (Fu Ling, in three 
studies), Semen Coicis (Yi Yi Ren, in three studies), Radix Glycyrrhizae (Gan Cao, in 
three studies). 
The duration of treatments in the included studies varied from six weeks to six 
months. Only one trial (Ignjatovic et al., 2000) included treatment of six weeks. Five 
trials were of eight weeks’ duration (Li et al., 2007; Shi, Hu, et al., 2005; Tang et al., 
2013; Xie 2008; Yin et al., 2007). Four trials (Greenway et al., 2006; Mi, 1998; Wei et 
al., 2008; Zhang, 2011) had treatment of 12 weeks’ duration. Lenon (2012) had 
treatment of 12 weeks’ duration and 12 weeks of follow-up. 
Four trials (Hioki et al., 2004; Lenon et al., 2012; Li et al., 2004; Wang et al., 2007) 
also had a 24 week trial period, with one trail (Wang et al., 2007) having a follow-up 
of 2 months. 
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Only two trials indicated follow-up periods after the last treatment, one for 12 weeks 
(Lenon et al., 2012) and the other for one week (Greenway et al., 2006). The 
remaining trials did not provide any information on follow-up.  
The intervention in the CG consisted of placebo (five trials), WM (six trials), and 
dietary therapy and/or exercise (nine trials). 
When co-intervention was not involved in the trials, with CHM in the active 
intervention group, four studies compared CHM with placebo (Greenway et al., 2006; 
Ignjatovic et al., 2000; Lenon et al., 2012; Wang et al., 2007). One study employed 
WM in the CG (Shi, Hu, et al., 2005). 
Co-intervention with CHM was applied in nine studies. One study compared CHM 
plus dietary therapy and exercise with placebo plus the same dietary therapy and 
exercise (Hioki et al., 2004). CHM plus other therapy was compared to the same 
other therapy alone in five trials (Hioki et al., 2004; Li et al., 2007; Li et al., 2004; Wei 
et al., 2008; Xie 2008; Zhang, 2011). Another three trials compared CHM plus other 
therapy with WM plus same other therapy (Mi, 1998; Tang et al., 2013; Yin et al., 
2007) 
6.3.6 Types of outcome measures 
6.3.6.1 Body weight 
Thirteen studies assessed BW (Greenway et al., 2006; Hioki et al., 2004; Ignjatovic 
et al., 2000; Lenon et al., 2012; Li et al., 2007; Mi, 1998; Shi, Hu, et al., 2005; Tang et 
al., 2013; Wang et al., 2007; Wei et al., 2008; Xie 2008; Yin et al., 2007; Zhang, 2011) 
at the end of treatment period. One assessed BW at the end of follow-up period 
(Greenway et al., 2006). 
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6.3.6.2 Body mass index 
Ten RCTs evaluated BMI at the end of treatment period (Greenway et al., 2006; 
Hioki et al., 2004; Ignjatovic et al., 2000; Lenon et al., 2012; Li et al., 2007; Li et al., 
2004; Tang et al., 2013; Xie 2008; Yin et al., 2007; Zhang, 2011). One trial assessed 
it at the end of the follow-up period (Greenway et al., 2006). 
6.3.6.3 Body fat composition 
Five trials assessed the BF composition at the end of the treatment period (Hioki et 
al., 2004; Ignjatovic et al., 2000; Li et al., 2007; Li et al., 2004; Yin et al., 2007) (Hioki 
2004, Ignjatovic 2000, Li 2004, Li 2007, Yin 2007). 
6.3.6.4 Waist circumference 
Four studies measured the WC (Lenon et al., 2012; Li et al., 2007; Tang et al., 2013; 
Zhang, 2011).  
6.3.6.5 Hip circumference 
One trial measured the HC (Lenon et al., 2012).  
6.3.6.6 Adverse events 
Six included studies reported adverse events (Greenway et al., 2006; Lenon et al., 
2012; Li et al., 2007; Li et al., 2004; Wang et al., 2007; Xie 2008). Among them one 
study reported that no adverse events were observed (Wang et al., 2007). Another 
trial found no adverse events in TG but one mild case in CG (Li et al., 2004).The 
other four trials reported 74 adverse events in herbal group and 28 cases in the CG. 
The rest eight included studies did not report any information on adverse events. 
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6.4.1 Random sequence generation (selection bias) 
All included trials stated that participants were randomly assigned into treatment and 
CGs. Only three included trials provided the methods used for randomisation, 
including random number tables in two studies (Hioki et al., 2004; Li et al., 2007) and 
computer-generated random table in one study (Lenon et al., 2012). The other 11 
trials did not describe the methods used for randomisation. 
6.4.2 Allocation concealment (selection bias) 
None of the 14 included studies described the methods used for allocation 
concealment. 
6.4.3 Blinding (performance bias and detection bias) 
Only one trial employed blinding of participants, personnel and outcome assessors 
(Lenon et al., 2012).  
6.4.3.1 Blinding of participants and personnel 
Five studies employed placebo as control interventions to blind participants 
(Greenway et al., 2006; Hioki et al., 2004; Ignjatovic et al., 2000; Lenon et al., 2012; 
Wang et al., 2007). The rest of the nine trials used different forms of treatments in 
two groups which made the blinding of participants unlikely. 
6.4.3.2 Blinding of outcome assessors 
Only one trial blinded outcome assessors (Lenon et al., 2012). The remaining 13 
studies did not provide sufficient information on blinding. It is unlikely that three of 
them employed blinding of outcome assessors as only one author conducted the trial 
(Mi, 1998; Xie 2008; Zhang, 2011). 
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6.4.4 Incomplete outcome data (attrition bias) 
The attrition bias was only assessed for the effects immediately after the last 
treatment. Eight included studies had an identical number of participants randomised 
and reported in the results for the outcomes (Mi 1998, Shi 2005, Tang 2013, Wang 
2007, Wei 2008, Xie 2008, Yin 2007, Zhang 2011). Howver, it is unclear if all 
participants completed the trials or the authors selectively reported the participants 
with completed trial data only. Five studies reported a total of 26 withdrawals/drop-
outs (Greenway et al., 2006; Hioki et al., 2004; Lenon et al., 2012; Li et al., 2004) Li 
2007. Three of them indicated that those withdrawals/drop-outs did not comply with 
the treatment protocol ( Lenon et al., 2012) Hioki 2004, Li 2007. Two of them 
mentioned that those withdrawals/drop-outs were due to side-effects (Greenway et 
al., 2006) Hioki 2004. The Li (2004) trial indicated that it was due to loss of follow-up. 
Apart from the Lenon (2012) and Li (2007) trials, none of the other trials applied the 
ITT method to their data analysis. 
6.4.5 Selective reporting (reporting bias) 
To determine whether the studies selectively reported their results, published papers 
were to be compared with their protocol. However, none of the included studies 
reported their protocol prior to publishing the final results. Therefore, in the current 
review, the selective reporting was assessed by comparing the results with the 
outcome measures listed in the methods section in the same published papers. All 
studies reported results for all the outcome measures listed in the methods section. 
 
  
 196
6.4.6 Other bias 
Except for two RCTs (Mi, 1998; Wang et al., 2007) which did not provide any 
information on the baseline, the majority of included studies (12 out of 14) reported 
that the demographic data at the baseline were comparable. 
Apart from the two trials (Li et al., 2007; Mi, 1998) which did not provide any selection 
criteria, the rest of the 12 studies described valid and feasible inclusion and exclusion 
criteria which can be implemented into practice.  
 
6.5 Effects of interventions 
The effects of CHM compared to placebo, WM and other therapy, with or without co-
intervention, are reported as below. 
6.5.1 CHM versus placebo 
Four studies compared real CHM with placebo (Greenway et al., 2006; Ignjatovic et 
al., 2000; Lenon et al., 2012; Wang et al., 2007). 
6.5.1.1 Body weight 
The extracted data from two studies (Ignjatovic et al., 2000; Lenon et al., 2012) 
showed that there were no significant differences in BW at the end of the treatment 
period (MD -7.75, 95% CI -20.76 to 5.25) (Figure 6.4). The heterogeneity was 
(I2=92%). 
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Figure 6.4: Comparison of CHM and placebo for BW 
 
6.5.1.2 Body mass index 
The extracted data from two trials (Ignjatovic et al., 2000; Lenon et al., 2012) also 
indicated that there was no significant difference in BMI at the end of treatment 
period (MD -3.47, 95% CI -8.56 to 1.62) (Figure 6.5). The heterogeneity was 
(I2=92%). 
 
Figure 6.5: Comparison of CHM and placebo for BMI. 
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6.5.1.3 Body fat composition 
These two RCTs also showed that there was no significant difference in BF 
composition upon completion of the treatment (MD -1.09, 95% CI -2.33 to 0.15) 
(Figure 6.6). No heterogeneity existed (I2=0%). 
 
 
Figure 6.6: Comparison of CHM and placebo for body fat composition. 
 
6.5.1.4 Waist circumference 
Two RCTs did not observe the significant difference in WC between two groups (MD 
-6.06, 95% CI -18.10 to 5.99) (Figure 6.7). The heterogeneity was (I2=94%). 
 
 
Figure 6.7: Comparison of CHM and placebo for waist circumference. 
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6.5.1.5 Hip circumference 
No significant difference in HC was found in these two studies either (MD -6.44, 95% 
CI -14.05 to 1.18) (Figure 6.8). 
 
 
Figure 6.8: Comparison of CHM and placebo for hip circumference. 
 
6.5.2 CHM versus Western medication 
Only one study compared the effects of CHM with WM (Shi, Hu, et al., 2005). 
6.5.2.1 Body weight 
There was no significant difference in BW between CHM and WM (Amfepramone) 
after (Mi, 1998)'s treatment (MD 0.22, 95% CI -7.12 to 7.56).  
 
6.5.3 CHM plus dietary therapy and exercise versus placebo plus same 
dietary therapy and exercise 
Only one trial compared CHM with placebo when using the same dietary therapy and 
exercise as co-intervention (Hioki et al., 2004). 
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6.5.3.1 Body weight 
This trial did not find any significant difference in BW at the end of treatment period 
(MD -3.40, 95% CI -8.61 to 1.81) (Greenway et al., 2006). 
6.5.3.2 Body mass index 
The trial did not observe significant difference in BMI at the end of treatment period 
(MD -0.90, 95% CI -2.90 to 1.10). 
6.5.3.3 Body fat composition 
The effect size analysis found there was no significant difference in BF composition 
(MD -2.20, 95% CI -4.43 to 0.03). 
6.5.4 CHM plus other therapy versus same other therapy 
Five RCTs compared CHM plus other therapy (either dietary therapy alone or dietary 
therapy combined with exercise) with the same other therapy (Li et al., 2007; Li et al., 
2004; Wei et al., 2008; Xie 2008; Zhang, 2011). 
6.5.4.1 Body weight 
The extracted data from two studies showed that the combined CHM group was 
superior to the other therapy alone group for BW at the end of treatment period (MD -
3.89, 95% CI -6.92 to -0.87) (Figure 6.9). No heterogeneity existed (I2 = 0%). 
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Figure 6.9: Comparison of CHM plus other therapy and the same other therapy for 
BW. 
 
6.5.4.2 Body mass index 
The extracted data from four RCTs (Li et al., 2007; Li et al., 2004; Yin et al., 2007; 
Zhang, 2011) demonstrated that the combined CHM group was more effective than 
the other therapy alone group for BMI (MD -1.41, 95% CI -2.24 to -0.59) (Figure 
6.10).The heterogeneity was moderate (I2=37%). 
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Figure 6.10: Comparison of CHM plus other therapy and the same other therapy for 
BMI. 
 
6.5.4.3 Body fat composition 
The three trials (Li et al., 2007; Li et al., 2004; Yin et al., 2007) did not find any 
significant difference in BF composition (MD -2.14, 95% CI -4.51 to 0.24) (Figure 
6.11). The heterogeneity was substantial (I2=61%). 
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Figure 6.11: Comparison of CHM plus other therapy and the same other therapy for 
body fat composition 
 
6.5.4.4 Waist circumference 
Three trials (Li et al., 2007; Li et al., 2004; Zhang, 2011) showed that the combined 
CHM group was more effective for WC than the other therapy alone group (MD -2.01, 
95% CI -3.50 to -0.51) (Figure 6.12). No heterogeneity existed (I2=0%). 
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Figure 6.12: Comparison of CHM plus other therapy and the same other therapy for 
Waist circumference. 
6.5.4.5 Hip circumference 
Two studies did not find any significant difference in HC (MD -0.26, 95% CI -1.58 to 
1.06) (Figure 6.13). 
 
Figure 6.13: Comparison of CHM plus other therapy and the same other therapy for 
Hip circumference. 
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6.5.5 CHM plus other therapy versus Western medication plus same 
other therapy 
Three trials compared CHM with Western medication when using the same other 
therapy (either dietary therapy alone or the combination of dietary therapy and 
exercise) as co-intervention (Mi, 1998; Tang et al., 2013; Yin et al., 2007). 
6.5.5.1 Body weight 
The extracted data from two trials (Tang et al., 2013; Yin et al., 2007) did not show 
any significant difference in BW (MD 0.34, 95% CI -2.27 to 2.95) (Figure 6.14). 
 
Figure 6.14: Comparison of CHM plus other therapy and WM plus the same other 
therapy for BW. 
6.5.5.2 Body mass index 
No significant difference was found in two trials (Tang et al., 2013; Yin et al., 2007) 
for BMI (MD -0.22, 95% CI -1.06, 0.61) (Figure 6.15). 
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Figure 6.15: Comparison of CHM plus other therapy and Western medication plus 
the same other therapy for BMI. 
6.5.5.3 Body fat composition 
Only Yin 2007 assessed the BF composition. It did not find any significant difference 
in it between two groups (MD -1.20, 95% CI -3.31 to 0.91). 
6.5.5.4 Waist circumference 
There was no significant difference in WC between two groups (MD -2.07, 95% CI -
4.35 to 0.21) (Tang et al., 2013). 
6.6 Discussion 
6.6.1 Summary of main results 
The current review identified 14 RCTs comparing CHM with placebo, WM, or other 
therapies (dietary therapy and/or exercise), with or without co-intervention. All the 
trials focused on BW, BMI and/or BF composition. Some also reported results of WC 
and HC. 
When used alone, CHM did not show any significant difference from either 
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placebo or WM for BW, BMI or BF composition.  
When combined with other therapy (ie. Diet therapy and/or exercise), CHM only 
demonstrated benefits for BW (MD -3.89, 95% CI -6.92 to -0.87; two trials), BMI (MD 
-1.41, 95% CI -2.24 to -0.59; four trials) and WC (MD -2.01, 95% CI -3.50 to -0.51; 
three trials) at the end of treatment when used as an adjunct therapy to other therapy. 
However, there was no significant difference in any outcome measures between 
CHM and Placebo or WM when used in addition to other therapy.  
Similar to the acupuncture review, majority of the included RCTs in the CHM review 
had high risk in performance bias (blinding of participants), as well as unclear risk in 
selection bias (random sequence generation and allocation concealment), detection 
bias (blinding of outcome assessment) and attrition bias (incomplete outcome data). 
These findings implied that the included trials were of low quality.  
6.6.2 Overall completeness and applicability of the evidence 
The current review identified the currently available RCTs to be included by 
searching fifteen English and three Chinese databases. Although the included 
studies applied different CHM formulas, some Chinese herbs were commonly used 
across RCTs. The top ten most frequently used CHMs were Radix et Rhizoma Rhei 
(Da Huang), Fructus Crataegi (Shan Zha), Rhizoma Atractylodis (Cang Zhu), Radix 
Salviae Miltiorrhizae (Dan Shen), Folium Nelumbinis (He Ye), Rhizoma Alismatis (Ze 
Xie), Semen Cassiae (Jue Ming Zi), Poria (Fu Ling), Semen Coicis (Yi Yi Ren), and 
Radix Glycyrrhizae (Gan Cao). According to CM theory, they belong to the categories 
of ‘Aromatic herbs that transform the dampness’. These Chinese herbs are widely 
used in clinical practice to regulate the Spleen and Stomach and eliminate dampness. 
In addition, two thirds of included studies assessed the effects of CHM as an adjunct 
therapy to co-intervention (such as Western medication, dietary therapy and/or 
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exercise) (nine trials). In particular, five trials compared CHM plus other therapy with 
the same other therapy alone. Only this comparison demonstrated the significant 
difference in BW, BMI and WC. This reflects the fact that it is a common practice to 
apply CHM as an additional therapy to other therapy (dietary therapy and/or exercise) 
for management of obesity. 
Similar to the acupuncture review, the CHM trials performed outside mainland China 
always reported CHM effects with measurable outcomes (such as BW, BMI, WC and 
HC). However, the trials conducted in mainland China did not report the detailed 
results of each outcome but tended to use the effective rate to show herbal effects. 
Such expression makes data synthesis and comparison of different studies infeasible 
due to lack of detailed data. Separate reporting of results for individual outcome 
measures is highly recommended.  
Again, similar to the acupuncture review, only one included study assessed the 
quality of life of obese participants (Lenon et al., 2012).  
6.6.3 Quality of the evidence 
Generally speaking, the quality across all the included RCTs was consistently low 
due to methodological limitations and small sample size. Methodological limitations 
refer to high or unclear risk of bias in selection (random sequence generation and/or 
allocation concealment), performance, detection and attrition. All the included RCTs 
claimed that randomisation was used. However, less than one-third (3 out of 14) 
provided appropriate methods used for randomisation and none of them reported the 
methods for allocation of randomisation. 
Substantial heterogeneity existed in BMI. The substantial heterogeneity may be 
attributed to a number of factors, including study factors (e.g. quality of reporting), 
participant factors (e.g. age, gender, and diagnosis) and treatment factors (e.g. 
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co-intervention, formulation). However, due to the limited number of trials involved, 
subgroup analysis was not performed to identify the confounding variables. 
6.6.4 Agreements and disagreements with other studies or reviews 
A number of SRs on green tea (Lu Cha Ye) for weight loss have been published, 
confirming its positive effects (Shixian et al., 2006; Westerterp-Plantenga, 2010). 
Therefore, the current review did not consider it as an intervention.  
Another published systematic review focused on CHM for the management of obesity 
which searched four English databases, two Korean databases, one Japanese 
database and three Chinese database identified 49 publications (Sui et al., 2012b). 
Both reviews have agreed the low quality and small sample size of included studies. 
However, only 10 duplicated RCTs were identified in these two reviews. This 
difference may be due to the different selection criteria. Sui’s review considered 
herbal compounds which were excluded from the current review and demonstrated 
that CHM was more effective than placebo or lifestyle modification for weight loss. In 
the current review, there was no significant difference in any outcome measure 
between CHM and placebo, with or without co-intervention. CHM only showed its 
potential benefits for BW, BMI and WC when used in addition to other therapy.  
6.7 Conclusions 
In conclusion, the present review investigated the effectiveness and safety of CHM 
for the management of adult patients with obesity by systematically reviewing 14 
RCTs. Similar methodological defects to the acupuncture review have been identified. 
No significant difference between CHM and the placebo groups was found, which 
may be due to the poor design and conduct of the RCTs. It is critical to investigate 
whether or not CHM is more effective than placebo. There is an urgent need to 
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perform a rigorously designed randomised, double-blind, placebo-controlled, clinical 
trial to examine the efficacy of CHM with comparison to placebo. 
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Chapter 7. Evaluation of efficacy and safety of a 
Chinese herbal medicine formula (RCM-104) in the 
management of obesity: A randomised, placebo-
controlled clinical trial 
7.1 Introduction 
As mentioned in the previous chapters, the current management of obesity by 
pharmacotherapy includes non-centrally acting anti-obesity agents such as Orlistat 
(Xenical), which inhibits the action of the intestinal lipase enzymes and hence blocks 
the absorption of fat in the intestines. The most common adverse events of Orlistat 
include oily faecal spotting, abdominal pain, and flatus with discharge, faecal urgency, 
fatty/oily stool, increased defecation, and faecal incontinence (Ballinger & Peikin, 
2002). 
Another pharmacotherapeutic product is the centrally acting anti-obesity agent, 
namely, Sibutramine (Reductil), which produces unwanted side-effects such as 
difficulties in sleeping, constipation, and dry mouth as well as increased heartbeat, 
increased blood pressure, awareness of the heartbeat (palpitations), headache, 
anxiety, or dizziness (James et al., 2010; Kaya, AydIn, Topsever, Filiz, Öztürk, 2004; 
Scheen, 2010). Consequently, the FDA of the US withdrew Sibutramine in October 
2010. 
Surgical procedures such as gastric bypass operations are generally reserved for 
people with morbid obesity (BMI > 40) who instituted but failed an adequate exercise 
and diet program (with or without adjoining drug therapy) or patients presenting with 
co-morbid conditions such as hypertension, impaired glucose tolerance, diabetes  
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mellitus, hyperlipidaemia, and obstructive sleep apnoea (Shippey & Macedonia, 
2003). 
CHM has been used for weight management both in China and in Western countries 
(Guo et al., 2002). However, there is a lack of rigorously conducted randomised, 
controlled clinical trials concerning CHMs for weight management in international 
peer-reviewed scientific literature. 
In 2004, Hioki et al. demonstrated the effectiveness and safety of a traditional 
Chinese formula (Bofutsusho-san) in obese Japanese women with impaired glucose 
tolerance. Findings from this study revealed significant improvement in both 
treatment and placebo groups compared to the baseline. However, WC and HC 
measurements of subjects in the Bofutsusho-san TG were also significantly improved 
compared to that of the CG (Hioki et al., 2004). 
A number of animal studies support the use of CHM formulas for treating obesity and 
have shown other beneficial effects. For example, the Bofutsusho-san formula has 
been shown to prevent thickening and vascular smooth muscle cell proliferation in 
rats (Ohno et al., 2005). Furthermore, an in vivo study demonstrated that a CHM 
formula significantly reduced the weight of overweight rats and suppressed their 
appetites (Talpur et al., 2001). A herbal treatment, known as 9D-ASR also led to a 
decrease in the weight of overweight rats (Sun & Yu, 2000; Sun, 2008). Another 
herbal formula (PM-F2-OB) also demonstrated anti-obesity effects in overweight rats 
(Kang et al., 2004). To evaluate the potential mechanism of the actions of many 
Chinese herbs that are traditionally used for weight management, Tian et al. carried 
out investigations of the effect of 31 herbs on rats and found that 17 of them inhibited 
the enzyme, fatty acid synthase (Tian et al., 2004). It was also interesting to note that 
some agents such as conjugated linoleic acid, catechins, and 
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synephrinehydroxycitric acid often used for weight reduction were also found in 
CHMs (Allison et al., 2001; Heber, 2003). 
Until recently, a widely used herbal supplements for weight loss contained ephedra 
alkaloids and herbal forms of caffeine, which are constituents of Mahuang (Allison et 
al., 2001). Many clinical trials have been conducted to investigate the effectiveness of 
these two constituents for treating obesity (Boozer et al., 2002; Boozer et al., 2001). 
However, certain adverse effects associated with ephedrine and caffeine, such as 
central nervous system stimulation and increases in blood pressure and serum 
glucose, have been reported (Allison et al., 2001). The use of ephedra can lead to 
life-threatening adverse cardiac events (Nazeri et al., 2009), which include 
myocardial infarction, stroke, and death outside of a hospital setting (Hallas et al., 
2008). Consequently, the sale of products containing ephedrine has been prohibited 
in the US (Coffey et al., 2004; Kawata et al., 2003). There have also been reported 
cases of hepatotoxicity caused by Chinese dietary weight loss formulas containing 
fenfluramine and nitroso-fenfluramine. Kidney diseases or urothelial carcinoma 
related to the use of Chinese herbs containing aristolochic acids have also been 
reported (Yang et al., 2011). 
RCM-104 is a CHM formula prepared at RMIT with three herbal ingredients that are 
commonly used in daily practice. These three herbs were carefully selected based on 
both CM theory and existing published literature of basic research. A previous study 
on green tea extract had shown a 4.6% decrease in BW and 4.5% decrease in WC 
after 12 weeks, possibly via inhibition of intestinal lipases and stimulation of 
thermogenesis (Chantre & Lairon, 2002). 
The aim of this study was to evaluate the efficacy and safety of RCM-104 through a 
rigorous double-blinded, randomised, placebo-controlled clinical trial. 
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7.2 Methods 
This trial was conducted according to the methods described previously in the clinical 
study section of Chapter 4, General methodology. 
7.3 Results 
7.3.1 Pre-clinical trial screening questionnaires 
7.3.1.1 Demographic characteristics 
In total, 273 responded to our advertisement and 133 were screened and finally 126 
were included in this pre clinical survey. The distribution was spread over 154 
suburbs of Melbourne. The mean of BMI was 35.20 ± 4.96, 74% of subjects were 
female and 59% were university educated (Table 7.1) 
 
Table 7.1: Demographic characteristics 
Characteristics N (%) 
Age 37.40 ± 10.01 (rang 19 to 60)  
BMI 35.20 ± 4.96  (range 29.07 to 51.44)  
Gender Male 32 (25.4) 
Female 94 (74.6) 
Marital status Married 61 (48.4) 
Single 38 (30.2) 
Divorced 7  (5.6) 
Other 20 (15.8) 
Highest education Secondary school/college year 37 (29.4) 
University/post-grad 75 (59.5) 
Before Year 12 7  (5.6) 
Other 7  (5.6) 
  
 215
7.3.1.2 Current weight and weight history 
Details of weight history and weight gains is presented in the Table 7 2. The highest 
weight gain was varied from 5 kg (project manager) to 40 kg (teacher). When 
analysing the event associated with weight gain, it was revealed that having children 
is the most blamed for gaining weight (27.7%) while the breaking-up of relationships 
(15%) and marriages (15%) constitute both weight gain and weight loss.   
 
Table 7.2: Current weight and weight history 
EVENTS Yes % 
Breaking-up of significant relationships 19 15 
Marriage 15 12 
Divorce 11 8.7 
Quitting smoking 10 7.9 
Medication use 13 10.3 
Having children 35 27.7 
Caring for family 16 12.6 
Starting a new job 9 7.14 
Changing jobs 11 8.7 
Retiring 2 1.58 
Becoming an empty-nester 0 0 
Enduring death or illness in family 6 4.7 
Suffering from significant illness 9 7.1 
Taking medication or going off one’s antidepressants 10 7.9 
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7.3.1.3 Eating patterns and eating behaviours 
As described in the Table 7.3, 111 (88.1%) people think that they need to change 
what and how to eat. The number of people eating three meals per day was 89 
(71.8%). Some 104 varied what they eat each day (83.9%) and some114 (91.2%) 
have snacks or eat between scheduled meals and 51 (41.1%) eat before bedtime.  
No one had anorexia nervosa, only 12% had a binge-eating disorder, and 17.8% had 
a compulsive eating disorder. Most of 106 participants reported that they eat when 
gathered with friends (87.6%). Some 104 reported eating when bored (84.6%) and 
some 103 reported eating when not hungry (82.4%). Only 25% of participants 
reported doing grocery shopping but 59.2% prepare their own meals. (Table 7.3) 
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Table 7.3: Eating patterns and eating behaviours 
Eating pattern No-n(%) Yes-n(%) 
Are you happy with your current eating pattern? 87 (70.2) 37 (29.8) 
Do you think you need to change what you eat or how 
you eat? 
14 (11.2) 111 (88.1) 
I eat exactly the same things every day 114 (91.2) 11 (8.8) 
I vary what I eat each day 20 (16.1) 104 (83.9) 
What I eat during the week differs from what I eat on 
the weekends 
35 (28.2) 89 (71.8) 
I eat three or more meals per day   35 (28.0) 90 (72.0) 
I eat one or two meals per day 82 (70.9) 34 (29.1) 
I have a regular eating pattern 52 (41.6) 73 (58.4) 
I tend to skip meals 77 (62.6) 46 (37.4) 
I eat breakfast every day 41 (32.8) 84 (67.2) 
I eat just before bedtime 73 (58.9) 51 (41.1) 
I get up at night and eat in the middle of the night 116 (92.8) 9 (7.2) 
Do you have snacks or eat between scheduled 
meals? 
11 (8.8) 114 (91.2) 
Compulsive overeating 100 (82.0) 22 (18.0) 
Binge eating disorder 109 (88.6) 14 (11.4) 
Anorexia nervosa 123 (100) 0 
Bulimia (making yourself vomit after eating) 120 (97.6) 3 (2.4) 
Laxative abuse 121 (98.4) 2 (1.6) 
Do you eat when you are not really hungry? 22 (17.6) 103 (82.4) 
Do you eat when you are bored? 19 (15.4) 104 (84.6) 
Do you eat when you are fearful? 94 (75.2) 31 (24.8) 
Do you eat when you are anxious? 72 (58.1) 52 (41.9) 
Do you eat when you are tired? 64 (51.6) 60 (48.8) 
Do you eat when you are nauseated? 106 (85.5) 18 (14.5) 
Do you eat when you are reading? 86 (69.4) 38 (30.6) 
Do you eat when you are watching TV? 28 (22.4) 97 (77.6) 
Do you eat when you are talking on the phone? 110 (88.7) 14 (11.3) 
Do you eat when you are working on computer? 70 (56.5) 54 (43.5) 
Do you eat when you are gathered with friends? 15 (12.4) 106 (87.6) 
 
 
7.3.1.4 Commercial diets or other efforts at weight loss 
Significant numbers of participants (74.2%) have tried commercial diets or weight 
loss programmes. The most popular programme was TOPS (Take Off Pounds 
Sensibly,  weight loss programme (Watchers) (38.8%) and liquid diets (e.g., Optifast) 
(32.4%). Herbal remedies like Herbal Life was 20%. Only 29% have consulted 
dieticians. 
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7.3.1.5 Physical activities 
Most people do not have problems with daily activities. There is some limitation to the 
tasks that require bending, stooping or kneeling (25%) or climbing several steps 
(17.3%). No one needed special equipment for mobility such as a cane, wheelchair, 
walker, crutches, etc. Only 3.8% were doing daily weight training exercises and 23% 
were exercising by walking (Table 7.4). Low motivation or interest (71.4%), 
embarrassment (45%) and lack of support 30.3% prevent daily exercises in 
participants. However, 24.6% had physical limitations and pain (28.5%) which 
prevented them from regular exercises.  
 
Table 7.4: In response to: To what extent are you able to carry out the following daily? 
Description (1=Very limited; 2=Somewhat limited; 3=Not limited) 1 2 3 
Bathing and dressing yourself 1.3 2.7 96 
Personal hygiene/toileting 1.3 0.7 98 
Climbing several steps 3.3 17.3 79.3 
Climbing one step 2 2 95 
Rising from a soft/low seat 0.7 17.3 82 
Walking inside your home 1.4 2 96 
Walking less than 1 block  0.7 3.4 95.9 
Walking several blocks 2 12 86 
Walking more than 1 kilometre 5.3 16.7 78 
Moderate household tasks  
(moving furniture, vacuuming, scrubbing floors) 
2.7 9.5 87.8 
Tasks that require bending (stooping, kneeling) 5.4 25.5 69.1 
Lifting and carrying groceries 2.7 12.1 85.2 
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7.3.1.6 Health related complaints 
Generally, only 13.2 % of participants were trouble-free with their health. Some 34% 
suffered from headache and 59.2% were depressed with regard to their weight. Most 
of them did not have problems with alcohol (98.5%), however, some 29% smoked 
and some 38.3% had problems with tobacco. Some 28.9% suffered shortness of 
breath, 60.4% snored at night, 63% felt sleepy during the day and 56.1% hade 
disturbed sleep. Regarding gastrointestinal disorders: 35% had heartburn, 22.8% had 
diarrhoea and 14.7% had constipation.  
The participants also suffered from musculoskeletal problems: 29.5% had painful 
joints or arthritis as well as painful feet (21%) and shoulder pain (23%) (Table 7.5) 
 
Table 7.5: Health related complaints 
Disorders N (%) Disorders N (%) 
joint pains  23 (18.3) migraine  13 (10.3) 
back pain  46 (36.5) heart disease  1 (0.8) 
hip pain  12 (9.5) arthritis  3 (2.4) 
knee pain  35 (27.8) emphysema  1 (0.8) 
ankle/feet pain  27 (21.4) cancer  0 
sleep apnoea  18 (14.3) diabetes  1 (0.8) 
daytime sleepiness  23 (18.3) irregular periods  8 (6.3) 
blood clots  1 (0.8) reflux disease (heartburn),  7 (5.6) 
severe psychiatric problems  2 (1.6) fatty liver  3 (2.4) 
depression,  14 (11.1) high cholesterol  6 (4.8) 
anorexia  0 menstrual problems 6 (4.8) 
swelling of feet  10 (7.9) asthma  7 (5.6) 
headaches  18 (14.3) seizures  1 (0.8) 
high blood pressure 8 (6.3) snoring  19 (15.1) 
kidney disease 0 rashes  3 (2.4) 
urinary stress incontinence 6 (4.8) stroke  0 
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7.3.2 Radomised placebo-controlled clinical trial 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1: Flow diagram 
 
  
134 Initial interviewed and assessed 
117 Randomised 
59 RCM-104 group 
55 Received 
Placebo 
58 Placebo group 
42 Remaining for ITT 50 Remaining for ITT 
41 Completed 
trial 
46 Completed 
trial 
57 Received RCM-
104 
 
17 excluded (not meeting 
criteria) 
2 Change of 
mind 
3 Change of 
mind 
7 Dropped out 
(personal choice, 
did not return) 
 
13 Dropped out 
(personal choice. Did 
not return) 
4 Dropped out (1 
tired due to 
caffeine; 2 
personal choice) 
 
1 Dropped out 
(personal choice) 
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7.3.2.1 Baseline data of randomised participants 
Of 134 obese subjects screened, 117 fulfilled the inclusion criteria and were 
randomised into placebo (n = 59) and TGs (n = 58, Table 7.6 and Figure 7.1). 
Thirteen (13) subjects of the TG and 17 subjects of the placebo group prematurely 
withdrew before the commencement of the treatment phase or did not return for the 
assessment after the first treatment period due to personal and other reasons. 
Ninety-two (92) subjects were included in an ITT analysis. No subjects were removed 
or withdrew from the study due to serious adverse events. 
 
Table 7.6: Demographic and baseline health characteristics of all randomised 
subjects by group. 
 RCM-104 (n=59,  Mean ± 
SD) 
Control (n=58 –
Mean ±SD) 
P-value 
Gender    
     Male 10 10 0.97 
     Female 49 48  
Age (years) 39.3 ± 13.2 40.4 ±10.2 0.61 
Weight (kg) 99.5 ± 15.1 98.2 ± 17.3 0.67 
                Male 105.5 ± 15.1 108.3 ± 21.1 0.41 
                Female 98 ± 14.7 96.8 ± 16.1 0.67 
Body mass index (BMI) 35.3 ± 4.8 36.0 ± 5.5 0.47 
Heart rate (beats/min.) 72.6 ± 9.2 73±11.4 0.84 
Systolic blood pressure 
(mm hg) 
122.8 ±15.5 126.2 ± 19.8 0.30 
Diastolic blood pressure 
(mm hg) 
80.8 ± 10.8 82.9±13.7 0.16 
HbA1c (%) 5.3 ± 0.3 5.6 ± 0.8 0.008 
Triglyceride (mmol/L) 1.5 ± 0.8 1.6 ± 0.8 0.50 
Cholesterol (mmol/L)    
    Total (mmol/L) 5.6 ± 1.5 5.5 ±1.5 0.71 
  Low-density lipoprotein 
(LDL-mmol/L) 
3.6 ± 0.8 3.6 ± 1.5 1.00 
  High-density lipoprotein 
(HDL-mmol/L) 
1.5 ± 0.08 1.4 ± 0.23 0.002 
Insulin (mIU/L) 10.7 ± 9.2 15.1 ± 3.6 0.001 
Glucose (mmol/L) 4.8 ± 0.5 5.2 ± 1.5 0.058 
Homa-index (%) 2.3 ± 2.2 3.9 ± 1.0 <0.001 
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7.3.3 Anthropometric measurements 
Anthropometric measurements are BW, BMI and BF composition which are collected 
during each visit. 
7.3.3.1 Body weight, body mass index, and body fat composition 
At baseline, the placebo group had a mean weight (98.2 ± 17.3 kg) and mean BMI 
(36.0 ± 5.5 kg/m2) similar to those in the TG (99.5 ± 15.1 kg), (35.3 ± 4.8), 
respectively. ANCOVA was used for assessing treatment outcomes in weight and 
BMI between the two groups after 12 weeks of treatment using the baseline as a 
covariate. When both groups were compared after 12 weeks of treatment with the 
baseline as covariate, there was a significant difference between the two groups on 
weight (P = 0.006, Figure 7.2) and BMI (P = 0.027, Figure 7.3). Note that we used 
Hochberg's step-up procedure to control Type I error to assess statistical 
significance. In doing so, we included BW, BMI, and BF composition as the three 
core variables that were used to assess the efficacy of the treatment. Within the TG, 
the reduction in weight and BMI were statistically significant. 
 
 223
 
Figure 7.2: Average BW (kg) after 12-week treatment (* indicates significance, 
ANCOVA, P≤ 0.05). 
 
 
Figure 7.3: Average BMI (kg/m2) after 12-week treatment (* indicates significance, 
ANCOVA, P≤ 0.05) 
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Figure 7.4: Average BF composition (%) after 12-week treatment. (# indicates 
significance, ANCOVA, P≤ 0.05). 
  
7.3.3.2 Waist and hip circumferences 
Both WCs of subjects in RCM-104 group decreased from 108.5 ± 12.2 cm to 106.5 ± 
12 cm and HC from 124.3 ± 12 cm to 122.8 ± 11.8 cm respectively. On the other 
hand, in contrast, in the placebo group the WC slightly decreased from 107.3 ± 10.9 
cm to 106.3 ± 12.2 cm and the HC slightly increased from 124.7 ± 12.4 cm to 125.1 ± 
12.6 cm. However, the ratio between WC/HC was not significantly different (Figure 
7.5). 
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Figure 7.5: Waist and hip circumferences (cm) after 12-week treatment. 
 
7.3.3.3 Resting metabolic rate (RMR) and heart rate 
The resting metabolic rates increased in both groups by more than 100 kcal/day. 
However, both within group and between the groups analysis did not reveal 
significant changes in RMR for both groups  
(Figure 7.6). 
 
Figure 7.6: Resting metabolic rate and heart rate after 12-week treatment. 
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7.3.4 Serological outcome measures 
7.3.4.1 Glucose, insulin and HOMA-R index 
At the baseline, there are significant differences in glucose, insulin level and HOMA-
R between the groups. The ANCOVA analysis, taking the baseline into account, 
revealed no significant differences between the groups (Figure 7.7). 
 
Figure 7.7: Glucose, insulin and HOMA-R index. 
 
7.3.4.2 Cholesterol, triglyceride, HDLC, LDLC and HbA1C 
At the baseline, the lab data of both groups are compatible except for HbA1C. After 
12-week treatment, the analysis using ANCOVA revealed the significance between 
the two groups in HDLC and HbA1C (P<0.05) (Figure 7.8) 
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Figure 7.8: Change of cholesterol, triglyceride, HDLC, LDLC and HbA1C after 12-
week treatment. (* indicates significance, ANCOVA, P≤ 0.05). 
 
 
7.3.4.3 Kidney and liver function tests & FBE 
The tests were carried out as a safety measure to monitor the effects of RCM-104 on 
kidney and liver functions detailed respectively. No significant changes were 
observed between real treatment and placebo groups at the baseline or at the end of 
the trial period. 
The FBEs were used for the processes of screening and monitoring changes of 
eosinophils and basophils as shown. There were no significant differences between 
the two groups. 
7.3.5 Quality of life (QOL) 
There are two QOL instruments: Weight-Related Symptom Measure (WRSM) and 
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Obesity & Weight-Loss Quality of Life measure (OWLQOL). 
7.3.5.1 Weight-related symptoms and how much they bother you 
At baseline, there were no statistically significant differences in any of the twenty 
quality of life measures (Weight-related symptoms and how much they bother you) 
between the two groups. The RCM-104 group showed significant improvement 
compared to the baseline on only two items of the quality of life measure, which 
assessed shortness of breath and physical stamina (P = 0.001), while the placebo 
group showed no significant improvement on any of the items after controlling for 
Type I error due to multiple testing via the Holm’s step-down procedure. (The 
smallest P-value was compared against α/m, the next smallest against α/ (m − 1), 
etc., where α = 0.05 and m = 20 variables. Note that we have only included five of the 
twenty variables in Table 7.6 on the basis of having the smallest P-values. All other 
variables had associated P-values, which were large enough not to have reached 
significance). When the RCM-104 group was compared to the placebo group (after 
twelve weeks of treatment, an ANCOVA analysis with the baseline as the covariate, 
and using the Holm step-down procedure, as described above, for controlling Type I 
error), the only quality of life measure that showed significant difference in symptoms 
between the two groups was shortness of breath (P = 0.002) with the RCM-104 
group showing significant reduction in symptoms (P = 0.001, Table 7.7). 
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Table 7.7: Weight-related symptoms and how much they bother you 
SYMPTOMS  
Study 
period 
RCM-104 (n=48)# 
Value ± SD  
Placebo (n=42) 
Value ± SD  
P-value** 
Shortness of breath Baseline 1.2 ± 1.27 1.1 ± 1.23  
Final 0.6 ± 0.92 1.2 ± 1.21  
P-value* 0.001 0.760 0.002 
Sensitivity to cold  Baseline 1.0 ± 1.57 0.8 ± 1.12  
Final 0.5 ± 0.92 0.9 ± 1.23  
P-value* 0.008 0.628 0.011 
Leakage of urine Baseline 0.4 ± 1.09 0.4 ± 0.73  
Final 0.4 ± 0.91 0.8 ± 0.93  
P-value* 0.521 0.005 0.005 
Increased sweating Baseline 0.9 ± 1.56 0.7 ± 1.20  
Final 0.5 ± 1.11 0.8 ± 1.15  
P-value* 0.030 0.547 0.057 
Decreased physical 
stamina 
 
Baseline 1.6 ± 1.91 1.2 ± 1.54  
Final 0.7 ± 1.23 1.1 ± 1.53  
P-value* 0.001 0.660 0.049 
Joint pain Baseline 1.5 ± 1.62 1.8 ± 1.83  
Final 0.8 ± 1.18 1.6 ± 1.56  
P-value* 0.003 0.748 0.007 
 
WRSM is 7-point scaled: 0 = not at all; 1 = hardly; 2 = somewhat; 3 = moderately; 4 = 
a good deal; 5 = a great deal; 6 = a very great deal.  
*Comparison within the group between baseline and final visits using Wilcoxon-
signed rank test.  
**Comparison between groups at the end of trial. 
For the above, the P values were assessed using Holm’s step-down procedure, with 
α = 0.05/20 = 0.0025 for assessing the smallest P-value, α = 0.05/19 = 0.0026 for the 
next smallest P-value, and so forth. Significant P-values are indicated in bold. Note: 
only results for symptoms showing small P-values are displayed. Sample size for TG 
reduced from 50 to 48 as quality of life data were unavailable for two participants. 
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7.3.5.2 Weight-loss quality of life (your feelings about your weight) 
Similarly, after twelve weeks, eleven items of the weight-loss quality of life (your 
feelings about your weight) questionnaire were significantly improved in the TG, while 
only two items were significantly improved in the placebo group. When the RCM-104 
group was compared to the placebo group (after twelve weeks of treatment, an 
ANCOVA analysis with the baseline as the covariate, and using the Holm step-down 
procedure for controlling Type I error) it was found that there were no statistically 
significant differences between the two groups on all of the seventeen items except 
for one (‘I get discouraged when I try to lose weight‘) on the OWLQOL measure. 
(Here we used α = 0.05/17 = 0.0029 for assessing the smallest P-value (Table 7.8). 
Table 7.8: Obesity and weight-loss quality of life (OWLQOL) – your feelings about 
your weight. 
OWLQOL questionnaires are 7-point scaled: 0 = not at all; 1 = hardly; 2 = somewhat; 
3 = moderately; 4 = a good deal; 5 = a great deal; 6 = a very great deal. 
SYMPTOMS 
Study 
period 
RCM-104 
(n=50) 
Value ± SD 
Placebo 
(n=42) 
Value ± SD 
p-value 
Because of my weight, I try to 
wear clothes that hide my shape 
Baseline 4.0±0.3 3.2±0.3  
Final 3.2±0.3 2.8±0.2  
p-value 0.001* 0.038 0.021** 
I feel frustrated that I have 
less energy because of my 
weight 
Baseline 3.5±0.3 3.2±0.3  
Final 2.7±0.3 2.8±0.2  
p-value 0.001* 0.042 0.025** 
I feel guilty when I eat 
because of my weight 
Baseline 3.2±0.3 3.0±0.3  
Final 2.5±0.3 2.7±0.3  
p-value 0.001* 0.113 0.093** 
I am bothered about what 
other people say about my 
weight 
Baseline 2.7±0.3 2.9±0.3  
Final -2.3±0.3 2.5±0.3  
p-value 0.024* 0.034 0.590 
Because of my weight, I try to 
avoid having my photograph 
taken 
Baseline 3.2±0.3 3.4±0.3  
Final 2.5±0.3 3.0±0.3  
p-value 0.002* 0.008 0.374 
My weight prevents me from Baseline 2.7±0.3 2.9±0.3  
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doing what I want to do Final 2.3±0.3 2.3±0.3  
p-value 0.031* 0.001 0.608 
I worry about the physical 
stress that my weight puts on 
my body 
Baseline 3.7±0.3 3.9±0.3  
Final 3.0±0.3 3.4±0.3  
p-value 0.002* 0.026 0.329 
I feel depressed because of 
my weight 
Baseline 2.9±0.3 2.8±0.3  
Final 2.4±0.3 2.6±0.3  
p-value 0.001* 0.142 0.106 
I feel ugly because of my 
weight 
Baseline 3.0±0.3 3.1±0.3  
Final 2.5±0.3 2.5±0.3  
p-value <0.001* 0.002 0.072** 
I worry about the future 
because of my weight 
Baseline 3.6±0.3 3.4±0.3  
Final 2.6±0.3 3.2±0.2  
p-value* <0.001 0.389 0.702 
I envy people who are thin Baseline 2.7±0.3 2.6±0.3  
Final 2.4±0.3 2.4±0.3  
p-value* <0.001 0.406 0.267 
I feel that people stare at me 
because of my weight 
Baseline 2.2±0.3 1.8±0.3  
Final 1.9±0.3 1.5±0.3  
p-value* 0.012 0.262 0.332 
I have difficulty accepting my 
body because of my weight 
Baseline 2.9±0.3 2.9±0.3  
Final 2.4±0.3 2.6±0.3  
p-value* 0.005 0.202 0.179 
I am afraid that I will gain 
back any weight that I lose 
Baseline 3.7±0.3 3.7±0.3  
Final 3.1±0.3 3.3±0.3  
p-value* 0.001 0.018* 0.149 
I get discouraged when I try to 
lose weight 
Baseline 3.7±0.3 3.1±0.3  
Final 2.9±0.3 3.1±0.3  
p-value* <0.001 0.806 0.002** 
*Comparison within the group between baseline and final visits  
**Comparison between groups at the end of trial   
 
For both the above, the P-values were assessed using the Holm step-down 
procedure, with α = 0.05/17 = 0.0029 for assessing the smallest P-value, α = 0.05/16 
= 0.0031 for the next smallest P-value, and so forth. Significant P-values are 
indicated in bold.  
*Comparison within the group between the baseline and the final visits using 
Wilcoxon-signed rank test. **Comparison between groups at the end of the trial. 
Note: only symptoms showing small P-values are displayed.  
#The sample size for the TG was reduced from 50 to 48 as quality of life data 
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7.3.7 Food records 
The diet records monitored the nutrition intakes of participants through the trial. 
Participants were instructed not to change their diet. However, some reductions have 
been observed both groups but analysis revealed no significant changes in all 
substances between groups. (Fig.7.10) 
 
Figure 7.10: Diet records of twelve-week treatment 
 
7.3.8 Medication compliance 
Overall, compliance with medication was 88%: with 88.6% in the placebo and 87% in 
the TG respectively. There was no significance between the two groups which 
indicates successful blinding. (Fig 7.11) 
 
Figure 7.11: Medication compliance of both groups 
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7.3.9 Self-reported undesired symptoms 
Within the RCM-104 group, there were reports of nausea (3 cases) and headache 
(nine cases) while there were two reports of decrease in appetite in the placebo 
group. Both of these symptoms occurred during the first treatment period and none of 
these were serious. No subject withdrew from the study due to adverse events. 
 
7.3.10 Follow up 
Only anthropometric measurements were followed up. The data show that both 
groups continued to lose weight significantly.  
 
 
Figure 7.12 Average weight and BMI at the end of follow up period      
7.4 Discussion 
7.4.1 Background and clinical effects of RCM-104 
RCM-104 was evaluated for its clinical efficacy and safety in a RCT. The trial was 
conducted over a period of twelve weeks during which the subjects were required to 
visit the clinic monthly for collection of medication and self-administered evaluation 
forms. There was a high level of willingness to participate in this study as all 117 
subjects who satisfied the inclusion criteria gave informed consent to participate 
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in the trial. The results of the present study showed that the demographic and the 
baseline data analysis showed no statistically significant differences between groups 
except HbA1C, HDL and Homa-R index. However, after 12 weeks of treatment, there 
were statistically significant differences in BW, BMI and BF composition between the 
participants of RCM-104 and the placebo groups and significant improvements in the 
quality of life of participants in the RCM-104 group. 
RCM-104 is composed of three herbs: Camellia Sinensis (Lu Cha Ye-Green tea), 
Semen Cassiae (Jue Ming Zi), and Sophora Japonica (Huai Hua). While the 
mechanism of actions of this formula is unknown, a study has shown that green tea 
extract stimulates thermogenesis and fat oxidation and has the potential to influence 
BW and body composition by increasing energy expenditure (Dulloo et al., 2000). 
It has been suggested that synergistic interactions between catechin-polyphenol and 
caffeine augment and prolong sympathetic stimulation of thermogenesis and that this 
may play an important role in the management of obesity (Dulloo et al., 2000). Thus 
the actions of green tea may contribute to reducing BF as previous experimental and 
clinical studies have reported that green tea extract, which is rich in catechins and 
caffeine, is an effective potentiator of sympathetically mediated thermogenesis 
(Shixian et al., 2006). Further actions of green tea include EGCG’s inhibition of the 
enzyme catechol-O-methyltransferase, which prolongs the action of the catecholic 
compound on energy expenditure (Shixian et al., 2006). Studies also suggested that 
EGCG stimulates thermogenesis, with caffeine enhancing this action. Other studies 
have found that catechin polyphenols and caffeine increase 24-hour energy 
expenditure and fat oxidation in humans, which contribute to weight reduction 
(Shixian et al., 2006). The present study found some increase in RMR; however, the 
difference between the two groups was not significant. 
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In CM practice, Jue Ming Zi is known to clear heat. It moistens and lubricates the 
intestines, and therefore acts as a mild laxative (Bensky et al., 2004). The anti-
obesity effects of this herb, however, may be attributed to the inhibition of fatty acid 
synthase (Tian et al., 2004), which is shown in the reduction of BF composition. 
Traditionally, Huai Hua is used to cool blood and stop bleeding, which is an anti-
inflammatory effect. The anti-obesity effect of Huai Hua is attributed to its diuretic and 
laxative actions (Huang, 1999a). 
In addition to biological factors, psychological factors also play a big role in obesity 
and disordered eating (Stice, Presnell, Shaw, & Rohde, 2005). For example, it is not 
uncommon for individuals to engage in binge eating as a means of regulating 
negative emotions and reducing stress. Mindfulness behaviour cognitive therapy 
(MBCT) is a form of cognitive-behaviour therapy that involves mindfulness meditation 
and aims to improve emotion regulation by increasing awareness to thoughts, 
feelings and behaviours. The follow up results has showed participants continued 
lose their weight during the follow-up period. This may due to the fact that 
participants became more aware of the weight and mindfulness of their eating and 
physical exercise.  
In human studies, green tea has been found to significantly increase energy 
expenditure, lower BW, and decrease WC without changing heart rate or blood 
pressure (Shixian et al., 2006). Obesity is associated with many other health 
problems (Patterson et al., 2004) and even small reductions in weight can lead to 
significant improvements in quality of life of obese individuals (Blissmer et al., 2006). 
In this study, we found that RCM-104 significantly improved many aspects of the 
quality of life consistent with the theory of CM diagnosis. The results shows that 
RCM-104 improved the symptoms of the Stomach Heat and Spleen and Kidney 
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Yang deficiency such as  shortness of breath, sensitive to cold, leakage of urine and 
lumbar pain. The reduction of joint pain among the participants in this study may also 
be due the anti-inflammatory action of Huai Hua and Jue Ming Zi (Huang, 1999a). 
Cholesterol levels have been unchanged, which is not consistent with an animal 
study by (Li, 2002) that Huai Hua lowered hepatic and blood cholesterol levels, but 
may be due to the relatively small proportion of Huai Hua in RCM-104.  
It is important to note that over the last fifty years, there has been a dramatic 
increase in clinical research into CM (Barnes et al., 1999). Overall, clinical research 
in CM can be divided into two categories. The first adheres to traditional formulae, 
which were formed according to CM theory. In vitro and animal studies have been 
carried out after confirmation of safety and efficacy. The other category is 
mechanism-based, of which, the mechanism of action must be well understood 
before trialing in humans for clinical efficacy (Tang & Leung, 2001). The present 
study adopted a mechanism-based approach to elucidate potential mechanisms of 
action on a clinically effective original formula, a combination to ensure more reliable 
outcomes for new herbal product development. 
From a clinical practice point of view, studies fully adhering to CM theory would be 
more beneficial. This requires intervention to be tailored individually to reflect the 
nature of clinical practice. This approach ensures that research on the mechanism of 
a formula or constituents be carried out only after clinical efficacy is confirmed, to 
avoid irrelevant basic research. It is well understood that the design and conduct of 
clinical trials in CM need to comply with guidelines and requirements of both WM and 
CM. For example a trial on individually tailored traditional CM formulae for bronchial 
asthma that incorporated CM diagnosis and individualised treatment (Hsieh, 1996) 
had demonstrated the feasibility of this approach. Another study that compared a 
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standardised herbal formula with individualised CM groups had resulted in 
comparable results between the two approaches (Bensoussan et al., 1998). The 
results of these studies provide an encouraging indication of the benefits of applying 
this approach to validate the efficacy and safety of CHM.  
In addition, CM practice may treat acute symptoms, underlying deficiencies or both 
concurrently. A combined approach is desirable for the conduct of trials to evaluate 
the effect of treating deficiency without episodic exacerbation. Bensoussan et. al. 
(1998) demonstrated that during the treatment phase, subjects receiving standard 
treatment and individualised intervention were significantly better than the placebo 
group. However, only subjects in the individualised TG retained the effectiveness of 
the treatment during the follow-up period, which indicates the advantages of treating 
the cause of disease.   
With the growing popularity of evidence-based medicine and acceptance of CM in 
Western countries such as Australia, a validated and replicable scientific approach is 
required for future development. There are a number of studies that have 
demonstrated the feasibility of such an approach. The results of the RCT for RCM-
104 were up to our expectations and are supported by existing literature in terms of 
clinical efficacy. As obese individuals often have other associated health issues, 
guidelines for obesity management prefer modest and safe weight loss and good 
weight maintenance to target an ideal weight (Goldstein, 1992; Ludbrook, 1998). 
7.4.2 Safety 
There has been general concern of the lack of safety of specific CHM. Kidney failure 
due to herbal weight loss pills has been reported (Kwan et al., 2006). The results of 
this study have shown only mild undesirable adverse events such as headache and 
nausea. They occurred during the first treatment period. This is consistent with 
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reports from previous studies (Choan et al., 2005; Yance & Sagar, 2006). A study by 
Pisters et al in 2001 showed that a single oral consumption of 800 mg EGCG  might 
cause mild headache (Hsu et al., 2008; Pisters et al., 2001). A study by Hsu et al. 
2008 did not detect EGCG in the serum sample of subjects at the dosage of 302 mg 
of EGCG per day. In the present study, RCM-104 contained 314.04 mg of EGCG in 
the daily dosage. It has been previously reported that green tea could cause slight 
gastrointestinal disturbances such as nausea (Hsu et al., 2011). Although Jue Ming 
Zi is included in the list of poisonous plants of North Carolina, without specifying 
dosage, Russell et al. stated that toxic effects are only associated with the intake of 
large quantities (Russell et al., 1997). However, an animal study has shown no 
changed serum aspartate aminotransferase, creatine phosphokinase, lactic 
dehydrogenase activity at the dosage of 1.19% of BW per day (Putnam et al., 1988). 
Another animal study did not see any sign of chronic ingestion when consuming 
0.15% Jue Ming Zi of the diet and intermittent mild diarrhoea was observed in 
animals consuming high doses (5%) of Jue Ming Zi in their diet (Voss & Brennecke, 
1991). Jue Ming Zi has been safely used in CM practice for hundreds of years. In this 
study we used 2.4 g of Jue Ming Zi extract which is less than half of the 
recommended dosage of 5 g of extract per day (Huang, 1999b). Huai Hua has been 
used in many Asian countries as daily tea. In daily practice, overuse of Huai Hua can 
cause mild diarrhoea in some cases (Huang, 1999b). The recommended safe 
dosage for this herb is 5 g (Bensky et al., 2004) of extract per day but only 1.2 g per 
day was used in this study. Based on the dosages used in this study and the 
findings, RCM-104 appeared to be safe and well-tolerated by the subjects.  
There were no statistically significant differences between the groups in all events 
therefore it is unlikely that the side-effects were associated with the CHM 
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capsules. Apart from five subjects who withdrew from the trial because of side-effects, 
all other subjects who experienced side-effects completed the trial. Based on the 
reported cases of unexpected adverse events together with the laboratory results of 
liver and kidney function tests, it is reasonable to conclude that RCM-104 was well 
tolerated by subjects in the obesity trial.  
7.4.3 Conclusion 
RCM-104 is well tolerated and appears to be effective in reducing weight and 
improving the quality of life in obese individuals after twelve weeks of use. Long-term 
follow-up studies in larger populations are required to determine if weight loss is 
sustained. 
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Chapter 8. General discussion and future directions 
8.1 Introduction 
The WHO estimates that there are currently more than one billion overweight adults 
in the world (Anderson & Caswell, 2009); therefore, obesity represents a major public 
health problem (Formiguera & Canton, 2004). The aim of this thesis is to provide a 
clear understanding of the current state of the management of obesity from both 
Western and CM perspectives. The SRs demonstrated that both acupuncture and 
CHM are effective for reducing weight in obese individuals only when combined with 
other adjunct therapies. However, the reviews identified the methodological design 
issues of the RCT so the conclusions need to be drawn very cautiously. Judging by 
the results of the reviews, the RCM-104 was formed and evaluated in a rigorously 
designed RCT.    
8.2 Systematic reviews 
This project searched through 6929 records (Acu: 2,610; CHM: 4319), the majority of 
which are from Chinese databases. However, only 37 papers (Acu: 23; CHM: 14) 
satisfied inclusion criteria which indicates that the criteria for the selected study were 
very strict and were set up at a high standard.. A total of 3136 participants (Acu: 1968; 
CHM: 1168) were included in these reviews and most of them were conducted in 
China and published in Chinese. 
8.2.1 Acupuncture for obesity 
The acupuncture for obesity SR of this project comprehensively searched both 
Chinese and English databases but only 23 papers satisfied the strict inclusion 
criteria of this systematic review. The results of this study showed that acupuncture 
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alone does not reduce weight but that it reduced BMI compared to the sham CG. 
This was consistent with a previous study which showed that EA on acupuncture 
points such as Zusanli (ST36) and Sanyinjiao (SP6) have a beneficial weight-
reducing effect on overweight and obesity. Another in vivo study, found that strong 
EA stimulation of humans had significantly better effects than weak EA stimulation of  
rats (Yu et al., 2011). A previous study indicated that acupuncture may work through 
improving the sense of well-being thus suppressing an excessive desire for food 
(Eich et al., 2005), regulating metabolism and thereby enabling the body to utilise 
food efficiently instead of storing it as fat (Hsu et al., 2005; Wei & Liu, 2004). 
Acupuncture combined with diet control has an important effect on weight rebounding 
obesity (Chen, 2008b). Previous studies have shown that acupuncture combined with 
dietary therapy and aerobic exercise reduces weight, BMI, and serum leptin levels 
significantly when compared to diet adjustment combined with aerobic exercise alone 
(Yang et al., 2010a). This is consistent with the result of this review which showed 
the combination of acupuncture and dietary therapy has significant effects on the 
reduction of BW, BMI, BFC, WC and HC. On the other hand, the Nourshahi, 
Ahmadizad et al. (2009) and Wang, Ge et al. (2009) studies showed that 
acupuncture combined with diet and exercise does not result in greater weight loss or 
reduction in adipose quantity or improvement in BMI than diet and exercise alone 
(Nourshahi et al., 2009; Wang et al., 2009). 
From a CM perspective, acupuncture therapy has been shown to greatly reduce BMI 
and abdominal adipose tissue (Zhang et al., 2011). In obesity, acupuncture has been 
shown to have a clear therapeutic effect and to produce long-term warming of the 
Spleen (Shi, Zhang, et al., 2005). Acupuncture points along the Stomach meridian 
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have a reducing effect on weight in obese patients with the TCM diagnosis of excess-
heat syndrome (Bai & Fu, 2007a). 
There are many factors influencing the therapeutic effects of acupuncture for weight 
reduction. Treatment effects may be increased if there is good cooperation between 
the doctor and the patient (Wang & Al, 2006). Tong and Chen 2011 demonstrated no 
neurological side-effects, and side-effects such as diarrhoea in acupuncture 
treatment, which means that acupuncture therapy is a safe and effective method of 
treatment for overweight and obesity (Tong et al., 2011). Acupuncture treatment is 
not only an important method of treatment of obesity; it can also function as 
cardiovascular disease prevention and treatment for the complications of obesity (Liu 
et al., 1992). 
In conclusion, acupuncture may be a safe and effective form of obesity treatment in 
combination with diet, exercise and cognitive therapy. Acupuncture can be more 
beneficial if it is individualised according to CM syndrome differentiation. However, 
the current available evidence is limited in quantity; while the quality of some of the 
literature is low. Although limited, the publication of recent research provides clinical 
evidence in support of the effectiveness of acupuncture.  
The positive results from acupuncture trials for obesity are not entirely convincing 
due to the lack of l quality experiments with good methodology. In short, there is an 
urgent need to develop an elaborately designed study to evaluate the long-term 
effectiveness of acupuncture treatment for obesity (Cho et al., 2009). Further 
randomised long-term clinical trials are required to provide more convincing evidence 
(Liang & Koya, 2010). 
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8.2.2 Chinese herbal medicine for obesity 
CHM has access to over one thousand different types of natural materials, which are 
used in complex formulations. Herbal mixtures effectively promote short-term weight 
loss; however, the safety of long-term herbal use requires further investigation 
(Heber, 2003). Studies revealed some herbs had similar effects to Western anti-
obesity drugs with fewer side-effects (Sui et al., 2012a). Scientific research on CHM 
and replacement therapy represents a potentially important source for new 
discoveries in obesity treatment and prevention (Heber, 2003). Data shows that Shan 
Zha fruit extract can affect the liver and reduce hyperlipemia in fat tissue (Niu et al., 
2011).  
Pu’er tea has has antioxidant effects, the potential to regulate blood fat, reduce blood 
sugar and regulate the immune system (Chu et al., 2011).  
This thesis systematically reviewed fourteen trials, ten of which were conducted in 
China; only four were published in English. The analysis of the systematic review did 
not demonstrate the effectiveness of CHM formulae in the treatment of obesity in 
RCTs. However, it has shown weight and BMI reduction by CHM formulae when 
used as adjunct treatment with other therapies.  
8.3 Randomised placebo-controlled clinical trial (RCM-104) 
The RCT of this project was designed taking into consideration the result of the 
systematic reviews of the literature. The RCM-104 formula consisted of herbs that 
are most frequently used in the management of obesity from both CM and WM 
perspectives. The pharmacological actions of the ingredients and CHM functions 
were taken into consideration during the formulation of RCM-104. 
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Clinical trials of Chinese medicine have been criticised for poor methodological 
quality of RCTs. Furthermore, the CM used for treating diseases other than obesity 
was also of poor quality and was reported by most SRs (Bian et al., 2006). The 
design of this clinical trial addressed all of these issues to ensure high quality design 
that would comply with the guidelines. The results of this RCT has shown that RCM-
104 is effective in reducing weight, BMI and BFC in obese individuals.The effects, 
however, have been reported in the systematic review which was included in this 
project.   
8.4 Strengths of this thesis 
This project is a flow-on from systematic analysis of existing published RCTs for the 
formulation, design and evaluation of the efficacy and safety of a CHM formula 
(RCM-104). The aim of the SRs is to evaluate the effects of acupuncture and CHM 
for the treatment of obesity. The reviews have been conducted since 2005 and they 
have been constantly updated until the finalisation of this thesis. Furthermore, these 
SRs are more comprehensive and analytical compared with earlier reviews of the CM 
RCTs for obesity. The assessment of reviews was based on both CM theories and 
Western medical science.   
The RCT of RCM-104 complied with GCP and ICH guidelines, therefore it was a 
rigorous trial. The results of the RCT have been published in high-leveljournals and 
have attracted much interest. This way strengthened  evidence for the effectiveness 
of CHM in the treatment of obesity.  
8.5 Limitations 
During the searches for SRs, languages were restricted to English and Chinese. 
Other languages, such as German, Japanese and Korean, were excluded because 
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of a lack of accessibility to databases and a lack of language proficiency by the 
author. In fact, most of the included studies were conducted in China. Therefore, a 
potential language of publication bias may affect the results of this study and may 
affect the generalisability of the conclusions.  
CM is traditionally tailored to each individual according to CM syndrome 
differentiations. This study treated all participants with the same either RCM-104 or 
placebo capsules which did not reflect true Chinese medicine clinical practice. The 
participants were asked not to change their diet however, the reduction of food intake 
has been observed. This may due to participants became more mindful about their 
eating when recording their food. The participants may change their daily routine or 
exercises during trial which may affect the outcomes, however the trial did not 
monitor of life style changes during clinical trial. This should be taken in consideration 
in future trials.  
8.6 Implications for further study on CHM and acupuncture for 
obesity 
Based on the findings of the analyses of systematic reviews of the RCTs, more 
rigorous, clinical trials on CM for obesity of higher methodological quality are needed. 
The following are recommendations for addressing certain issues. 
8.6.1 RCT design methodologies 
The methodological reporting quality of the majority of included studies in the SRs 
was weak largely with respect to the procedures used for blinding, randomisation 
sequence generation, and allocation concealment. The paucity of reporting of 
methodology, herbal quality and other details required by the Consolidated 
Standards of Reporting Trials (CONSORT) statement in clinical trials of CM has been 
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a point of criticism (Gagnier et al., 2006). Furthermore, in 2006, a published review 
by Bian et al., (2006) indicated that the overall methodological quality of RCTs on CM 
treatments for obesity were poor based on the author’s assessments of clinical trial 
designs and RCT methodologies in CM research; this author recommended that RCT 
design should be improved in future studies (Bian et al., 2006)  
The major weaknesses in methodology are the lack of attention paid to specific 
details for randomisation and blinding for allocation concealment. This can lead to 
ineffective blinding and increase biases during observations (Schulz et al., 2002; 
Schulz & Grimes, 2002). Double-blinding means that neither the patients nor the 
treating physicians know which intervention will be given to each participant (Stolberg 
et al., 2004). In addition, randomisation methods and allocation concealment are 
considered to be interrelated processes which are necessary for successfully 
achieving a properly blinded RCT (Schulz, 2001). These three domains were found 
to be weak in the risk of bias assessments. Adequate methodology and proper 
reporting should be addressed in future RCTs that investigate CM.  
8.6.1.1 Control groups 
The types of controls used were quite varied. They included placebo, sham 
acupuncture, WM, no treatment and other therapies. Aside from the concerns of 
ethics and limiting bias, how to choose a reasonable CG for RCTs has been 
discussed by Bian, Moher et al. (2006). This lack of standardised CG may result in 
differences in determining effectiveness. Therefore, this concern should be 
addressed for future RCTs that investigate obesity, and a standardised 
pharmacotherapy for obesity should be decided upon based on the GCP guidelines.  
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Additionally, comparing one CM with another CM is not suggested as a suitable 
control for an RCT. RCTs for CM are a recent development in China and a placebo is 
not easily accepted by local people, which leads to the problems of participant 
compliance and invalid results. To overcome the unwillingness of participants to 
accept a placebo, Chinese researchers have decided to compare a test CM formula 
with another CM used as control, in which the test CM was based on syndrome 
differentiation and appropriate herbal prescription, whereas the control CM formula 
was not. It was difficult, however, for the participants to recognise the control formula 
as just a placebo. Although this approach may overcome the participant compliance 
problem, it may compromise the findings of any significant differences between the 
two CM formulae because it would not be entirely clear what effect the control CM 
formula had on the disease condition.  
8.6.1.2 Data analysis 
Missing data were not accounted for properly in the studies in which participants 
dropped out. ITT is broadly applied to data analysis for dealing with missing data. 
Explaining the reasons for withdrawals and using ITT can reduce the bias in trials 
and their impacts on the results.  
8.6.1.3 Sample size calculations 
There was a large amount of variation in the numbers of participants across the 
studies. The methods used for calculating sample sizes were not provided in any of 
the RCTs and no rationales were given for the sample size choices. A small sample 
size can result in a study that is underpowered for detecting a real effect. Without any 
sample size calculations, it is difficult to determine which studies were likely to have 
 249
been underpowered and which had adequate power with regard to the outcome 
measures. 
8.6.1.4 Limitations of the RCT approach 
The SRs of the RCTs were guided by the Cochrane group and meta-analyses were 
performed for specific outcome measures when suitable data were provided by the 
authors. The included studies were all identified as randomised and controlled trials 
(RCTs), which belong to classification level 2 of the Cochrane reviews. Because an 
RCT is widely considered to be the gold standard design for determining the efficacy 
of an intervention in a clinical study, it is widely used in clinical trials; including 
investigations of CM. RCT results reflect the mean response of a population to an 
intervention rather than the responses of individuals. Due to difference between 
individuals, an individual’s reaction to the same treatment for a chronic disease may 
be different. Thus, effectiveness may also vary.  
One characteristic of treatments used in CM is that herbal formulae are designed to 
suit the individual. Among the included RCTs, some had syndrome differentiations. 
However, this could not completely reflect the essence of CM treatments. Thus, there 
is the issue of the degree to which an RCT can provide a reasonable evaluation of 
the efficacy of a CHM formula for treating patients with obesity. 
8.7 Future directions 
CHM and acupuncture are more effective compared with placebo or lifestyle changes 
in reducing weight. This means that they produce similar effects to Western anti-
obesity drugs but have fewer side-effects. However, these conclusions are limited to 
studies with small sample sizes and low quality methodologies (Sui et al., 2012a). 
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8.7.1 Chinese herbal medicine, acupuncture and dietary therapy 
Maintaining a balanced diet is one of the main lifestyle changes required. Nutrition 
professionals need to play a strong role in leading these nutritional education goals. 
They should emphasise the methods of sound weight-management during all 
counselling sessions. Advanced counselling skills can assist nutrition experts in 
having a long-term impact on the weight-management efforts of individual clients. 
The results of this study showed that the obese individuals from both groups 
changed their everyday diet leading to losing weight even after treatments. More 
research to evaluate the effects of combined Chinese medicine and dietary therapies 
is necessary. 
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8.7.2 Cost-effectiveness 
The cost-effectiveness of weight reduction therapies depends strongly on 
assumptions regarding the relationship between the BMI and quality of life. A study 
by Ma & Frick (2011) showed that early interventions make economic sense. 
Targeted interventions may be more cost-efficient than population-based 
interventions for young children (aged from 0 to 6 years); while according to Mernagh 
et al (2011) population-based interventions may have greater economic benefit for 
teenagers (aged 13 to 18 years). A low calorie diet was strongly recommended as 
the first choice for management of obesity (van Baal et al., 2008). Gastric band 
surgery has been shown to be a cost-effective treatment (Ananthapavan et al., 2010). 
It is a cost-effective alternative compared to no treatment, as it provides substantial 
benefits for severely obese patients (Craig & Tseng, 2002). It plays an important role 
in the management of adolescent morbid obesity. However, this therapy might not be 
suitable for all patients, such as severely obese adolescents. A study by Hersey et al. 
(2012) shows that a cognitive-behavioural method effectively reduces weight levels in 
the population. However, more improvements are required to promote continuous 
involvement in programme participants such as internet and telephone counselling to 
improve the effects of the cognitive-behavioural weight management programme. 
8.7.3 Mindfulness Based Cognitive Therapy (MBCT) 
In addition to biological factors, psychological factors also play a big role in obesity 
and disordered eating (Stice, Presnell, Shaw, & Rohde, 2005). For example, it is not 
uncommon for individuals to engage in binge eating as a means of regulating 
negative emotions and reducing stress. MBCT is a form of cognitive-behaviour 
therapy that involves mindfulness meditation and aims to improve emotion regulation 
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by increasing awareness to thoughts, feelings and behaviours. Preliminary studies 
show that MBCT is effective in reducing weight and binge eating behaviours (Baer, 
Fischer, & Huss, 2005; Kristeller, Wolever, & Sheets, 2013; Tapper et al., 2009) and 
further rigorous studies are needed to examine its efficacy.  
8.7.4 Further clinical practice 
These analyses of modern and classical literature provided data and discussion on 
the pathogenesis of obesity, syndrome differentiation in obesity and the mechanisms 
of CM used for its treatment. These analyses also explored which herbs and 
formulae were frequently used for treating obesity in classical and modern CM. It is 
hoped that this data and associated discussion may aid practitioners to apply more 
evidence-based and more effective approaches for the use of Chinese herbs and 
formulae for treating patients with obesity. 
8.7.5 Research on CM syndromes of obesity relevant to obesity severity 
There are various CM syndromes of obesity, whereas WM classifies obesity into 
obesity. There is a need to clearly determine the correlations between CM 
syndromes and the stages of obesity defined in WM. The mmultivariate statistical 
method provided an analysis of the correlations between CM syndromes and grades 
of obesity, which could possibly provide a more objective basis for a CM diagnosis 
and treatment principles. The use of such objective approaches should be 
considered when selecting participants for inclusion in future RCTs.  
Among the published CM clinical trials, were included ones specifically for obesity. In 
addition, according to CM principles of aetiology and pathogenesis, obesity at 
different stages affects different visceral organs (Zang organs) and, consequently, 
the selection of herbs is also different. Therefore, in future clinical trials, the study 
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designs should consider a pragmatic method to incorporate individualised treatment 
for better results. This should minimise variations due to differences in obesity stages 
and syndromes.  
Furthermore, by aligning the severity of the symptoms and signs (i.e., classification) 
with the syndromes during selection, or using stratification based on these factors at 
the baseline, it may be possible to maximise the selection of the appropriate herbs 
and, thereby, obtain optimal, clinically relevant results. Nevertheless, all sources of 
variation may be difficult to control for this complex disease. Thus, large sample sizes 
may be needed to detect treatment effects, especially when the CM is compared to 
the placebo.  
 
8.7.6 The pharmacological mechanism of actions of RCM-104  
There is a need to investigate the pharmacological and biochemical roles of CHMs 
used for treating obesity from different aspects. By comparison, the effectiveness of 
Huai Hua has already been widely confirmed. Nevertheless, the comparative 
functions and effectiveness of Huai Hua, Lu Cha Ye and Jue Ming Zi need to be 
further investigated. The pharmacological mechanism of the actions of RCM-104 for 
treating obesity should be further investigated to provide a scientific profile for their 
clinical use for obesity. 
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 Appendix 1 Clinical trial general information 
 
 
 
 
 
The RMIT Chinese Medicine Research Group 
School Of Health Sciences 
RMIT University 
 
 
Clinical Trial for Obesity 
2007 
GENERAL INFORMATION 
 
 
Sponsor: Professor Charlie Xue  
Investigator: Dr George Lenon 
Contact No:(03) 9925 6587  or   0400 821 631 
Trial No:   
Protocol No: lenon04/07 
 
To All Participants 
Please return SCREENING QUESTIONNAIRE which is enclosed 
in this information packto Dr George Lenon once completed. We 
will assess your eligibility for participation based on your provided 
information. 
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Appendix 1-2  Plain Language Statement 
 
 
 
Division of Chinese Medicine  
School of Health Science 
RMIT University 
 
Plain Language Statement 
Phone: 9925 6587 or 0400821631  Facsimile:  9925 7178 
Project title:  Efficacy and safety of a Chinese herbal medicine formula in the 
management of simple obesity: Randomised placebo-controlled clinical trial 
This is an invitation to participate in a study evaluating the effectiveness and safety of 
a Chinese herbal medicine used for the treatment of obesity. 
Principal investigator Other investigator(s)  
Name: George Lenon Name: Charlie Changli Xue 
Qualifications: B.Hlth.Sc. (Hons), 
PhD 
Qualifications: BMed, PhD 
School: Health Sciences School: Health Sciences 
Phone:  99256587 or 0400821631 Phone: 99257745 
Email: george.lenon@rmit.edu.au Email: charlie.xue@rmit.edu.au 
 
Other investigator/s 
 
Other investigator(s) 
Name: Chun Guang Li Name: David Story 
Qualifications: B.Med., M.Med., PhD Qualification:  BSc, PhD, Cert Mangt 
School: Health Sciences  School: Health  Sciences 
Phone: 99257635 Phone: 99257675 
Email: chunguangli@rmit.edu.au Email: david.story@rmit.edu.au 
 
Other investigator/s 
 
Other investigator(s) 
Name: Kang Xiao Li Name: Neil Mann 
Qualifications B.Med. M. App. Sc. Qualifications: BAppSc., BSc. (hons), 
Dip Ed., PhD 
School: Health Sciences School: Applied science 
Phone: (03) 93766788 Phone: 99255095 
Email: Kangli@aapt.net.au Email: neil.mann@rmit.edu.au 
Other investigator/s Other investigator/s 
Name: Yung-Hsien Chang Marc Cohen 
Qualifications: B.Med, PhD Qualification:  MBBS (Hons), BSc 
(hons), PhD 
School:  School: Health  Sciences 
Phone: 886 4 22062890 Phone: 99257440 
Email: yhchang@mail.cmu.edu.tw Email: marc.cohen@rmit.edu.au 
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Dear Participant,  
You are invited to participate in a research project being conducted by RMIT-
University. This information sheet describes the project in straightforward language, 
or ‘plain English’. Please read this sheet carefully and be confident that you 
understand its contents before deciding whether to participate.  If you have any 
questions about the project, please ask one of the investigators. 
Why is it being conducted? Who is involved in this research project?  
The prevalence of obesity has risen to alarming levels in both developing and 
developed countries. Chinese medicine has been used for weight management for 
thousands of years. There is general concern about efficacy and safety of weight 
management in both conventional and alternative medicine therapies. Specifically, 
there is limited evidence of efficacy of Chinese herbal products in the treatment of 
obesity. Thus, more rigorous randomised controlled trials are needed to assess the 
efficacy and safety of Chinese herbal medicine. The aim of this study is to evaluate 
the beneficial effects and safety of a Chinese herbal medicine formula which contains 
herbal substances that have been clinically used for the management of obesity.  
This study will be conducted by the Dr George Lenon with Kang Xiao Li, PhD 
candidate and the results will be used in PhD thesis of Kang Xiao Li. Other 
investigators include Professor Charlie Xue, A/Professor Chun Guang Li, Professor 
David Story, A/Professor Neil Mann and Professor Yung-Hsien Chang. This 
investigation is funded by the Emerging Research Grant and Division of Chinese 
medicine, School of Health Sciences, RMIT University. 
This project has been reviewed and approved by the Human Research Ethics 
Committee of RMIT University. The project is covered by RMIT University, Broad form 
Public and Product Liability Insurance. 
What is the project about? What are the questions being addressed? 
This project is to evaluate the effectiveness and safety of a Chinese herbal medicine 
formula in the double blind, randomised, placebo-controlled clinical trial. You are 
invited to participate in our study together with other 80 participants. You will be 
assigned by chance to either placebo (group that taking capsules that contain 
inactive ingredients) or real Chinese herbal medicine treatment group. The placebo 
group will take the capsules that contain inactive ingredients. That is, you will have a 
50% chance be allocated into an inactive treatment procedure. It is necessary to 
have a placebo group so that the effect of new Chinese medicine formula treatment 
can be compared with inactive treatment.  
The results of this study will provide public an informed choice of treatments for 
obesity which indirectly contribute to the prevention of many obesity-related diseases.  
If I agree to participate, what will I be required to do? 
If you would like to participate in the above study, you must be between18 to 60 
years and have BMI greater than 30 kg/m2. You will not be able to participate if you 
have uncontrolled high blood pressure, cardiovascular diseases, lactating or 
pregnant (for female), psychosis or taking lipid lowering drugs or weight control 
therapy in the last 6 months or taking hormone replacement therapy (HRT). It will be 
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in your benefit to fully disclose any known current or previous medical condition/s. 
This is to minimise risk to the participants and because participants will be insured for 
any adverse effects as a result of this study, based on known or provided information. 
If you agree to participate in the study for a ten-week period, you will be asked to: 
 sign a informed consent form, complete assessment questionnaires and blood 
test at the initial visits; 
 take Chinese herbal medicine or placebo capsules three times per day,  
 attend the clinical trial clinic every four  weeks for the assessment and 
exchange the        medication bottles for the period of 12 weeks;  
 have another blood test at the end of the trial; 
 take adequate contraception if you are female and sexually active. 
After the treatment period you will be required to continue to fill out the evaluation 
forms and mail back in the prepaid, self-addressed envelope during the twelve-week 
follow up period.  
Please Note: On the day scheduled for visit, it is required that you fast overnight (that 
is, don’t eat or drink anything except water after 10.00 pm the night before) prior to 
arriving at the Division of Chinese Medicine for blood collection.   
About the safety issues of the Chinese herbal medicine (CHM) that you will take 
All Chinese herbal substances to be used in the treatment have been listed on the 
Australian Register of Therapeutic Goods by the Therapeutic Goods Administration 
(TGA) in Australia.  They are used in every day practice worldwide and have been 
regarded as safe for human consumption.  To the date there is no side effect of the 
included herbs has been reported. 
Active ingredients Reported side effects 
Semen Cassiae (Jue Ming Zi), No side effect reported (Zhu 1998, Huang 1999) 
Flos Sophorae (Huai Hua), No side effect reported (Zhu 1998, Huang 1999) 
Camellia Sinensis (Lu Cha Ye),  No side effect reported (Zhu 1998, Huang 1999) 
 
What are the risks or disadvantages associated with participation? 
The Chinese herbal medicine preparation administered in capsule form in this study 
is designed to reduce the unpleasant taste of the Chinese herbal substances.  In rare 
cases, stomach irritation may occur which can be prevented by taking more water. 
The capsule of RCM-104 contains some caffeine (Each daily dosage of 12 capsules 
is approx. 1.5 cups of coffee). Participants are advised to consider this when 
consuming other caffeinated products.  
This is double blind, randomised placebo-controlled trial, which means you will have 
50% chance to take placebo (inactive) capsules.  
About the blood tests 
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Two 20 ml (approximately 1 tablespoon) of blood samples will be taken, one at the 
beginning and the other at the end of the study. Venipuncture (the taking of blood 
from a vein) will be performed by a registered nurse who is experienced in blood 
collection. The method used is identical to that used for routine medical tests. A 
tourniquet is applied above the elbow to dilate the veins in the arm. A suitable vein is 
identified in the inner part of the elbow and the skin overlying it is cleaned with an 
alcohol swab. A needle is then passed into the vein and blood is drawn. The needle 
is then withdrawn, a cotton swab passed over the puncture site and gentle pressure 
is applied for approximately two minutes. Adverse effects of taking blood are the 
minor discomfort associated with the needle passing through the skin and the 
possibility of minor bruising near the puncture site.The risk of infection is only 
minimalwhen venipuncture is performed under sterile conditions as described above.  
What are the benefits associated with participation? 
After clinical trial all participants will be given an individualised nutrition advice upon 
their request.  
If the treatment found effective, participants from placebo groups will be provided 
with free 12-week herbal treatments of trial medication.  
 
What will happen to the information I provide? 
All information provided by you and data collected through this study are well protected 
by password protected computer program of locked filing cabinet.  The subjects’ records 
may be inspected by authorised persons for the purpose of original data audit. Subjects 
will have access to their records at the time prearranged with investigator. In all other 
aspects, we will not divulge your results to any person, including the medical 
practitioners, except at your request and signed authorization. Group results will only be 
used for publication purposes, with no reference to the participant’s name. 
All data will be collected in a professional and confidential manner. All measurements 
undertaken will be fully explained and questions can be asked at any point of time if 
in doubt. All results and blood tubes will be marked with a subject code and stored 
this way without identification of the participant’s name. All data and information 
about you will be filed and stored in the office of Dr George Lenon or storage of 
Chinese medicine research group for 15 years. Only above named investigators will 
have access to any documents. Participants can access their own results at any time. 
What are my rights as a participant? 
Please be aware: Participation in this study is solely voluntary. It is your absolute 
right as a participant in this study to withdraw at any time. No questions will be asked 
and you will receive no prejudicial treatment from the investigating group or RMIT 
University. You also have the right to ask the investigators any questions concerning 
the project at any time. 
Whom should I contact if I have any questions? 
Thank you for taking the time to read this proposal, and for considering being a 
participant in this project. If you require any clarification of the principals and 
procedures of the study, please do not hesitate to contact the investigators (contact 
details listed below). 
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Yours Sincerely 
Dr George Lenon, Kang Xiao Li, Professor Charlie Xue, Associate Professor Chun 
Guang Li, Professor David Story, Associate Professor Neil Mann 
Contact details:  
George Lenon,  email: george.lenon@rmit.edu.au, Phone: 99256587 Kang Xiao Li, 
email: Kangli@aapt.net.au, Phone: 0411367678. 
Charlie Xue email: charlie.xue@rmit.edu.au, Phone: 9925 7745. 
Chun Guang Li, email: chunguan.li@rmit.edu.au, Phone: 99257635. 
David Story, email: david.story@rmit.edu.au, Phone:  99257675 
Neil Mann, email: Neil.mann@rmit.edu.au, Phone: 99255095 
 
 
 
Any complaints about your participation in this project may be directed to the 
Executive Officer, RMIT Human Research Ethics Committee, Research & Innovation, 
RMIT, GPO Box 2476V, Melbourne, 3001.  The telephone number is (03) 9925 2251.   
Details of the complaints procedure are available from the above address.  
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Appendix 1-3  RMIT screening questionnaires for obesity study 
 
 
 
 
 
RMIT SCREENING QUESTIONNAIRES FOR OBESITY STUDY 
1. PERSONAL CONTACT INFORMATION 
Name: ____________________________________Date:_____________________________ 
Date of Birth: ____________________     Age today:______________ Male/Female 
Home address: _______________________________________________________________ 
Home phone number: _______________ Work phone number: _________________________ 
Mobile phone number: _______________e-mailaddress: ______________________________ 
What is the best method to contact you during the normal working hours?__________________ 
If we cannot find you, is there an alternative person we can call?: 
Name:___________________phone number:________________________________________ 
What is the highest level of education that you achieved (Circle?) 
Primary School Grade_______Secondary School/ College Year_____University/Post-graduate 
Are you attending school now? Yes. □   No □ 
What is your occupation? _______________________________________________________ 
Describe_____________________________________________________________________ 
Marital status:   Married □, Single □, Divorced, □ Others 
 
2. QUESTIONS ABOUT YOUR CURRENT WEIGHT AND WEIGHT HISTORY 
Current weight_____________Kilograms,   Current height__________________centimeters 
Current hip circumference__________centimeters, Waist:__________________centimeters 
BMI (if available) __________ 
As you can best recall, what was your weight at these times in your life: 
What has been your lowest weight as an adult? _____ Kg   Age: ________ 
What has been your highest weight? _____ Kg  Age: ________ 
Have any of the following life events been associated with significant weight change? How many 
kg?____________ 
Breaking up of significant relationships _____, Marriage_____, Divorce___,   
Quitting smoking___, Medication use___, Having children___, Caring for family___,   
Starting a new job___, Changing jobs___, Retiring___, Becoming an empty nester___,   
Enduring death or illness in family___, suffering from a significant illness___,  
Taking a medication or going off One (especially anti-depressants)____,  
Other life event__________________________________________________________________ 
For women: 
1st Pregnancy:  weight gained______________ weight lost after pregnancy_________ 
2nd Pregnancy: weight gained______________ weight lost after pregnancy_________ 
3rd Pregnancy:  weight gained______________ weight lost after pregnancy_________ 
4th Pregnancy:  weight gained______________ weight lost after pregnancy_________ 
Please provide the same details if you have more than 4th pregnancy. 
How long did you maintain the weight after the baby birth?________________________________ 
 
3. ABOUT YOUR EATING PATTERNS 
 Yes   No 
Are you happy with your current eating pattern?   
Do you think you need to change what you eat or how you eat   
I eat exactly the same things every day   
I vary what I eat each day   
What I eat during the week differs from what I eat on the weekends   
I eat three or more meals per day     
I eat one or two meals per day   
I have a regular eating pattern   
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I tend to skip meals   
I eat breakfast every day   
I eat just before bedtime   
I get up at night and eat in the middle of the night   
Do you have snacks or eat between scheduled meals?   
 
4. ARE YOU TROUBLED NOW, OR IN THE PAST, BY ANY EATING DISORDERS? 
EATING DISORDERS    Yes No 
Compulsive overeating   
Binge eating disorder   
Anorexia nervosa   
Bulemia (making yourself vomit after eating)   
Laxative abuse   
 
5. THESE ARE QUESTIONS ABOUT EATING BEHAVIOURS: 
    Yes No 
Do you eat when you are not really hungry?   
Do you eat when you are bored?   
Do you eat when you are fearful?   
Do you eat when you are anxious?   
Do you eat when you are tired?   
Do you eat when you are nauseated?   
Do you eat when you are reading?   
Do you eat when you are watching TV?   
Do you eat when you are talking on thephone?   
Do you eat when you are working on computer?   
Do you eat when you are gathered with friends?   
Other behaviours (please specify)   
Other occasions or activities  (Please list)________________________________________ 
Home shopping for groceries 
 Yes No 
Does someone in your home shop for groceries?   
Is grocery shopping planned for a menu   
Is it more on an “as needed basis?”   
Do you prepare your own meals?   
Who prepares most of your meals?   
Commercial diets or other efforts at weight loss 
Commercial diets or other efforts at weight loss Yes No 
Have you tried commercial diets or other efforts at weight loss?   
TOPSWeight Watchers    
Overeater Anonymous   
Liquid diets (e.g., Optifast)   
Diet pills: Meridia, Zenical,   
Diet pills: phen- fen, Redux   
NutriSystem / Jenny Craig   
Seattle Sutton   
Obesity Surgery   
Registered Dietician   
Herbal remedies like Herb life,   
Metabolite or other herbals.   
Others (please specify)   
 
6.QUESTIONS ABOUT NUTRITION INFORMATION 
     Yes    No 
Have you met with a dietician before?   
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If so, did you find it helpful?   
If helpful, what did you learn?   
If not helpful, please state any reasons that you found them unhelpful 
If you kept food records and stopped keeping them, why did you stop?   
 Not at 
all  

Definite
ly 
 1 2 3 4 5 
Do you think that you know enough about diet and nutrition at present?  Tick one.      
Do you think that you are able to use the knowledge that you have learnt about diet 
and nutrition at present?  Tick one 
     
 
7. THE FOLLOWING QUESTIONS ARE RELATED TO PHYSICAL ACTIVITIES 
To what extent are you able to carry out the following daily activities? 
 Very limited Somewhat 
limited 
Not limited 
Bathing and dressing yourself    
Personal hygiene/toileting    
Climbing several steps    
Climbing one step    
Rising from a soft/low seat    
Walking inside your home    
Walking less than 1 block     
Walking several blocks    
Walking more than 1 kilometre    
Moderate household tasks  
(moving furniture, vacuuming, scrubbing floors) 
   
Tasks that require bending(stooping, kneeling)    
Lifting and carrying groceries    
Gardening    
 
What is the most common physical limitation in performing any daily activity? (Check up to 3): 
Shortness of breath ____ Fear of falling ____ Back pain ____ Lack of energy ____ Leg pain __ 
Chest tightness/discomfort ____ Fatigue ____ Light headedness/dizziness ____ 
Leg weakness ____ Balance problems ____  
Other (please list):_____________________________________________________________ 
Do you use any special equipment for mobility? Check all that apply: 
Cane ____ Prescription shoes ____ Wheelchair ____ Walker ____ Brace (back) __Lift Chair__  
Crutches ____ Brace (leg) ____ Hospital Bed ____ None ____ 
 
Exercise and Fitness: 
Do you participate in 
regular exercise? 
Never Monthly  Weekly  Daily 
Resistance training     
 weight training 
exercises 
    
Walking (in addition 
to work/daily tasks) 
    
Cycling     
Swimming     
Callisthenics     
Other     
 
Activities_____________________________________________________________________ 
Do you participate in sports or recreational activities? List______________________________ 
Have you ever been told that you have a condition for which you should NOT exercise? Yes____ 
No____ 
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If yes, what is that condition?___________________________________________________ 
 
What limits your ability to be more physically active? Check all that apply Yes No 
Physical size   
Deconditioning/being out of shape   
Pain   
Physical limitations   
Boredom   
Depression   
Unsure how to exercise appropriately   
Low motivation or interest   
Embarrassment   
Lack of resources (equipment, clothing, shoes, space)   
Lack of support or encouragement   
 
What activities would you like to be able to do better (activities you were once able to do but no longer can, due to 
yourcurrent health and physical limitations): List some or 
all:_________________________________________________________________________ 
What is the most physically active thing you do during the 
week?_______________________________________________________________________ 
If you could choose any physical activity that you would like to be able to do, what would it be? 
__________________________________________________________________________ 
8. HEALTH RELATED COMPLAINTS: (Please circle all that apply). 
None, joint pains, back pain, hip pain, knee pain, ankle/feet pain, sleep apnoea, daytime sleepiness, blood clots, 
severe psychiatric problems, depression, anorexia, swelling of feet, headaches, high blood pressure, kidney 
disease, asthma, seizures, snoring, rashes, stroke, urinary stress incontinence, bulimia, binge eating, shortness of 
breath, migraine, heart disease, arthritis, emphysema, cancer, diabetes, irregular periods, reflux disease 
(heartburn), fatty liver, high cholesterol, menstrual problems. 
9. QUESTIONS ABOUT YOUR GENERAL HEALTH 
How do you rate your overall health? (Circle) 
Excellent___Good___Fair ___ Poor___ Severe ill health_________________________________ 
When did you last see your doctor?________________________________________________ 
Were any specific concerns discussed?____________________________________________ 
Have you recently had any tests done? If so, can you remember whether there were any abnormalities? (Blood 
tests, X-rays, CT scans, EKG, and so forth)________________________ 
What medications are you presently taking? (Please write names and dosages of the prescription 
medicines)___________________________________________________________________ 
Are you presently taking any over-the-counter medicines, herbals or vitamins? If so, please list 
these:_______________________________________________________________________ 
Do you have any allergies, bad reaction or intolerance to drugs, foods and others (for example dust, metals, 
plastics, latex etc)? If so, please write these here? 
____________________________________________________________________________ 
Please list your known medical diagnoses (for example, diabetes, high blood pressure, 
etc)_________________________________________________________________________ 
Have you had surgery in the past? Please list type & date 
____________________________________________________________________________ 
 
The following section asks you to think about specific problems you might have. If a condition applies to 
you, please check the box and then make any comments you think we might find helpful. We may also ask 
you further questions during our chats with you. 
10. NEUROLOGICAL PROBLEMS 
 Yes No 
Seizures   
Do you take medicine for seizures?   
Headaches that impair your ability to fulfil activities in daytime   
Do you take medicine for headaches?   
Visual disturbances (double vision, blind spots, etc)   
Stroke/TIAs   
Unexplained dizzy spells   
 
If you have any other neurological (nerve or brain) symptoms, please describe 
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____________________________________________________________________________ 
 
11. MENTAL HEALTH or ILLNESSES 
 Yes No 
Depression/symptoms of depression (low energy, sleeping, low interest in usual 
activities, crying frequently, and so forth) 
  
Do you feel depressed because of your weight?   
Do you take medicine for depression?   
Anxiety or panic attacks   
Bipolar disorder   
Attention Deficit Disorder/Hyperactive Disorder Deficit   
Have you ever been in counselling for any of these problems?   
Have you ever had a problem with Substance Abuse/Addiction problem Previous or 
Current? 
  
Have you ever had a problem with alcohol Previous___ Current____ If relevant, how 
long has you stopped drinking alcohol? 
  
Have you ever had a problem with tobacco Previous___ Current____ If relevant, how 
long have you stopped smoking? _ 
  
Have you ever had a problem with street drugs Previous___ Current____ If relevant, 
how long have you stopped using street drugs? 
  
What are your average hours of sleep per night? _________. Is your sleep restful?   
 
12 HEART AND BLOOD VESSEL PROBLEMS 
 Yes  No 
Hypertension (high blood pressure)   
Heart disease, heart attack, congestive heart failure   
Heart murmur   
Irregular heart beat   
Chest pain   
Ankle or feet swelling   
Varicose veins   
Blood clot (venous thrombosis)   
If you have any other heart or blood vessel related symptoms, please 
describe_____________________________________________________________________ 
_13. LUNG /RESPIRATORY/PULMONARY DISEASES 
 Yes No 
Do you need to use supplemental oxygen, now?   
Are you short of breath?   
Are you short of breath at rest?   
Are you short of breath lying flat?   
Are you short of breath walking?   
How far can you walk before you need to stop because of breathing 
problems? 
  
Have you ever used nicotine products? (cigarettes, chewing tobacco, 
cigars, pipes) ? 
  
Do you smoke now?   
If yes: number of cigarettes per 24 hours?   
Have you tried to quit?   
Have you quit for more than one month?   
If you do not smoke now how long ago did you quit?   
Have you ever been diagnosed with asthma, emphysema or COPD?   
Do you have a history of pneumonia?   
Do you have a history of bronchitis?   
Are you troubled by a cough?   
Have you been told that you snore at night?   
Do you feel sleepy during the day?   
Is your sleep disturbed?   
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Have you been told that you stop breathing when asleep?   
Have you been diagnosed with sleep apnoea?   
Do you have any other breathing related symptoms?   
If you have any other breathing related symptoms, please describe  
14. GASTROINTESTINAL 
 Yes No 
Do you have nausea or vomiting?   
Do you have abdominal pain?   
Do you have heartburn?   
Do you have belching?   
Do you have ulcer disease?   
Do you have rectal bleeding?   
Do you have haemorrhoids?   
Do you have constipation?   
Do you have diarrhoea?   
Do you have a hernia?   
Do you have gall bladder disease or gallstones?   
Do you have Celiac disease?   
Do you have inflammatory bowel disease (Crohn’s or Ulcerative 
Colitis)? 
  
Do you have diagnosed “Irritable Bowel Syndrome”?   
 
If you have any other intestinal symptoms, please describe 
____________________________________________________________________________ 
 
14. URINARY TRACT DISEASES 
 Yes No 
Do you have difficulty passing urine?   
Do you have difficulty holding urine so that you have incontinence?   
Do you have recurrent bladder or kidney infections?   
Do you have a history of infertility?   
 
For Men: 
 Yes No 
Do you have history of enlarged prostate?   
Do you have history of prostate cancer?   
Do you have difficulty having or sustaining an erection?   
 
For Women: 
 Yes No 
Have you been diagnosed with polycystic ovarian syndrome?   
Do you have regular menstrual cycles?   
Do you have normal menstrual periods?   
What was the date of your last normal menstrual period?   
Are you menopausal?   
Are you currently trying to get pregnant?   
Are you using contraception?   
 
If you have any other urinary or genital symptoms, please describe 
_____________________________________________________________________
_______ 
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15. BLOOD DISEASES 
 Yes No 
Do you have sickle cell anaemia or sickle cell trait?   
Do you have a history of anaemia (“low blood”) ?   
Do you bruise easily?   
 
If you have any other blood related symptoms, please describe 
____________________________________________________________________________ 
16. MUSCULOSKELETAL 
 Yes No 
Do you have aching muscles?   
Do you have painful joints or arthritis?   
Do you have painful Hands?   
Do you have painful Elbows?   
Do you have painful Shoulders?   
Do you have painful Feet?   
Do you have painful Knees?   
Do you have painful Hips?   
Do you have back pain or vertebral disc problems?   
Have you ever had torn ligaments?   
Do you have any other symptom related to your bones joints or 
muscles? 
  
 
If you have back problems, please describe location in the back and any tests or therapy that 
you have 
had_________________________________________________________________________
____________________________________________________________________________ 
 
If you have any other symptom related to your bones joints or muscles, please describe. 
__________________________________________________________________________ 
 
17. ENDOCRINE (GLANDULAR) 
 Yes No 
Have you ever had Diabetes Mellitus (high blood sugar) ?   
Have you ever had thyroid disease?   
Have you ever had high cholesterol or triglycerides?   
Have you ever had gout?   
 
If you have any other hormonally related symptoms, please describe 
____________________________________________________________________________ 
____________________________________________________________________________
____________________________________________________________________________ 
Other 
Do you have any other physical or psychological concerns that you wish to discuss at this clinic 
visit, that are not coveredin the questioning above? Yes____ No____ 
List_________________________________________________________________________
____________________________________________________________________________ 
____________________________________________________________________________
____________________________________________________________________________ 
 
18. HISTORY OF FAMILY ILLNESSES THAT CAN INFLUENCE YOUR HEALTH: 
Has anyone in your family (including grand-parents, parents, uncles, If yes/ No 
 295
aunts, brothers, sisters, children, grand-children, nieces and 
nephews) had any of the following problems? 
Who? 
High blood pressure   
High blood cholesterol   
Overweight or Obesity   
For each of those relatives that has or had a problem with weight: 
Were they or are they heavier than you are? 
  
Approximately what weight do you think they are or were?   
Do you know if they had any treatment for their weight problem?   
Do you know if they had any health problems that may have been 
related to their weight<<Need to repeat this section for each relative 
who is overweight>>? 
  
Diabetes mellitus   
Cancer   
Where was the Cancer?   
Thyroid disease   
Stroke   
Lung problems   
Liver problems   
Kidney problems   
Heart disease   
Other   
19. SLEEP PROBLEMS ARE NOT UNCOMMON IN OBESITY. THE FOLLOWING QUESTION 
ADDRESSES THISISSUE. 
 Yes No 
Have you been told that you snore?   
Have you been told that you hold your breath or stop breathing when 
you sleep?  
  
Do you ever wake up and feel that you need to gasp for a breath?   
Do you frequently waken with headaches?   
Do you frequently fall asleep when you are reading?   
Do you have daytime sleepiness?   
Have you ever fallen asleep while driving or while stopped at a red light 
when you were driving?  
  
Do you still feel exhausted even after at least 8 hours of sleep?   
Have you ever had a sleep study?   
If so, were you told that you have sleep apnoea?   
If so, do you use it every night?   
Thank you for completing this information form. Please return in the enclosed prepaid self-
addressed envelope. 
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Appendix 2  Recruiting instruments 
 
 
 
 
 
 
The RMIT Chinese Medicine Research Group 
School Of Health Sciences 
RMIT University 
 
 
Clinical Trial For Obesity 
2007 
RECRUITING INSTRUMENTS 
 
 
Trial Number: 2007/313 
 
Protocol Number: 0407lenon 
 
 
 
 
 
Participant’s Name:______________________________ 
 
Date:_________________________________________ 
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Appendix 2-1  RMIT Prescribed Consent Form 
HREC Form 2a 
RMIT HUMAN RESEARCH ETHICS COMMITTEE 
Prescribed Consent Form For Persons Participating In Research Projects Involving Tests and/or 
Medical Procedures and interview/questionnaire or disclosure of personal information 
Portfolio Science, Engineering and Technology  
School of Health Sciences 
Name of participant:  
 
Project Title: Efficacy and safety of a Chinese herbal medicine 
formula in the management of simple obesity: 
Randomised, placebo-controlled clinical trial 
Name(s) of 
investigators:    (1) 
George Lenon Phone: 99256587 
(2) Kang Xiao Li Phone: 0411367678 
(3) Charlie Xue Phone 9925 7745 
(4) Chun Guang Li Phone: 9925 7635 
(5) David Story Phone: 99257675 
(6) Neil Mann Phone: 99255095 
(7) Yung-Hsien Chang Phone: 886 4 22062890 
 
I have received a statement explaining the tests/procedures and interview/questionnaire 
involved in this project. 
I consent to participate in the above project, the particulars of which - including details of tests 
or procedures and need for the interview and questionnaire - have been explained to me. 
I authorise the investigator or his or her assistant to use with me the tests or procedures and to 
interview me or administer a questionnaire referred to in 1 above. 
I acknowledge that: 
The possible effects of the tests or procedures have been explained to me to my satisfaction. 
I have been informed that I am free to withdraw from the project at any time and to withdraw any 
unprocessed data previously supplied (unless follow-up is needed for safety). 
The project is for the purpose of research and/or teaching.  It may not be of direct benefit to me. 
(d)        The privacy of the personal information I provide will be safeguarded and only 
disclosed where I have consented to the disclosure or as required by law.    
(e)      The security of the research data is assured during and after completion of the study.  
The data collected during the study may be published, and a report of the project outcomes will 
be provided to George Lenon, Kang Xiao Li, Charlie Xue, Chun Guang Li, David 
Story,Neil Mann and Yung-Hsien Chang Any information which will identify me will not 
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be used. 
(f)         Having read plain language statement, I agree to the general purpose, methods 
and demands of the study. 
Participant’s Consent 
Name:  Date:  
(Participant) 
 
Name:  Date:  
(Witness to signature) 
 
Participants should be given a photocopy of this consent form after it has been signed. 
 
 Any complaints about your participation in this project may be directed to the Secretary, RMIT 
Human Research Ethics Committee, University Secretariat, RMIT, GPO Box 2476V, Melbourne, 
3001.  The telephone number is (03) 9925 1745.   
Details of the complaints procedure are available from the above address. 
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Appendix 2-2 Prescribed Consent Form  
HREC Form 2b 
RMIT HUMAN RESEARCH ETHICS COMMITTEE 
Prescribed Consent Form For Persons Participating In Research Projects Involving Interviews, 
Questionnaires or Disclosure of Personal Information 
 
 
Portfolio Science, Engineering and Technology  
School of Health Sciences 
Name of participant:  
 
Project Title: Efficacy and safety of a Chinese herbal medicine 
formula in the management of simple obesity: 
Randomised, placebo-controlled clinical trial 
Name(s) of investigators:    
(1) 
George Lenon Phone: 99256587 
(2) Kang Xiao Li Phone: 0411367678 
(3) Charlie Xue Phone 9925 7745 
(4) Chun Guang Li Phone: 9925 7635 
(5) David Story Phone: 99257675 
(6) Neil Mann Phone: 99255095 
(7) Yung-Hsien Chang Phone: 886 4 22062890 
 
1. I have received a statement explaining the interview/questionnaire involved in this project. 
2. I consent to participate in the above project, the particulars of which - including details of 
the interviews or questionnaires - have been explained to me. 
3. I authorise the investigator or his or her assistant to interview me or administer a 
questionnaire. 
4. I acknowledge that: 
 
Having read Plain Language Statement, I agree to the general purpose, methods and demands 
of the study. 
I have been informed that I am free to withdraw from the project at any time and to withdraw any 
unprocessed data previously supplied. 
The project is for the purpose of research and/or teaching. It may not be of direct 
benefit to me. 
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The privacy of the personal information I provide will be safeguarded and only disclosed where I 
have consented to the disclosure or as required by law.   
The security of the research data is assured during and after completion of the study.  The data 
collected during the study may be published, and a report of the project outcomes will be 
provided to George Lenon, Kang Xiao Li, Charlie Xue, Chun Guang Li, David Story and Neil 
Mann and Yung-Hsien Chang.  Any information which will identify me will not be used. 
 
Participant’s Consent 
 
 
Participant
: 
 Date:  
(Signature) 
 
 
Witness:  Date:  
(Signature) 
 
 
Participants should be given a photocopy of this consent form after it has been signed. 
 
Any complaints about your participation in this project may be directed to the Executive Officer, 
RMIT Human Research Ethics Committee, Research & Innovation, RMIT, GPO Box 2476V, 
Melbourne, 3001.  The telephone number is (03) 9925 2251.   
Details of the complaints procedure are available from the above address.   
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Appendix 3  Case report form 
 
 
 
 
The RMIT Chinese Medicine Research Group 
School Of Health Sciences 
RMIT University 
 
 
 
 
Clinical Trial For Obesity 
2007 
CASE REPORT 
FORM 
Visit No.:______________ 
 
 
Trial Number:_____________ 
 
Protocol Number:__________ 
 
 
Participant’s Initials:_______________________ID number:______________________ 
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INSTRUCTION PAGE FOR COMPLETING CASE 
REPORT FORMS 
 
This should state the following: 
Pen:     
Always use a black ball-point pen when writing in CRF. 
Text:    
Please write clearly in legible English. 
Identification of participant:  
Please ensure that the patient number & initials are clearly stated on the designated 
portion of each page. 
Missing/unavailable data:  
Please do not leave data boxes empty. If data is missing, put a single line through the 
blank section and add a comment stating why the data was not available eg “not done”   
Abnormal data:  
Please the give reason for any abnormal data in the space provided in the CRF. 
Corrections:  
Please do not make changes with correction fluid. Draw a single line through the incorrect 
value so that it is still legible.  Write the correct value clearly as near as possible to the 
original value.  Initial and date the change. 
Dates:  
Please write dates using the order day, month, year. 
Times:  
Please document times using 24-hour notation. 
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Appendix 3-1 Assessment record 
 
 
 
 
 
The RMIT Chinese Medicine Research Group 
Obesity Clinical trial 
 
ASSESSMENT RECORD 
Participant’s Initials:_______________________ID number:_____________________ 
Visit No.:__________________Date:_________________________________________ 
Anthropometric measurements 
Weight,  …………..Kg 
Height …………..Cm 
Body Mass Index (BMI)  
WC (WC) …………….Cm 
Hip Circumference (HC) …………….Cm 
Waist to hip ratio (WC/HC)  
Diastolic blood pressure …………….mmHg 
Systolic BP …………….mmHg 
Body fat composition …………….% 
Basal Metabolic rate …………….kcal/day 
 …………….kcal/day 
Serological data 
Cholesterol …………mmol/L. 
Low density lipoprotein (LDL) …………mmol/L. 
High density lipoprotein (HDL) …………mmol/L. 
Triglycerides ……………mg/dL 
Fasting insulin  ………….μIU/mL 
Fasting glucose  …………mg/dl 
HOMA-R  
HbA1c ……..-……… % 
 
Signature of Investigator:__________________________________________ 
Date:____________________________________________________________ 
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Appendix 3-2 Weight-Related Symptom Measure 
 
 
 
 
THE RMIT CHINESE MEDICINE RESEARCH GROUP 
 
 
CLINICAL TRIAL FOR OBESITY 
 
 
Weight-Related 
Symptom Measure 
 
This survey asks for your views about your health and your weight. 
 
Trial Number:____________ 
 
Protocol Number__________ 
 
Participant’s Initials:_______________________ID number:______________________ 
 
Visit No.:__________________Date:_________________________________________ 
 
 
Copyright © University of Washington, 2004. All rights reserved. (WRSM Standard U.S. Version 1)
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Weight-Related Symptoms and How Much They Bother You 
 
For each of the following questions, read the list of symptoms below, and mark an  in the one box 
that best describes your answer.  
 
a. In the past 2 weeks, did you have the 
following symptoms?  
b. If Yes, how much did these symptoms bother 
you?  
No  Yes  SYMPTOMS  
Not at 
all  Hardly 
Some- 
what  
Moder 
ately  
A 
good 
deal  
A 
great 
deal  
A very 
great 
deal  
0  1  Shortness of breath  0  1  2  3  4  5  6  
0  1  Tiredness  0  1  2  3  4  5  6  
0  1  Sleep problems  0  1  2  3  4  5  6  
0  1  Sensitivity to cold  0  1  2  3  4  5  6  
0  1  Increased thirst  0  1  2  3  4  5  6  
0  1  Increased irritability  0  1  2  3  4  5  6  
0  1  Back pain  0  1  2  3  4  5  6  
0  1  Frequent urination  0  1  2  3  4  5  6  
0  1  Pain in the joints (hips, 
knees, etc.)  
0  1  2  3  4  5  6  
0  1  Water retention  0  1  2  3  4  5  6  
0  1  Foot problems  0  1  2  3  4  5  6  
0  1  Sensitivity to heat  0  1  2  3  4  5  6  
0  1  Snoring  0  1  2  3  4  5  6  
0  1  Increased appetite 0  1  2  3  4  5  6  
0  1  Leakage of urine 0  1  2  3  4  5  6  
0  1  Lightheadedness 0  1  2  3  4  5  6  
0  1  Increased sweating 0  1  2  3  4  5  6  
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0  1  Loss of sexual desire 0  1  2  3  4  5  6  
0  1  Decreased physical 
stamina 
0  1  2  3  4  5  6  
0  1  Skin irritation 0  1  2  3  4  5  6  
 
Please go back to the questions you just answered to make sure you did not miss any items.  
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Appendix 3-3 Obesity and Weight-Loss Quality of Life 
 
 
 
 
 
 
THE RMIT CHINESE MEDICINE RESEARCH GROUP 
 
 
CLINICAL TRIAL FOR OBESITY 
 
Obesity and Weight-Loss 
Quality of Life 
This survey asks for your views about your health and your weight. 
 
 
Trial Number:____________ 
 
Protocol Number:__________ 
 
 
Participant’s Initials:_______________________ID number:_______________________ 
 
Visit No.:__________________Date:_________________________________________ 
 
Copyright © University of Washington, 2004. All rights reserved. (OWL-QOL Standard U.S. Version 1
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Your Feelings About Your Weight 
Below is a list of statements about your quality of life in relation to being overweight and trying 
to lose weight.  
For each of the following statements, please mark an  in the one box that best describes your 
answer at this time.  
 
Not 
at all  
Hardl
y  
Som
e- 
what  
Mode
r 
ately  
A 
good 
deal  
A 
great 
deal  
A 
very 
great 
deal  
1. Because of my weight, I try to wear clothes 
that hide my shape  
0 1 2 3  4  5 6 
2. I feel frustrated that I have less energy 
because of my weight  
0 1 2 3  4  5 6 
3. I feel guilty when I eat because of my weight  0 1 2 3  4  5 6 
4. I am bothered about what other people say 
about my weight  
0 1 2 3  4  5 6 
5. Because of my weight, I try to avoid having 
my photograph taken 
0 1 2 3  4  5 6 
6. Because of my weight, I have to pay close 
attention to personal hygiene 
0 1 2 3  4  5 6 
7. My weight prevents me from doing what I 
want to do  
0 1 2 3  4  5 6 
8. I worry about the physical stress that my 
weight puts on my body 
0 1 2 3  4  5 6 
9. I feel frustrated that I am not able to eat what 
others do because of my weight  
0 1 2 3  4  5 6 
10. I feel depressed because of my weight 0 1 2 3  4  5 6 
11. I feel ugly because of my weight  0 1 2 3  4  5 6 
12. I worry about the future because of my 
weight  
0 1 2 3  4  5 6 
3. I envy people who are thin  0 1 2 3  4  5 6 
14. I feel that people stare at me because of my 
weight  
0 1 2 3  4  5 6 
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15. I have difficulty accepting my body because 
of my weight  
0 1 2 3  4  5 6 
16. I am afraid that I will gain back any weight 
that I lose  
0 1 2 3  4  5 6 
17. I get discouraged when I try to lose weight  0 1 2 3  4  5 6 
 
Please go back to the questions you just answered to make sure you did not miss any item
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Appendix 3-7 INSTRUCTIONS FOR KEEPING A DIET RECORD 
 
 
 
 
 
INSTRUCTIONS FOR KEEPING A DIET RECORD 
 
Participant’s initials:  _____________________ID:  _________ 
 
Period No.:_____________VisitNo.:____________Date_______ 
 
 
RECORD SHEET 
PLEASE FOLLOW THESE INSTRUCTIONS CAREFULLY 
Please record ALL food and drinks consumed (include all meals and snacks,     
sweets, drinks etc) 
Please record the food at the time of eating and NOT from memory at the end 
of the day. Remember to include any additions to foods already recorded such 
as sauces(eg. tomato, gravy), dressings (eg. salad dressings) or extras 
(stuffing,sugar, honey, syrups etc.,) butter or margarine (eg. added to bread, 
crackers,  vegetables etc)If you do not eat a particular meal or snack, 
simply draw a line across the page at this point. This will show that you have 
not eaten anything during this part of the day 
DESCRIBING FOOD AND DRINK: GUIDELINES 
 
1. Please give details of the method of cooking all foods (eg. raw, fried, grilled, 
boiled, steamed, microwaved, roasted, baked, poached, stewed) 
2. Give as many details as possible about the type of food that you eat eg.: 
 Brand name where applicable eg. (Flora margarine) 
 Typeeg. Margarine  (eg. Flora Light,  salt reduced, polyunsaturated) 
Breakfast cereal  (eg. Weetbix)Milk  (eg, Farm House, Rev, Skinny) Cake or 
biscuit (eg. fruit cake, chocolate coated Teddy Bear) Fruit  (eg. fresh, canned, 
dried, stewed) Soft drink ( eg. regular or low calorie) Cheese (eg. reduced fat 
(eg. Devondale Trim’n Tasty), cheddar, low fat (eg. Devondale Seven)Fish (eg. 
cod fillet) Meat (eg. sirloin steak, fat trimmed) Chicken (eg. breast, skin 
removed) 
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RECORDING THE AMOUNTS OF FOOD YOU EATIT IS VERY 
IMPORTANT TO RECORD THE QUANTITY OF EACH FOOD AND DRINK 
YOU CONSUME 
It is preferable that you weigh all your food and drink on the electronic 
scales provided but some times that may be inconvenient. 
HOW TO QUANTIFY YOUR FOOD IF IT IS IMPRACTICAL TO USE YOUR 
SCALES 
HOUSEHOLD MEASURES 
State the amounts of food or drink in household measures (eg. 1/4, 1/3, 1/2 or 
3/4 cups, tablespoons, teaspoons, etc.) State whether spoons are level, 
rounded or heaped. 
WEIGHTS MARKED ON PACKAGES 
All convenience foods have their weight marked on the packaging and this 
can be quoted (eg. half a 425g can  spaghetti). 
PLEASE REMEMBER, THESE ESTIMATION METHODS SHOULD ONLY BE 
USED IF ABSOLUTELY NECESSARY.  
IT IS VERY IMPORTANT THAT YOU DO NOT CHANGE YOUR EATING 
HABITS IN ANY WAY BECAUSE YOU ARE KEEPING A RECORD. 
THIS IS VERY EASY TO DO, BUT PLEASE REMEMBER, WE ARE 
INTERESTED IN YOUR  EATING HABIT
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DAY…………………  DATE……………. 
 
 
Record ALL food and drink consumed during the day including sweets, 
snacks, “nibbles”, sauces and dressings. 
 
Meal/ 
Snack 
Quantity 
eaten 
Details of food or drink and 
method of cooking 
Notes 
 
Early morning 
   
 
Breakfast 
   
 
During 
morning 
   
 
Lunch 
   
Meal/ 
Snack 
Quantity 
eaten 
Details of food or drink and 
method of cooking 
Notes 
 
During 
afternoon 
 
   
 
Evening 
meal 
   
 
During 
evening/ 
bedtime 
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Appendix 3-8  Chinese medicine questionnaire 
 
 
CHINESE MEDICINE QUESTIONNAIRE 
Key: 0 = None (you do not have this symptom) 
1 = Mild (you only have the symptoms once in a while and it doesn’t affect you daily life) 
2 = Moderate (the symptoms can cause an inconvenience to your daily life) 
3 = Severe (the symptoms affect the performance of daily duties) 
4 = Very Severe (the symptoms severely affect the performance of daily duties) 
 
PATTERN DIFFERENTIATION 0 1 2 3 4 
Accumulation of 
heat in the intestine 
and stomach 
1.Hunger  and craving for food      
2.  Rosy cheeks,      
3. Dry mouth with bitter taste      
4. Burning pain and upset in the stomach      
5. Red tongue with yellow and greasy coating      
6. Wiry and smooth pulse.      
Dysfunction of the 
spleen in 
transportation 
1.Listlessness, lassitude       
2.Slight oedema of limbs       
3. Impaired appetite      
4. Loose stools      
5. Swollen pale tongue with teeth marks  thin and white 
coating 
     
6. Soft-superficial and thready pulse      
Internal retention of 
phlegm 
1.Bodily heaviness, lassitude of limbs      
2.Fullness of the chest, phlegm accumulation,      
3. Vomiting and lack of appetite      
4. Listlessness and somnolence      
5. White and greasy tongue coating      
6.  Smooth pulse      
Deficiency of spleen 
yang and kidney 
yang 
1. Listlessness and somnolence      
2 Loose stools and frequency urination      
3 Spontaneous perspiration and short of breath      
4. Aversion to cold and cold limbs      
5. Pale swollen tongue with thin and white coating      
6.  Deep and thready pulse      
Liver Qi stagnation 
and blood stasis 
 
1. Purplish red face or dull red face       
2. Chest distress and hypochondriac distension      
3. Restlessness, irritability      
4. Sleeplessness or restless sleep      
5. Purplish red tongue body with red thorn      
6. Deep and wiry pulse or unsmooth pulse      
Interior heat due to 
deficiency of yin 
1. Afternoon or night fever      
2. Five palm heat      
3. Dreamful sleep and night sweating      
4. Dry throat and mouth      
5. Red tongue with fissure, little coating or no coating      
6. Thready and rapid pulse.       
FINAL COMMENT (by Chinese medicine practitioner) Ref. State Administration of TCM: Criteria of diagnosis and 
therapeutic effect of diseases and syndromes in TCM.       
